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Abstract
The THAP (Thanatos associated protein) domain is an evolutionarily conserved zinc-finger motif highly
similar to the sequence specific DNA binding domain of Drosophila P element transposase. Emerging data
suggest THAP proteins may function in DNA and chromatin dependent processes, including transcription.
However, the transcriptional regulatory function, mechanisms of action, and role of most THAP proteins in
normal and aberrant cellular processes remain largely unknown.
In this thesis, we demonstrate that several human THAP proteins contain transcriptional repressor activity
and specifically identify THAP10 and THAP11 as differentially expressed in human DNA damage and colon
cancer progression, respectively. THAP10 and THAP11 repressed basal and VP16 activator driven
transcription when tethered to promoters as heterologous Gal4-DNA binding domain fusion proteins and
physically associated with histone deacetylases in vitro and in vivo. THAP11 was found to be differentially
expressed in the SW480/SW620 cell culture model of human colon cancer progression and
immunohistochemical analysis of tissue microarrays similarly revealed increased THAP11 expression
concomitant with disease progression. The increase in THAP11 expression in colon cancer tumors and cell
lines suggests that THAP11 dependent transcriptional repression may contribute to disease progression.
Consistent with this hypothesis we find that knockdown of THAP11 in metastatic SW620 colon cancer cells
results in a modest but significant decrease in cell proliferation. Gene expression profiling in THAP11
depleted SW620 cells identified 80 differentially expressed genes, 70% of which were de-repressed by
THAP11 knockdown. Directly repressed THAP11 gene targets were found to contain chromatin bound
THAP11 near their transcription start sites. THAP11 mediated repression requires the multi-functional
transcriptional regulator HCF-1 (Host cell factor-1). THAP11 physically associates with and recruits HCF-1
to repressed promoters and knockdown of HCF-1 is sufficient to de-repress THAP11 target genes.
Collectively, this data provides the first characterization of a directly regulated, THAP11 dependent gene
expression program in human cells and suggests THAP11 may be an important transcriptional regulator in
human colon cancer. These results, in conjunction with previous findings from our laboratory and others,
suggest THAP proteins likely function as biologically relevant transcriptional regulators.
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ABSTRACT 
CHARACTERIZATION OF THAP10 AND THAP11 AS TRANSCRIPTIONAL 
REPRESSORS IN DNA DAMAGE AND COLON CANCER PROGRESSION 
James B. Parker 
Debabrata Chakravarti 
The THAP (Thanatos associated protein) domain is an evolutionarily 
conserved zinc-finger motif highly similar to the sequence specific DNA binding 
domain of Drosophila P element transposase.  Emerging data suggest THAP 
proteins may function in DNA and chromatin dependent processes, including 
transcription.  However, the transcriptional regulatory function, mechanisms of 
action, and role of most THAP proteins in normal and aberrant cellular processes 
remain largely unknown.   
In this thesis, we demonstrate that several human THAP proteins contain 
transcriptional repressor activity and specifically identify THAP10 and THAP11 as 
differentially expressed in human DNA damage and colon cancer progression, 
respectively.  THAP10 and THAP11 repressed basal and VP16 activator driven 
transcription when tethered to promoters as heterologous Gal4-DNA binding 
domain fusion proteins and physically associated with histone deacetylases in 
vitro and in vivo.  THAP11 was found to be differentially expressed in the 
SW480/SW620 cell culture model of human colon cancer progression and 
immunohistochemical analysis of tissue microarrays similarly revealed increased 
THAP11 expression concomitant with disease progression. The increase in 
THAP11 expression in colon cancer tumors and cell lines suggests that THAP11 
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dependent transcriptional repression may contribute to disease progression.  
Consistent with this hypothesis we find that knockdown of THAP11 in metastatic 
SW620 colon cancer cells results in a modest but significant decrease in cell 
proliferation.  Gene expression profiling in THAP11 depleted SW620 cells 
identified 80 differentially expressed genes, 70% of which were de-repressed by 
THAP11 knockdown.   Directly repressed THAP11 gene targets were found to 
contain chromatin bound THAP11 near their transcription start sites.  THAP11 
mediated repression requires the multi-functional transcriptional regulator HCF-1 
(Host cell factor-1).  THAP11 physically associates with and recruits HCF-1 to 
repressed promoters and knockdown of HCF-1 is sufficient to de-repress 
THAP11 target genes.   
Collectively, this data provides the first characterization of a directly 
regulated, THAP11 dependent gene expression program in human cells and 
suggests THAP11 may be an important transcriptional regulator in human colon 
cancer.  These results, in conjunction with previous findings from our laboratory 
and others, suggest THAP proteins likely function as biologically relevant 
transcriptional regulators. 
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Chapter 1:  Regulation of Transcription in Eukaryotes 
Overview 
Gene expression in eukaryotes is controlled by the dynamic interplay 
between regulatory mechanisms governing transcriptional activation and 
repression.  Dysregulation of either transcriptional activation or repression can 
result in aberrant spatiotemporal gene expression and corresponding defects in 
cellular and organismal physiology.  Numerous genetic studies utilizing gain-of-
function or loss-of-function mutations in various transcriptional regulators have 
revealed alterations in cell growth, differentiation, and apoptosis, thereby 
emphasizing the importance of proper transcriptional regulation in biological 
processes.  In addition, elaborate and complex gene expression patterns and the 
requisite increase in transcriptional control mechanisms have been suggested to 
account for the increased organismal complexity observed in metazoans versus 
lower eukaryotes (Levine and Tjian 2003).  Consistent with this idea is the 
correlation between absolute number and ratio of transcription factors per 
genome and apparent organismal complexity; yeast, fly and human genomes 
have been estimated to encode ~300, 1000, and 3000 transcription factors, 
respectively (Levine and Tjian 2003).  Thus, the identification and 
characterization of novel transcriptional regulators and their mechanisms of 
action is a necessary component of cellular and molecular biology. 
Eukaryotes utilize several distinct DNA-dependent RNA polymerases to 
transcribe their full complement of cellular RNAs.  RNA polymerase I (RNAPI) 
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transcribes the 45S precursor ribosomal RNA (rRNA) which is processed into 
mature 18S, 5.8S and 28S rRNAs (Russell and Zomerdijk 2005).  RNA 
polymerase III (RNAPIII) also transcribes untranslated RNAs including 5S rRNA, 
tRNAs, U6 RNAs, and some microRNAs (Dieci, Fiorino et al. 2007).  In contrast, 
RNA polymerase II (RNAPII) transcribes all protein coding mRNAs as well as 
long non-coding RNAs, and microRNAs (Lee and Young 2000; Lee, Kim et al. 
2004; Guttman, Amit et al. 2009).  Dysregulation of transcription catalyzed by 
each RNA polymerase has been implicated in the pathogenesis of human 
diseases, including cancer (White 2005; Marshall and White 2008).  However, 
given the breadth of DNA templates transcribed by RNAPII and the relevance of 
these gene products in establishing normal and disease processes, mechanisms 
governing RNAPII dependent transcription have been widely studied and will be 
briefly summarized here. 
Mechanisms of Regulation 
Transcription Initiation and Elongation 
Transcription by RNAPII initiates at core promoters following recruitment 
of the basal transcription machinery, operationally defined as the minimum set of 
proteins necessary to drive in vitro transcription from an isolated core promoter 
(Smale and Kadonaga 2003).  Core promoters can be classified into two types, 
focused or dispersed, which reflects their relative number and location of 
transcription start sites (Juven-Gershon, Hsu et al. 2008).  Focused promoters 
contain either a single transcription start site or a distinct cluster of start sites 
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over several nucleotides while dispersed promoters characteristically contain 
several start sites spanning 50-100 nucleotides.  Focused transcription initiation 
occurs throughout all eukaryotes and is believed to be the primary mechanism of 
transcription initiation in lower eukaryotes (Juven-Gershon and Kadonaga 2010). 
Conversely, dispersed promoters are typically restricted to vertebrates, owing to 
their frequent location in CpG islands which are present in approximately 70% of 
vertebrate promoters (Juven-Gershon and Kadonaga 2010).   
Despite this discrepancy the vast majority of studies to date have focused 
on mechanisms regulating transcription initiation from focused core promoters.  
Eight core promoter elements, characterized by DNA sequence, have been 
identified at focused promoters of RNAPII transcribed genes and include: TATA, 
initiator (Inr), downstream promoter element (DPE), upstream and downstream 
TFIIB recognition elements (BRE  and BRE ), motif ten element (MTE), u d X core 
promoter element 1 (XCPE1) and downstream core element (DCE) (Smale and 
Kadonaga 2003; Juven-Gershon and Kadonaga 2010).  None of these core 
promoter elements is universal and each element is found in only a fraction of 
core promoters.   
Core promoter elements, with the exception of the appropriately named 
TFIIB recognition elements, are recognized by distinct subunits of general 
transcription factor TFIID, a multi-subunit complex comprised of TATA-binding 
protein (TBP) and approximately 13 or 14 TFIID associated factors (TAFs) 
(Smale and Kadonaga 2003).  TFIID binding at core promoters is stabilized by 
TFIIA, followed by recruitment of TFIIB which associates through both DNA 
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recognition at BREs and direct contact with TFIID.  Binding of TFIID and TFIIB 
results in additional general transcription factor (TFIIE, TFIIF, TFIIH) and RNAPII 
binding, either sequentially or pre-associated as an RNAPII holoenzyme, to form 
the transcription preinitiation complex (PIC) (Thomas and Chiang 2006).  
Because preinitiation complexes are competent to initiate transcription, cells 
utilize numerous control mechanisms to regulate their assembly and activity. 
Core promoters delineate the site of transcription initiation but additional 
regulatory cues provided by cis-acting DNA sequences are necessary to achieve 
the range of dynamic gene expression observed in vivo.  Sequence specific DNA 
binding factors present at cis-acting DNA sequences, including proximal 
promoter elements and distal enhancers, can positively regulate transcription 
initiation by stimulating the assembly and activity of the basal transcription 
machinery at the core promoter (Lee and Young 2000).  Numerous sequence 
specific transcription factors have been shown to facilitate PIC assembly through 
direct interaction with TFIID and TFIIB (Deng and Roberts 2007; Cler, Papai et 
al. 2009).  The glutamine-rich transactivation domains of both Sp1 and CREB 
directly interact with the TFIID subunit TAF4 and mutation of the TAF4 residues 
responsible for Sp1 binding significantly diminish Sp1 mediated transcriptional 
activation (Gill, Pascal et al. 1994; Rojo-Niersbach, Furukawa et al. 1999; 
Asahara, Santoso et al. 2001).  Electron microscopy and biochemical studies 
using purified native TFIID in complex with either p53, c-Jun or Sp1 has revealed 
that these activators bind distinct surfaces on TFIID, including specific TAFs (Liu, 
Coleman et al. 2009).  This finding suggests that certain combinations of 
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promoter bound transcription factors may synergistically activate transcription by 
contacting unique, non-overlapping surfaces on TFIID (Liu, Coleman et al. 2009).   
Activator dependent recruitment of TFIID is thought to be especially important at 
dispersed, CpG island promoters which typically lack consensus TATA, Inr, and 
DPE elements (Smale and Kadonaga 2003).  Rather, CpG islands frequently 
contain multiple Sp1 binding GC-boxes and transcription start sites are often 
located 40-80bp downstream of these sites, suggesting Sp1 may stimulate 
transcription by recruiting basal transcription factors at these promoters (Smale 
and Kadonaga 2003).    
Recent genome-wide studies have identified basal transcription factor and 
RNAPII occupancy at transcriptionally inactive genes, indicating an essential role 
for post-recruitment regulatory mechanisms in controlling gene expression 
(Muse, Gilchrist et al. 2007; Zeitlinger, Stark et al. 2007; Core, Waterfall et al. 
2008).  Multiple events occur following preinitiation complex assembly and prior 
to productive transcript elongation, including transcription bubble formation, 
promoter escape, and promoter-proximal pausing (Fuda, Ardehali et al. 2009).  
Each step may potentially be regulated but numerous studies have identified 
promoter-proximal pausing as a key mechanism in regulated gene expression.  
Initially identified at Drosophila heat shock genes, promoter-proximal pausing is 
characterized by the stalling of RNAPII following transcription of 20-40bp of 
nascent mRNA (Margaritis and Holstege 2008).  Promoter-proximal pausing is 
governed by the association of pausing factors such as DRB sensitivity-inducing 
factor (DSIF) and negative elongation factor (NELF) with RNAPII (Margaritis and 
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Holstege 2008).  The conversion from promoter-proximal pausing to productive 
elongation is regulated by positive transcription elongation factor b (P-TEFb); a 
heterodimer composed of cyclin dependent kinase 9 (Cdk9) and one of the C-
type cyclins T1, T2a, T2b or K (Kohoutek 2009).  Recruitment of P-TEFb to 
stalled RNAPII results in phosphorylation of both the pausing factors as well as 
Serine 2 of the YSPTSPS heptapeptide repeat present in the C-terminal domain 
(CTD) of Rbp1 subunit of RNAPII.  These phosphorylations relieve pause factor 
induced stalling and promote the transition to productive elongation.   
P-TEFb activity is negatively regulated by its reversible association with 
the 7SK small nuclear ribonucleoprotein complex (7SK snRNP) composed of 
7SK snRNA and RNA binding proteins HEXIM1/2, LARP7, and BCDIN3 (Peterlin 
and Price 2006; Barboric, Lenasi et al. 2009).  A substantial fraction of active P-
TEFb associates with the dual bromodomain-containing protein Brd4 suggesting 
a mechanistic link between histone acetylation and transcriptional elongation 
(Jang, Mochizuki et al. 2005; Yang, Yik et al. 2005; Chiang 2009). In addition, 
sequence specific transcription factors including c-myc, NF-κB and the HIV-1 
transactivator Tat, also recruit P-TEFb to their respective target gene promoters 
indicating some activators function to regulate transcription at the level of 
elongation as well as initiation (Barboric, Nissen et al. 2001; Luecke and 
Yamamoto 2005; Barboric, Yik et al. 2007; Rahl, Lin et al. 2010).         
Sequence specific DNA binding factors also function as platforms for the 
assembly of non-DNA binding transcriptional co-regulators.  These recruited co-
regulators, frequently in the form of macromolecular protein complexes, modulate 
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transcription by altering chromatin structure or stimulating the recruitment and 
activity of the basal transcription machinery.  These mechanisms, either alone or 
in combination, are applicable to a variety transcription factors.  For example, 
activation of wingless (Wg/Wnt) target genes in Drosophila requires the 
metazoan-specific ETO-TAFH domain present near the amino-terminus of TAF4.  
The ETO-TAFH domain physically interacts with Pygopus, a critical component 
of the tri-partite Armadillo/Legless/Pygopus bridge, thereby enabling DNA bound 
T-cell factor (TCF) to interact with TFIID (Wright and Tjian 2009).  Interestingly, 
TFIID and RNAPII were found to be pre-loaded at Wg/Wnt target genes prior to 
activation suggesting the Pygopus/TAF4 interaction may function to stimulate 
transcription elongation by relieving promoter proximal stalling (Wright and Tjian 
2009).  The integration of chromatin modifying activities with transcriptional 
output is best exemplified by nuclear hormone receptors which positively and 
negatively regulate transcription through reversible association with co-activator 
and co-repressor complexes in a hormone dependent manner.  For example, 
liganded thyroid hormone receptor exchanges histone deacetylase (HDAC) 
containing co-repressor complexes with histone acetyltransferase containing 
(HAT) co-activator complexes, thereby altering chromatin structure through post-
translational modification of amino-terminal histone tails (Sharma and Fondell 
2002).  Following HAT recruitment, liganded receptor associates with the 
Mediator complex which in turn facilitates basal transcription factor and RNAPII 
recruitment and activation (Sharma and Fondell 2002; Belakavadi and Fondell 
2010).   
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Chromatin and Transcriptional Regulation 
DNA dependent processes, including transcription, occur not on naked 
DNA but in the context of chromatin; a highly-ordered, condensed, polymeric 
structure necessary to fit eukaryotic DNA into the physical constraints of the 
nucleus.  The basic repeating unit of chromatin is the nucleosome; approximately 
146bp of DNA wrapped 1.65 turns around an octamer of core histones (Lee and 
Young 2000).  The histone octamer is composed of a two heterodimers of 
histones H3 and H4 which are flanked by two heterodimers of H2A and H2B.  
The solved crystal structure of the nucleosome revealed a roughly cylindrical 
histone octamer particle with tightly wrapped DNA making multiple contacts with 
core histones along its phosphate backbone (Luger, Mader et al. 1997).  
Individual nucleosomes are separated by ~10-60bp of linker DNA resulting in a 
nucleosomal array approximately 10nm in diameter with a topology frequently 
described as ‘beads on a string’.  Binding of histone H1 to linker DNA stimulates 
further compaction of the nucleosomal array into a fiber of ~30nm in diameter.  
This chromatin fiber can further compact into 100-400nm interphase fibers or the 
highly condensed chromosomes observed in metaphase cells (Woodcock and 
Ghosh 2010).   
The assembly of DNA into nucleosomes and higher order chromatin 
structures is generally regarded as inhibitory towards transcription.  The highly 
condensed structure of heterochromatin suppresses transcription at these 
repetitive elements while the locally compacted chromatin at Hox loci ensures 
their expression in a developmentally regulated manner (Grewal and Jia 2007; 
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Eskeland, Leeb et al. 2010).  However, even the fully decondensed nucleosomal 
arrays found at transcriptionally permissible chromatin may occlude regulatory 
DNA sequences and inhibit transcription by preventing the association of 
sequence specific or general transcription factors with their cognate binding sites. 
Therefore, dynamic alteration of chromatin structure and function is an essential 
mechanism governing regulated gene expression.  The two primary chromatin 
modifying activities implicated in transcriptional regulation are post-translational 
modification of histones and ATP-dependent chromatin remodeling. 
Histone Modification    
Core histones provide the protein scaffold for nucleosome formation.  The 
globular domains of core histones mediate histone-histone and histone-DNA 
interactions while the flexible amino-terminal tails extend away from the histone 
octamer where they can be reversibly modified by a variety of post-translational 
modifications including: acetylation, methylation, phosphorylation, ubiquitination, 
sumoylation and ADP-ribosylation.  Lysine residues in histone tails are frequent 
acceptor sites for these modifications and have been shown to be acetylated, 
ubiqutinated, sumoylated, ADP-ribosylated and mono-, di-, and tri-methylated 
(Turner 2005; Messner, Altmeyer et al. 2010).  Arginine residues can be mono- 
or di-methylated; serine and threonine residues can be phosphorylated (Turner 
2005).   
Genome-wide studies in various model systems have revealed that 
specific histone modification patterns correlate with transcriptional activity and 
demarcate functional regions of chromatin (Schneider, Bannister et al. 2004; 
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Bernstein, Kamal et al. 2005; Pokholok, Harbison et al. 2005; Kolasinska-Zwierz, 
Down et al. 2009; Karlic, Chung et al. 2010).  Hyperacetylation of histones H3 
and H4 in conjunction with tri-methylation at H3 lysine 4 (H3K4me3) are 
observed at promoters of actively transcribed genes.  Tri-methylation at H3K36 
also denotes actively transcribed genes but this modification is enriched in the 
body of genes, preferentially at exons, suggesting a role for this modification in 
regulating co-transcriptional splicing (Kolasinska-Zwierz, Down et al. 2009; Fox-
Walsh and Fu 2010; Luco, Pan et al. 2010).  The robustness of these histone 
modifications as hallmarks of actively transcribed chromatin was recently used to 
identify numerous long intergenic non-coding RNAs (lincRNA) in genomic 
regions previously considered to be ‘gene deserts’ (Guttman, Amit et al. 2009).  
Other histone modifications such as methylation of H3K9 and H3K27 are 
enriched at transcriptionally silent regions including pericentromeric 
heterochromatin (H3K9me2/3), telomeres (H3K9me2/3, H3K27me2/3) and 
developmentally regulated genes (H3K9me2/3, H3K27me2/3).  In addition, 
acquisition of these repressive histone modifications is believed to play a critical 
role in epigenetic silencing of tumor and metastasis suppressor genes (Kondo, 
Shen et al. 2003; Herranz, Pasini et al. 2008).            
One mechanism histone tails and their associated modifications regulate 
transcription is through modulation of higher order chromatin structure 
(Kouzarides 2007).  Of particular importance is a short stretch of basic amino 
acids in the H4 tail which contacts a patch of acidic residues formed at the 
interface of H2A/H2B in an adjacent nucleosome.  This internucleosomal 
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association is believed to contribute to 30nm fiber formation as well as higher 
order fiber-fiber interactions (Dorigo, Schalch et al. 2003; Dorigo, Schalch et al. 
2004; Sinha and Shogren-Knaak 2010).  Indeed, deletion of H4 tail residues 14-
19, or acetylation of lysine 16 is sufficient to disrupt salt-dependent 30nm 
chromatin fiber formation in vitro (Dorigo, Schalch et al. 2003; Shogren-Knaak, 
Ishii et al. 2006).  These findings suggest that H4K16 acetylation likely plays an 
important role in maintaining an open chromatin environment amenable to 
transcription.   
In addition to regulating chromatin structure, a preponderance of evidence 
suggests that histone tail modifications also act as recognition motifs for a variety 
of effector proteins which in turn provide unique functionalities that modulate key 
rate limiting steps of the transcription cycle.  These effectors employ specialized 
domains to recognize histone tails in a modification sensitive manner.  The ability 
to discriminate between specific modifications in a context sensitive manner 
allows these effectors to participate in disparate transcriptional outcomes.  For 
example, bromodomains recognize acetylated lysines and bromodomain-
containing effectors frequently link histone acetylation with transcriptional 
activation.  The aforementioned dual bromodomain-containing Brd4 binds to 
primary response genes following signal dependent histone acetylation and 
recruits P-TEFb to stimulate transcription elongation and co-transcriptional 
mRNA processing (Hargreaves, Horng et al. 2009; Zippo, Serafini et al. 2009).  
Bromodomain-containing effectors also recognize non-histone substrates.  For 
instance, the bromodomains of TAF1 bind acetylated p53 facilitating TFIID 
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recruitment to DNA damage inducible promoters (Li, Piluso et al. 2007).  
Methylated histone tails are recognized by chromodomain-containing proteins 
such as Cbx5, Cbx1, and Cbx3 (formerly HP-1α, HP1-β, HP-1γ) which bind di 
and tri-methylated H3K9 (H3K9me2/3).  Binding of Cbx5 and Cbx1 at 
H3K9me2/3 represses transcription at retinoblastoma regulated genes and 
promotes chromatin fiber compaction characteristic of heterochromatin (Nielsen, 
Schneider et al. 2001; Fan, Rangasamy et al. 2004).  Likewise, mammalian 
Polycomb homologues (Cbx2, Cbx4, Cbx6, Cbx7, Cbx8) utilize chromodomains 
to tether the Polycomb repressive complex PRC1 to chromatin containing 
H3K27me2/3 resulting in chromatin compaction and gene silencing (Simon and 
Kingston 2009).  
    In addition to amino-terminal tail modifications, recent mass 
spectrometry based experiments have identified over 30 modifications in the 
globular domain of core histones (Mersfelder and Parthun 2006).  Comparison of 
these modifications with the nucleosome crystal structure reveals these 
modifications are concentrated at the solvent accessible histone surface, histone-
histone interfaces, and the histone lateral surface including residues that directly 
contact DNA (Mersfelder and Parthun 2006).  Globular domain modifications 
likely regulate transcription and other DNA dependent processes by altering 
chromatin structure as well as regulating effector protein recruitment. 
The reversible nature of post-translational histone modifications ensures 
that dynamic recruitment of histone modifying enzymes is a primary mechanism 
of transcriptional regulation.  Indeed, histone modifying activities found in co-
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regulator complexes are frequently indispensable to co-regulator function.  The 
yeast transcriptional co-activator Gcn5 contains intrinsic histone 
acetyltransferase (HAT) activity and ablation of HAT function disrupts Gcn5 
mediated transcriptional activation in vivo (Kuo, Zhou et al. 1998).  In an 
analogous manner, histone deacetylase (HDAC) activity is critical for co-
repressor complex function.  Small molecule HDAC inhibitors alleviate 
transcriptional repression concomitant with histone hyperacetylation and RNAi-
mediated depletion of HDAC3 disrupts repression by unliganded nuclear 
hormone receptors (Ishizuka and Lazar 2003).  Similar findings are observed 
with respect to histone methylation.  The histone demethylase Lsd1 functions in 
multiple co-repressor complexes that repress transcription by removing H3K4 
methylation (Wysocka, Milne et al. 2005).  In contrast, H3K4 methyltransferases 
associated with DNA binding or co-activator complexes stimulate transcription 
(Ruthenburg, Allis et al. 2007).  Synergism between demethylases and 
methyltransferases has also been reported to influence transcriptional output.  
For example, complex formation between H3K27 demethylases and H3K4 
methyltransferases allows the removal of repressive histone methylation with 
simultaneous deposition of activating methyl marks (Swigut and Wysocka 2007).              
Chromatin Remodeling    
Nucleosome dynamics are controlled by chromatin remodeling complexes 
which utilize energy derived from ATP hydrolysis to slide, evict or restructure 
nucleosomes.  Nucleosome sliding and/or eviction exposes the underlying DNA 
template to sequence specific or general transcription factors while nucleosome 
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restructuring allows incorporation of histone variants (H3.3) associated with 
active transcription.  Four distinct families of chromatin remodelers have been 
characterized:  SWI/SNF (switching defective/sucrose nonfermenting), ISWI 
(imitation switch), CHD (chromodomain, helicase, DNA binding), and INO80 
(inositol requiring 80) (Clapier and Cairns 2009).  Each remodeler family contains 
a catalytic subunit harboring a conserved ATPase domain and at least one 
unique flanking domain which defines family membership.  These unique 
domains in conjunction with non-catalytic accessory subunits impart individual 
family members with specialized functions in distinct chromatin dependent 
processes, including transcription (Clapier and Cairns 2009).  For example, the 
SWI/SNF remodeler Brg1 has been implicated in glucocorticoid receptor 
mediated transcriptional activation concomitant with chromatin remodeling 
(Trotter, Fan et al. 2008).  Similar findings for SWI/SNF family member Brm have 
been observed in Drosophila where genetic studies revealed a global decrease 
in RNAPII binding and transcription following attenuation of Brm function 
(Armstrong, Papoulas et al. 2002).  Other remodeling complexes repress 
transcription as exemplified by the Mi-2/NuRD (nucleosomes remodeling and 
deacetylase) complex which couples chromatin remodeling and histone 
deacetylase activities in the same complex (Denslow and Wade 2007).  
Gene transcription is controlled by the combinatorial action of multiple 
regulatory factors and mechanisms (Figure 1.1).  DNA binding factors and their 
associated co-regulators interact with components of the transcription apparatus 
including general transcription factors and RNAPII.  Co-regulator complexes also 
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contain histone modifying enzymes and nucleosome remodelers which alter the 
chromatin template to either activate or repress transcription.  The importance of 
transcriptional regulatory mechanisms in maintaining normal cellular processes is 
underscored by the observation that approximately 10 percent of metazoan 
protein coding genes encode putative transcription factors.  However, the 
transcriptional regulatory mechanisms and endogenous gene targets associated 
with most of these factors remain incompletely understood. 
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Figure 1.1:  Mechanisms of transcriptional regulation.  General transcription factors (GTFs) bind to specific sequence 
elements in the core promoter. The relative postion of these core promoter elements with respect to the transcription start 
site (black arrow) are indicated.  Sequence specific transcriptional regulators (orange oval and yellow diamond), including 
activators and repressors, bind to DNA sequences located near the core promoter (proximal sites) and/or at distant 
enhancer regions. These sequence specific regulators can interact (green arrows) with GTFs, including TFIID (blue 
rectangle), TATA-binding protein (TBP, blue horseshoe), and RNAPII (red 'rocket') to activate or repress transcription. 
They also interact (green arrows) with co-regulators (green hexagon) that can interact (blue arrows) with the general 
transcription machinery or chromatin-modifying factors, such as histone modifying enzymes and nucleosome remodellers. 
Transcriptional activators can recruit, stabilize or stimulate these factors while repressors can disrupt or inhibit these 
factors.  Adapted from (Fuda, Ardehali et al. 2009). 
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Chapter 2:  Characterization of THAP10 and THAP11 as 
Transcriptional Repressors Expressed in Human DNA 
Damage and Colon Cancer Progression   
Summary 
 The Thanatos associated protein, or THAP, domain is an evolutionarily 
conserved zinc-finger motif restricted to metazoans.  THAP domains show 
significant homology to the sequence-specific DNA binding domain of Drosophila 
P element transposase and have been suggested to function in DNA and 
chromatin dependent processes.  However, the transcriptional regulatory 
capacity of most THAP proteins and their function in normal or aberrant 
physiological processes are largely unknown.  In this chapter, we identify human 
THAP10 and THAP11 as differentially expressed during DNA damage and colon 
cancer progression, respectively.  THAP10 mRNA was found to be induced by 
genotoxic chemotherapeutics in HeLa and HepG2 but not p53-null Saos-2 cells.  
Ecotopic overexpression of p53 was sufficient to markedly induce THAP10 
mRNA suggesting THAP10 may be a novel p53-regulated, DNA damage 
inducible gene.  THAP11 mRNA and protein was found to be upregulated in 
metastatic SW620 colon cancer cells relative to their isogenic, primary tumor 
derived SW480 counterparts.  Immunohistochemical analysis of human colon 
cancers revealed increased THAP11 staining frequency and intensity correlated 
with disease progression.  Both THAP10 and THAP11 were found to potently 
repress basal and activated transcription when targeted to promoters as 
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heterologous Gal4-DNA binding domain fusion proteins.  Consistent with 
transcriptional repression, both THAP10 and THAP11 were shown to associate 
with histone deacetylases in vivo and in vitro.  Taken together, these results 
suggest that THAP10 and THAP11 dependent transcriptional repression may 
contribute to the gene expression programs associated with DNA damage and 
colon cancer progression, respectively. 
Introduction 
Introduction to the THAP Domain 
The Thanatos associated protein (THAP) domain is a recently identified, 
evolutionarily conserved protein motif containing a high degree of similarity to the 
sequence-specific DNA binding domain of Drosophila P element transposase 
(Roussigne, Kossida et al. 2003).  THAP domains are approximately 90 amino 
acids in length and characterized by an N-terminally located C2-CH (Cys-Xaa2-4-
Cys-Xaa35-50-Cys-Xaa2-His) zinc-finger signature, several invariant residues 
including Pro26, Trp36, Phe58, and Pro78 (numbering with respect to THAP1) 
and a C-terminal AVPTIF box (Figure 2.1) (Roussigne, Kossida et al. 2003).   
Genome sequencing and bioinformatic analyses have identified over 300 
THAP proteins making this domain the second most prevalent DNA binding, zinc-
coordinating motif after C2-H2 containing zinc-fingers (Sabogal, Lyubimov et al. 
2010).  However, unlike C2-H2 zinc-finger proteins, THAP proteins are restricted 
exclusively to animals; none have been identified in the genomes of plants, 
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yeast, fungi, or bacteria.  Therefore, it appears that THAP proteins have evolved 
to serve specific functions relevant to animal physiology.   
Orthologs of human THAP genes have been found in genomes of 
vertebrates including mouse, rat, dog, cow, chicken, pig, frog and fish (Table 2.1) 
(Clouaire, Roussigne et al. 2005).  However, human orthologs have not been 
identified in genomes of flies or worms.  Twelve distinct THAP domain containing 
proteins have been identified in humans, each of which contains a single N-
terminally located THAP domain (Figure 2.1A) (Roussigne, Kossida et al. 2003).  
Only a subset of these (THAP0, 1, 2, 4, 7, and 11) has orthologs in rodents.  
Additionally, only THAP1, 4, 7, and 11 are also conserved in X. laevis while 
THAP0, 1, 7, 9, and 11 are conserved in D. rerio. 
Structure-Function Analysis of THAP domains 
Much of our current understanding regarding THAP domains as DNA 
binding modules comes from studies characterizing THAP domain function in 
Drosophila P element transposase and human THAP1.  Drosophila P element 
DNA encodes the mobile DNA element as well as transposase and 
transpositional repressor proteins (Kaufman, Doll et al. 1989). The 207 amino 
acid KP repressor protein, arising from a naturally occurring internal deletion in P 
element DNA, is ostensibly a truncated P element transposase; both contain 
identical N-terminal 199 amino acids including THAP domain (Lee, Mul et al. 
1996).  While investigating the molecular mechanisms by which repressor 
proteins inhibit transposition, Lee et al. discovered that KP repressor contains 
site specific DNA binding activity indistinguishable from the transposase itself 
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(Lee, Beall et al. 1998).  Point mutation of the first two zinc coordinating 
cysteines abolished in vitro binding to P element DNA sequences as determined 
by DNase I footprinting, thus providing important initial evidence that THAP 
domains could function as modular, site specific DNA binding zinc fingers (Lee, 
Beall et al. 1998).  More recently, Clouaire and co-workers have used an in vitro 
selection approach to determine an 11-nucleotide high affinity DNA binding 
sequence for human THAP1 termed THABS (THAP1 Binding Sequence) 
(Clouaire, Roussigne et al. 2005).  In vitro THAP1/THABS interaction studies 
revealed that, like the Drosophila KP repressor, THAP1 sequence specific DNA 
binding was also strictly zinc dependent.  Mutation of the conserved zinc 
coordinating cysteine and histidine residues completely abolished DNA binding 
as did metal chelation performed either with EDTA or the zinc specific chelator 
1,10-o-phenanthroline (Clouaire, Roussigne et al. 2005).  Further underscoring 
the role of zinc in proper THAP domain function, add-back experiments 
performed in the presence of chelator demonstrated that supplemental zinc but 
not iron, calcium or magnesium was capable of rescuing chelator mediated 
inhibition of DNA binding (Clouaire, Roussigne et al. 2005).  In addition to the 
conserved zinc coordinating residues, THAP1, like all THAP domains, also 
contains several invariant residues (Pro26, Trp36, Phe58, and Pro78).  
Importantly, site directed mutagenesis of these residues also abrogated the 
THAP1/THABS sequence specific DNA association (Clouaire, Roussigne et al. 
2005).  Taken together, these experiments strongly suggested that THAP 
domains possess zinc dependent, sequence specific DNA binding activity.  
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Furthermore, the defining amino acids of THAP zinc fingers were also 
demonstrated to be indispensable for their function as DNA binding domains. 
THAP domains, like other zinc fingers, display relatively low primary 
sequence identity.  However, recent structural analyses have revealed that 
diverse THAP domains adopt similar secondary and tertiary structures.  Nuclear 
magnetic resonance determined solution structures of THAP domains from 
human THAP1 and C. elegans C-terminal binding protein (CtBP), in addition to 
the x-ray crystal structure of Drosophila P element transposase, have each 
independently revealed a similar three-dimensional structure characterized as a 
β-α-β fold nucleated by tetrahedral coordination of a single zinc ion (Liew, 
Crossley et al. 2007; Bessiere, Lacroix et al. 2008; Sabogal, Lyubimov et al. 
2010).  In addition to the β-α-β fold, the remainder of THAP domains is 
comprised primarily of loops, with loop 4 the most variable in length and 
sequence (Sabogal, Lyubimov et al. 2010).   
The first two zinc coordinating cysteines are positioned in a loop structure 
preceding the initial β-strand while the remaining zinc binding cysteine and 
histidine reside immediately C-terminal to the second β-strand.  This flanking of 
the β-α-β motifs with the zinc binding amino acids necessarily results in the 
formation of a two-stranded anti-parallel β-sheet upon zinc coordination (Liew, 
Crossley et al. 2007; Bessiere, Lacroix et al. 2008; Sabogal, Lyubimov et al. 
2010).   
The functional significance of this β-sheet with respect to sequence 
specific DNA binding was recently demonstrated by Sabogal et al. upon solving 
 21
the x-ray crystal structure of Drosophila P element transposase THAP domain 
(DmTHAP) bound to its cognate DNA element.  In DmTHAP, the β-sheet in 
conjunction with the N-terminal methionine was shown to contribute several 
direct and water mediated nucleotide specific contacts to both strands of major 
groove DNA (Sabogal, Lyubimov et al. 2010).  Furthermore, site directed 
mutagenesis of DNA binding β-strand residues His18 and Gln42 significantly 
weakened the binding affinity of DmTHAP for its DNA ligand as determined by 
electrophoretic mobility shift assay (Sabogal, Lyubimov et al. 2010).  The 
contribution of His18 towards sequence specific DNA binding also provides an 
explanation for the previous observation that KP repressor protein harboring an 
H18A mutation lost site specific but retained high affinity, nonspecific DNA 
binding activity (Lee, Beall et al. 1998).  Mutation of Lys24 in human THAP1, 
which occupies a β-strand position synonymous with His18 in DmTHAP, similarly 
disrupts in vitro DNA binding suggesting that Lys24 may contribute to sequence 
specific THAP1 β-strand/DNA contact (Bessiere, Lacroix et al. 2008).  However, 
because the NMR solution structure of human THAP1 was performed in the 
absence of DNA ligand, this possibility remains to be tested (Bessiere, Lacroix et 
al. 2008).     
Comparison of human THAP sequences reveals a high degree of amino 
acid variability in the predicted THAP β-sheets suggesting diverse THAP proteins 
likely recognize different DNA major groove sequences (Sabogal, Lyubimov et al. 
2010).  Indeed, the THAP zinc fingers of human THAP2 and THAP3 were shown 
to be incapable of binding the THAP1 specific THABS DNA sequence in 
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electrophoretic mobility shift assays despite sharing up to 50% sequence identity 
throughout their respective THAP domains (Bessiere, Lacroix et al. 2008).  The 
relative contribution of the individual divergent β-sheet residues to this apparent 
sequence specificity remains to be determined. 
In addition to the sequence specificity imparted by β-sheet contacts with 
the DNA major groove, Sabogal and co-workers also demonstrated that 
DmTHAP additionally interacts with minor groove DNA.  Sequence specific minor 
groove DNA contacts are mediated through loop 4 residues Arg65 and Arg67 
while Arg66 provides nonspecific DNA interaction by contacting the phosphate 
backbone of minor groove DNA (Sabogal, Lyubimov et al. 2010).  Interestingly, 
the loop 4 regions in THAP domains are the most variable in terms of 
composition and length but each contains at least one basic residue (Liew, 
Crossley et al. 2007; Sabogal, Lyubimov et al. 2010).  Molecular modeling 
studies have indicated that even the dramatically shortened loop 4 regions of 
human THAP11 and C. elegans CtBP likely make contact with minor groove 
DNA (Sabogal, Lyubimov et al. 2010).  However, it has been suggested that the 
potential for diminished loop 4/minor groove contacts in THAP11 may 
necessitate a modified DNA binding mechanism, involving perhaps homo- and 
hetero-dimerization (Sabogal, Lyubimov et al. 2010).  In support of this 
hypothesis, mouse THAP11 (termed Ronin) has recently been shown to 
associate both with itself and THAP7; however the relevance of these 
associations in the context of sequence specific DNA binding has not yet been 
reported (Dejosez, Krumenacker et al. 2008). 
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In addition to the defining C2-CH zinc finger, all THAP domains also 
contain a characteristic C-terminal AVPTIF motif (amino acids ) and four highly 
conserved residues Pro26, Trp36, Phe58, and Pro78 (numbering with respect to 
THAP1) each essential for in vitro DNA binding (Figure 2.1B) (Roussigne, Cayrol 
et al. 2003; Clouaire, Roussigne et al. 2005).  The aforementioned structural 
studies have independently determined that the four invariant residues form a 
hydrophobic core, anchored by the unique tryptophan (Trp36) positioned within 
the conserved α-helix.  In THAP1, Trp36 makes hydrophobic contacts with 
several surrounding residues including the conserved Phe58, Pro26 and Pro78 
which lies within the AVPTIF motif (Bessiere, Lacroix et al. 2008).  These 
contacts contribute to the overall THAP protein fold by bringing the C-terminal 
AVPTIF motif in contact with the conserved α-helix (Bessiere, Lacroix et al. 
2008).  Accordingly, perturbation of the invariant residues or the AVPTIF box 
likely inhibits DNA binding by disrupting overall THAP domain structure. 
Collectively, these data demonstrate that the β-sheet and flexible loop 4 
structure of THAP domains target DNA via a bipartite recognition of adjacent 
major and minor groove DNA (Sabogal, Lyubimov et al. 2010).  The reliance on 
the two-stranded β-sheet as a sequence specific DNA binding structure is 
atypical amongst zinc-finger proteins (Sabogal, Lyubimov et al. 2010).  Classical 
C2-H2 type zinc-fingers typically utilize α-helices to form nucleotide specific 
contacts.  In contrast, the THAP domain α-helix appears oriented away from the 
DNA-protein interface where it functions in overall domain structure and may 
provide a scaffold for protein-protein interactions.  While not directly assessing 
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the function of the conserved α-helix, recent work in our laboratory demonstrated 
that the THAP domain of THAP7 was necessary and sufficient for in vitro 
association with HDAC3 demonstrating that THAP domains may also function as 
protein-protein interaction modules (Macfarlan, Kutney et al. 2005). 
THAP Proteins in Biological Processes 
THAP proteins have been implicated in a diverse array of physiological 
processes including cell proliferation, apoptosis, and maintenance of pluripotency 
(Roussigne, Cayrol et al. 2003; Cayrol, Lacroix et al. 2007; Dejosez, 
Krumenacker et al. 2008; Balakrishnan, Cilenti et al. 2009; Zhu, Li et al. 2009).  
The DNA binding properties of THAP domains naturally suggests that THAP 
proteins may regulate these cellular processes in a DNA and chromatin 
dependent manner but this has been directly demonstrated in only a few 
instances (Cayrol, Lacroix et al. 2007; Dejosez, Krumenacker et al. 2008; Zhu, Li 
et al. 2009).   
THAP1, the first characterized human THAP protein, was initially identified 
as a pro-apoptotic nuclear protein that localized in PML nuclear bodies and 
physically associated with the pro-apoptotic Par-4 (prostate and apoptosis-4) 
protein (Roussigne, Cayrol et al. 2003).  Roussigne et al. found that over-
expression of THAP1 could potentiate both serum withdrawal and cytokine 
induced apoptosis.  Importantly, this pro-apoptotic function was shown to be 
dependent on the presence of the THAP domain since over-expression of a 
THAP deleted construct failed to affect apoptosis by the aforementioned stimuli 
(Roussigne, Cayrol et al. 2003).  Subsequent work from the same laboratory 
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revealed that THAP1, through modulation of pRb/E2F target genes, could also 
regulate the proliferation and cell cycle progression of vascular endothelial cells 
(Cayrol, Lacroix et al. 2007).  Knockdown of THAP1 using RNA interference 
reduced expression of several pRB/E2F target genes including RRM1 
(ribonucleotide reductase 1); a gene previously known to be required for S-phase 
DNA synthesis.  Subsequent chromatin immunoprecipitation and electrophoretic 
mobility shift assays demonstrated THAP1 bound to the RRM1 promoter at a 
DNA sequence highly similar to the previously characterized THABS consensus 
sequence, thereby providing the first report of a directly regulated endogenous 
THAP target gene (Cayrol, Lacroix et al. 2007).   
THAP1 has recently been identified as a genetic determinant for mixed-
onset primary torsion dystonia (DYT6 dystonia), a neurological disorder 
characterized by involuntary twisting movements and abnormal postures (Fuchs, 
Gavarini et al. 2009).  Various types of dystonia can be distinguished genetically 
with most inherited in an autosomal dominant manner with incomplete 
penetrance.  To identify the DYT6 gene, Fuchs et al. systematically sequenced 
genes in the DYT6 disease haplotype, a 23 cM region on chromosome 8 
previously linked to disease progression in affected Amish-Mennonite families.  
This approach identified two independent mutations within the THAP1 gene that 
co-segregated with affected individuals and obligate carriers.  The first mutation 
identified is an insertion/deletion mutation resulting in a frameshift at amino acid 
44 that further generates a premature stop codon at residue 73 (Fuchs, Gavarini 
et al. 2009).  This frameshift mutation likely results in a non-functional protein 
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owing to deletion of important DNA binding determinants within the THAP 
domain including zinc coordinating residues (Cys54, His57) and the AVPTIF box.  
The second isolated mutation encodes an F81L missense mutation within the 
conserved AVPTIF motif (Fuchs, Gavarini et al. 2009).  Importantly, Fuchs et al. 
demonstrated that the F81L mutant possessed substantially reduced affinity for 
the THAP1 consensus DNA element as determined by electrophoretic mobility 
shift assay.  These mutations suggest that DYT6 dystonia may manifest as a 
result of perturbation in a THAP1 dependent gene expression program.  
Identification and characterization of downstream THAP1 gene targets may 
provide both novel DYT6 therapeutic opportunities and important insights into the 
mechanism of THAP1 mediated transcriptional regulation. 
While the mechanism of THAP1 dependent transcriptional regulation is 
incompletely understood, work in our laboratory has described a detailed 
molecular mechanism by which THAP7 functions as a transcriptional repressor 
(Macfarlan, Kutney et al. 2005; Macfarlan, Parker et al. 2006).  THAP7 was 
isolated in a yeast two-hybrid screen while searching for interacting partners of 
TAF-1β (template activating factor-1β), a subunit of the INHAT (inhibitor of 
acetyltransferase) complex which represses activated transcription by precluding 
histone acetyltransferases access to their histone tail substrates (Seo, 
McNamara et al. 2001; Seo, Macfarlan et al. 2002; Macfarlan, Kutney et al. 
2005).  THAP7 was shown to associate with chromatin in intact cells through a 
THAP domain independent interaction with amino-terminal histone tails 
(Macfarlan, Kutney et al. 2005).  The histone tail binding activity of THAP7 was 
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found to reside within its C-terminal 77 amino acids and, similarly to TAF-1β, 
sensitive to the post-translational modifications of the histone tails (Macfarlan, 
Kutney et al. 2005).   
The preferential association of THAP7 with hypoacetylated histone H4 
tails suggested that THAP7 may transduce and/or establish a histone code 
amenable to transcriptional repression (Macfarlan, Kutney et al. 2005).  Indeed, 
when tethered to a transcriptionally active promoter as a Gal4-DNA binding 
domain fusion protein, THAP7 was found to potently repress transcription and 
concomitantly decrease histone acetylation at the targeted promoter (Macfarlan, 
Kutney et al. 2005; Macfarlan, Parker et al. 2006).  THAP7 dependent 
transcriptional repression was found to be partially sensitive to HDAC (histone 
deacetylase) inhibition and THAP7 was subsequently shown to interact directly 
with HDAC3 and the nuclear receptor co-repressor NCoR (Macfarlan, Kutney et 
al. 2005).  Domain mapping studies surprisingly revealed that the THAP domain 
of THAP7 was necessary and sufficient for HDAC3 association indicating that 
THAP domains can mediate both DNA and protein interactions (Macfarlan, 
Kutney et al. 2005).  While this initial characterization of THAP7 did not identify 
an endogenous target gene it nevertheless provided an important first realization 
that THAP proteins could function as transcriptional regulators.  Additionally, this 
work expanded the repertoire of THAP protein functionality to include protein-
protein as well as protein-DNA interactions.     
In addition to THAP1 and THAP7, recent work by our laboratory 
(presented herein) and others has demonstrated that THAP11 possesses 
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transcriptional repressor activity in several distinct biological contexts (Dejosez, 
Krumenacker et al. 2008; Zhu, Li et al. 2009).  Dejosez and co-workers identified 
THAP11 (termed Ronin) in a yeast two-hybrid assay designed to identify novel 
capase-3 targets which may play a role in maintaining embryonic stem cell 
pluripotency.  Mice bearing homozygous deletion of THAP11/Ronin were found 
to be embryonically lethal.  Further characterization of this phenotype revealed 
that the inner cell mass of THAP11 null blastocysts failed to proliferate when 
cultured in vitro while forced overexpression of THAP11 in embryonic stem cells 
prevented spontaneous differentiation upon culture in the absence of leukemia 
inhibitory factor (LIF), suggesting THAP11 functions in maintaining embryonic 
stem cell pluripotency and viability (Dejosez, Krumenacker et al. 2008).  Dejosez 
et al. hypothesized that the role of THAP11 in maintaining embryonic stem cell 
pluripotency may involve a transcriptional regulatory function similar to that 
observed with THAP1 and THAP7.  Gene expression profiling of embryonic stem 
cells transiently transfected with a THAP11 expression construct revealed a 
remarkable trend towards global transcriptional repression (Dejosez, 
Krumenacker et al. 2008).  Similarly, inducible expression of THAP11 under 
control of a doxycycline regulated promoter resulted in a sharp decrease in 
global nascent mRNA synthesis and a corresponding increase in the levels of 
histone H3 dimethyl-lysine 9 (H3K9me2), a histone modification correlated with 
transcriptional repression (Dejosez, Krumenacker et al. 2008).  Dejosez et al. 
reported specific increases in H3K9me2 in genomic regions upstream of GATA4 
and GATA6 coincident with THAP11 occupancy in undifferentiated embryonic 
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stem cells.  Since neither GATA4 nor GATA6 are expressed in undifferentiated 
embryonic stem cells, these results indicated that THAP11 may maintain 
embryonic stem cell pluripotency by transcriptional repression of differentiation 
associated genes through chromatin and epigenetic modifications (Dejosez, 
Krumenacker et al. 2008). 
Emerging data suggests THAP proteins may function in DNA and 
chromatin dependent processes.  However, the transcriptional regulatory 
properties of most human THAP proteins and their role in physiological 
processes are largely unknown.  The overall goal of this thesis work is to 
understand and characterize members of this recently identified protein family in 
regards to transcriptional regulation, cell function, and their potential roles in 
human disease.  To begin to elucidate the physiological role of THAP domain 
containing proteins, we performed a systematic survey of publicly available gene 
expression data to identify conditions of differential THAP protein expression.  
Using this approach, two datasets were identified which revealed increased 
THAP10 and THAP11 mRNA expression in human DNA damage and colon 
cancer progression, respectively.  THAP11 protein level was subsequently 
shown to correlate with disease progression in a panel of primary and metastatic 
human colon cancer specimens and cell lines.  In addition, both THAP10 and 
THAP11 were found to potently repress transcription as heterologous Gal4 DNA-
binding domain fusion proteins and directly associate with histone deacetylases 
(HDACs).  Furthermore, preliminary experiments with previously uncharacterized 
THAP4 and THAP8 also suggest these proteins repress transcription.      
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Experimental Procedures 
Plasmids and Cloning 
 Mammalian Gene Collection (MGC) verified full-length cDNA clones for 
human THAP4, 6, 8, 10 and 11 were purchased from Open Biosystems.  THAP 
protein coding sequences were PCR amplified from their respective MGC clone 
and inserted into mammalian expression vectors pCMX-PL1, pcDNA3.1(-) 
myc/his (Invitrogen) or p3xFLAG-CMV14 (Sigma) using standard molecular 
cloning procedures.  THAP proteins were also cloned into pCMX-Gal41-147 for use 
in Gal4 repression assays and pGEX-4T1 (GE Lifesciences) for use in bacterial 
protein expression.  Plasmids encoding pcDNA3.1(-)myc/his-HDAC1, -HDAC3, 
and -HDAC4 were described previously (Macfarlan, Kutney et al. 2005).  
pcDNA3.1(+) plasmids encoding FLAG epitope tagged HDAC1 (Addgene 
plasmid 13820), HDAC3 (Addgene plasmid 13819), HDAC4 (Addgene plasmid 
13821), and HDAC5 (Addgene plasmid 13822) generated in the laboratory of 
Eric Verdin were purchased from Addgene.  Reporter plasmids pRL-SV40 and 
p4xMH100-TKLuc were described previously (Macfarlan, Kutney et al. 2005) and 
pL8G5-Luc was provided by the laboratory of Roland Schüle with the permission 
of Saadi Khochbin.  Plasmids pCMV-Lex-HA (Addgene plasmid 14591) and 
pCMV-LexVP16-HA (Addgene plasmid 14593) generated in the laboratory of 
Matija Peterlin were purchased from Addgene.  Sequences of all recombinant 
constructs were verified by automated DNA sequencing. 
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Bacterial Protein Expression and Purification 
 Recombinant glutathione-S-transferase (GST), GST-THAP10, GST-
THAP11 or the indicated THAP11 truncation mutants were produced in 
Escherichia coli strain Rosetta-2 BL21(DE3) (Novagen) as previously described 
(Macfarlan, Kutney et al. 2005).  Induced GST fusion proteins were isolated from 
bacteria and purified according to the method of Frangioni and Neel with minor 
modifications (Frangioni and Neel 1993).  Briefly, bacterial cell pellets were 
washed once in ice-cold STE buffer (10mM Tris-HCl pH 8.0, 150mM NaCl, 1mM 
EDTA), resuspended in STE containing 0.2mg/ml lysozyme and incubated on ice 
for 15 minutes.  Protease inhibitors (Roche) were added as well as dithiothreitol 
to a final concentration of 5mM.  Sarkosyl was added to a final concentration of 
1.5% and the bacteria were lysed by sonication using a probe tip microsonicator 
(Misonix).  Lysates were clarified by centrifugation at 20,000 x g for 15 minutes at 
4°C.  Clarified lysates were adjusted to 2% Triton X-100 and incubated with 
glutathione sepharose for one hour at 4°C with gentle inversion.  Following 
incubation, glutathione sepharose was extensively washed with ice-cold PBS, 
resuspended in PBS supplemented with 1mM DTT and stored at 4°C short term.  
For long term storage GST fusion proteins were eluted with PBS containing 
20mM reduced glutathione and dialyzed at 4°C overnight against PBS containing 
1mM DTT.  Dialyzed proteins were adjusted to 20% glycerol, aliquoted and 
stored at -80°C.  Protein purity was assessed by SDS-PAGE and Coomassie 
Blue staining. 
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Generation and Purification of THAP11 Antibody 
A custom rabbit polyclonal antibody was generated against the carboxy-
terminus of human THAP11 (amino acids 132-313).  Recombinant GST-THAP11 
(132-313) was produced in E. coli and purified using glutathione sepharose as 
described above.  Protein was subjected to preparative scale SDS-PAGE and gel 
bands corresponding to GST-THAP11 (132-313) were excised and used as 
immunogen.  Animal immunizations and serum collection were performed by a 
commercial facility (Covance).  GST specific antibodies were depleted by 
passing crude serum over a crosslinked GST-glutathione sepharose column.  
Further affinity purification of anti-THAP11 antibodies was performed using 
immunogen immobilized on nitrocellulose as described elsewhere (Sambrook, 
Fritsch et al. 1989).  Briefly, one milligram of GST-THAP11 (132-313) was 
electrophoresed in a single-well SDS-PAGE gel and transferred to nitrocellulose.  
The nitrocellulose bound immunogen was identified by Ponceau S staining and 
excised.  The nitrocellulose strip was blocked for one hour with 3% bovine serum 
albumin (BSA) in PBS and then incubated overnight at 4°C  with one milliliter of 
anti-THAP11 antisera diluted (1:10) in PBS with 3% BSA.  The antibody solution 
was discarded and the nitrocellulose strip washed with 150mM sodium chloride 
for 20 minutes at room temperature and then with PBS for 20 minutes at room 
temperature.  The THAP11 antibody was eluted by incubating the nitrocellulose 
with 0.2M glycine pH 2.5, 1mM EGTA for 20 minutes at room temperature and 
immediately neutralized with 0.1 volume of 1M Tris-HCl pH 8.  One-tenth volume 
of 10x PBS was added to the affinity purified anti-THAP11 antibody which was 
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then concentrated by filtration using Microcon centrifugal filter devices according 
to manufacturer’s instructions (Millipore).          
Cell Culture and Treatment 
 Human cell lines HeLa (CCL-2), HepG2 (HB-8065), 293T/17 (CRL-
11268), Saos-2 (HTB-85), HT-29 (HTB-38), HCT-116 (CCL-247), SW480 (CCL-
228), SW620 (CCL-227) and Colo-320HSR (CCL-220.1) were purchased from 
the American Type Culture Collection (ATCC).  HT-29 and HCT-116 were 
maintained in McCoy’s 5A with 10% fetal bovine serum.   Colo-320HSR were 
grown in RPMI-1640 with 10% fetal bovine serum.  All other cells were 
maintained in Dulbecco’s modified eagle medium (high glucose) containing 10% 
fetal bovine serum.  Cells were maintained in a 37°C humidified incubator at 5% 
CO2.  To induce DNA damage, exponentially growing HeLa, HepG2, and Saos-2 
cells were treated with the indicated dose of camptothecin, etoposide or cisplatin 
(all purchased from Sigma unless otherwise noted) for 8 hours.  DNA damaging 
agents were dissolved immediately prior to use in DMSO.  Vehicle control and all 
serial dilutions contained equivalent amounts of DMSO (0.1%). 
Immunoblotting and Immunofluorescence 
 Whole cell extracts were prepared from subconfluent cells using modified 
RIPA buffer (20mM Tris-HCl pH 7.6, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
IGEPAL CA-630, 1% sodium deoxycholate, 0.25% SDS).  Nuclear and 
cytoplasmic extracts were prepared by the method described by Dignam et al 
(Dignam, Lebovitz et al. 1983).  Extracts were clarified by centrifugation at 
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20,000 x g for 15 minutes at 4°C and protein concentrations determined by BCA 
assay (Pierce).   
For Immunoblots, 30μg of whole cell or nuclear extracts were separated 
on precast 8-16% polyacrylamide gels (Invitrogen).  Protein was transferred to 
nitrocellulose membrane and stained with Ponceau S to confirm equal protein 
loading.  Membranes were then blocked in PBS containing 0.05% Tween-20 
(PBST) and 5% non-fat dry milk for one hour at room temperature.  Membranes 
were incubated with primary antibody overnight at 4°C in PBST with 5% non-fat 
dry milk.  Membranes were washed three times with PBST and incubated with 
the indicated secondary antibodies in PBST-5% non-fat dry milk for one hour at 
room temperature.  Membranes were again washed three times with PBST and 
developed with ECL plus chemiluminescence detection reagent (GE 
Lifescience).  Commercially available primary antibodies used for immunoblotting 
include:  β-actin (Sigma), FLAG M2 (Sigma) myc 9B11 (Cell Signaling), and 
Histone H3 (Abcam).  Horseradish peroxidase conjugated anti-mouse and anti-
rabbit secondary antibodies were purchased from Sigma. 
For indirect immunofluorescence, cells grown on glass coverslips were 
fixed with 4% paraformaldehyde in PBS for 10 minutes at room temperature.  
Fixed cells were rinsed three times with PBS and permeabilized with 0.2% Triton 
X-100 in PBS for 5 minutes at room temperature.  Coverslips were washed twice 
with PBS, blocked with PBS-10% BSA for 30 minutes at 37°C, and incubated 
with affinity purified anti-THAP11 (1:100) in PBS-3% BSA for one hour at 37°C.  
Coverslips were then washed three times with PBS and incubated with Alexa-
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488 conjugated anti-rabbit antibody (1:1000, Invitrogen) in PBS-3% BSA for one 
hour at 37°C.  Coverslips were again washed three times in PBS, counterstained 
with DAPI and mounted in Prolong antifade reagent (Invitrogen).  Samples were 
analyzed using a Zeiss LSM 510 META laser scanning confocal microscope.            
Immunohistochemistry and Tissue Microarrays 
 Tissue microarray slides prepared from formalin fixed, paraffin embedded 
samples were obtained from the Cooperative Human Tissue Network (National 
Cancer Institute).  Tissue microarrays were deparafinized in two changes of 
xylene and rehydrated in a graded alcohol series using standard procedures.  
Slides were subjected to heat-induced antigen retrieval by microwaving in citrate 
buffer (10mM Sodium Citrate, 0.05% Tween-20, pH 6.0) followed by blocking 
endogenous peroxidases with 3% hydrogen peroxide.  Immunohistochemical 
staining for THAP11 was performed using affinity purified anti-THAP11 antibody 
(1:100), Vectastain Elite ABC detection reagents, and DAB (3,3'-
diaminobenzidine tetrahydrochloride) substrate (Vector Laboratories).  
Hematoxylin and eosin counterstained slides were evaluated by an independent 
pathologist using a semi-quantitative dual-scoring system as described 
elsewhere (Wei, Chiriboga et al. 2006).  Briefly, the intensity of THAP11 
immunoreactivity was scored numerically (0=negative, 1=weak, 2=moderate, 
3=strong) as was the percentage of THAP11 immunopositive cells (0=0%, 1=1-
10%, 2=11-50%, 3=51-100%).  The scores for intensity and percent 
immunopositivity were added and samples categorized into low/weak expression 
(combined score ≤ 3) or high/strong expression (combined score > 3) groups.    
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GST Pulldown Assays 
Equivalent amounts of GST or the indicated GST-THAP proteins were 
bound to glutathione sepharose and equilibrated in 1ml of pulldown buffer (20mM 
Tris-HCl pH 7.6, 150mM KCl, 5mM MgCl2, 1mM DTT, 10μg/ml BSA, and 0.5% 
IGEPAL CA-630).  In vitro translated radiolabeled histone deacetylases (HDACs) 
were produced using the TNT-T7 coupled in vitro transcription/translation system 
(Promega) with 35S-methionine according to manufacturer’s instructions.  35S-
labeled HDAC was added to the GST proteins in pulldown buffer and incubated 
for one hour at room temperature with gentle inversion.  Beads were then 
washed three times in pulldown buffer and once in pulldown buffer without BSA.  
Bound proteins were eluted by boiling in 2x Laemmli sample buffer and resolved 
by SDS-PAGE.  Gels were fixed and dried, and radiolabeled HDAC was detected 
by autoradiography.        
Co-immunoprecipitation 
 293T/17 cells in 10cm2 tissue culture dishes were co-transfected with 2μg 
each of the indicated pcDNA3.1-HDAC (FLAG or myc-his tagged) construct and 
either pCMX-THAP11 or p3xFLAG-THAP10 using Lipofectamine 2000 according 
to manufacturer’s instructions.  Twenty-four hours after transfection, cell 
monolayers were rinsed three times with ice-cold PBS, scraped into PBS and 
pelleted by centrifugation at 500 x g for five minutes at 4°C.  Cells were then 
lysed in 1ml of EBC buffer (50mM Tris-HCl pH 7.6, 125mM NaCl, 1mM EDTA, 
0.5% IGEPAL CA-630) for 15 minutes at 4°C with gentle inversion.  Whole cell 
extracts were clarified by centrifugation at 20,000 x g for 15 minutes at 4°C.  
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Immunoprecipitations were performed with 1μg of either anti-FLAG M2 (Sigma) 
or anti-myc 9B11 (Cell Signaling) monoclonal antibodies for 4 hours at 4°C with 
inversion.  Protein G agarose (20μl packed beads) was added and 
immunoprecipitations allowed to proceed for an additional two hours.  Beads 
were then washed three times with EBC buffer and bound proteins eluted by 
boiling in 2x Laemmli buffer.  Proteins were resolved by SDS-PAGE, transferred 
to nitrocellulose membrane and immunoblotted as described above with 
indicated antibodies. 
RNA Isolation and Quantitative RT-PCR 
Total RNA was extracted using Qiagen RNeasy Mini or 96-well kits.  
Isolated RNA was then subjected to quantitative real-time RT-PCR using an ABI 
PRISM 7900HT 384-well real time PCR machine, TaqMan one-step RT-PCR kit 
and pre-developed primers/TaqMan probe mixes for β-actin, p21, p53, 
GADD45A, THAP1, THAP4, THAP7, THAP10, and THAP11 (Applied 
Biosystems). 
Gal4 Repression Assay 
For repression of basal transcription, 293T/17 cells in 48-well tissue 
culture plates were co-transfected with p4xMH100-TKLuc (100ng), pRL-SV40 
(5ng), and the indicated Gal4-DBD fusion protein at 1, 5, or 25ng plasmid DNA 
using Lipofectamine 2000 according to manufacturer’s instructions.  Repression 
of VP16 activator driven transcription was performed similarly except pL8G5-Luc 
was substituted for p4xMH100-TKLuc and pCMV-Lex-HA or pCMV-LexVP16-HA 
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(5ng) were included as indicated.  Empty pCMX-PL1 plasmid was added where 
necessary to maintain equal DNA amounts.  The reported DNA amounts 
represent quantity transfected per 6-wells, or one column of the 48-well plate.  
Luciferase activities were measured 24 hours after transfection using the Dual 
Luciferase Assay kit (Promega) according to manufacturer’s instructions. 
Results 
THAP10 Expression is Induced by DNA Damage 
 Increased THAP10 gene expression was noted in a microarray dataset 
characterizing the gene expression profile of HeLa cells treated with the 
topoisomerase poison camptothecin (Carson, Zhang et al. 2004).  To confirm 
and extend this finding, we treated HeLa cells with camptothecin, etoposide and 
cisplatin and examined the mRNA levels of THAP10, p21, and GADD45A by 
quantitative RT-PCR.  As shown in Figure 2.2A, THAP10 mRNA levels were 
induced in a dose dependent manner by each DNA damaging drug with 
camptothecin being the most sensitive.  The dose dependent induction of 
THAP10 mRNA by camptothecin closely correlated with the induction of 
apoptosis as evidenced by immunoblotting for PARP cleavage (Figure 2.2B), 
suggesting THAP10 may be involved in DNA damage dependent apoptosis.  
Importantly, the relative level of THAP10 mRNA induction by each treatment was 
comparable to that observed with prototypical DNA damage inducible genes p21 
and GADD45A.  HeLa cells are considered to have an attenuated p53 dependent 
response to DNA damage due to the presence of the human papillomavirus E6 
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oncogene, which accelerates proteasome mediated degradation of p53 protein 
(Scheffner, Werness et al. 1990).  Therefore, we also examined the DNA 
damage dependent induction of THAP10 mRNA in cells with wild-type p53 
(HepG2) or null p53 (Saos-2) status.  Treatment of HepG2 cells under identical 
conditions as HeLa cells yielded similar results for both THAP10 and GADD45A 
gene expression (Figure 2.3A).  However, p21 expression was markedly 
enhanced in HepG2 despite both GADD45A and p21 being well-characterized 
p53 target genes.  When performed in p53-null Saos-2 cells, treatment with DNA 
damaging agents failed to appreciably increase the mRNA levels of THAP10, 
p21, or GADD45A (Figure 2.3B).  To determine if the p53-null status of Saos-2 
cells was at least partially responsible for the lack of THAP10 mRNA induction, 
these cells were transiently transfected with wildtype p53 and assayed for 
THAP10 and p21 mRNA levels.  As shown in Figure 2.4A, ectopic expression of 
p53 alone was sufficient to robustly increase THAP10 (as well as p21) mRNA 
levels.  Taken together, these results suggest that THAP10 mRNA induction by 
DNA damage may be partially dependent on p53 and suggests that THAP10 
may play a role in the transcriptional response to DNA damage.    
THAP11 Expression in a Cell Culture Model of Colon Cancer Progression 
Increased THAP11 mRNA expression was identified in a microarray 
dataset originally designed to elucidate gene expression differences in the 
SW480/SW620 cell culture model of colon cancer progression (Provenzani, 
Fronza et al. 2006).  SW480 and SW620 cells are isogenic colon carcinoma 
derived cell lines isolated from a single patient at different stages of disease 
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progression (Hewitt, McMarlin et al. 2000).  SW480 cells were established from 
the primary colon adenocarcinoma while SW620 were derived from a 
subsequent lymph node metastasis (Hewitt, McMarlin et al. 2000).  Accordingly, 
SW480 and SW620 cells are a frequently used model system to study the 
molecular underpinnings associated with colon cancer progression.  We 
therefore reasoned that SW480/SW620 cells may also provide an ideal cell 
culture system to further evaluate THAP11 function.   
To corroborate the microarray finding, we prepared total RNA and whole 
cell extracts from exponentially growing SW480 and SW620 cells and 
determined the relative amount of THAP11 mRNA and protein by quantitative 
RT-PCR and immunoblotting, respectively.  While both cell types express 
THAP11, SW620 cells express approximately 4-fold more THAP11 mRNA than 
SW480 cells (Figure 2.5A).  Consistent with elevated THAP11 mRNA levels, 
SW620 cells also demonstrated marked increases in THAP11 protein relative to 
SW480 cells (Figure 2.5B).  Immunofluorescence analysis showed endogenous 
THAP11 to be located almost exclusively within the nucleus (Figure 2.5C) 
consistent with a potential function in DNA/chromatin dependent processes 
including transcriptional regulation.  Examination of additional colon cancer cell 
lines by immunoblotting of nuclear extracts revealed weak but detectable levels 
of THAP11 in HCT-116 and HT29 cells (Figure 2.6).  In contrast, Colo320HSR 
cells contained nearly as much THAP11 protein as SW620 cells (Figure 2.6).  
These results suggest that gain of THAP11 expression may play a role in colon 
cancer cell function.      
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THAP11 Expression is Correlated with Colon Cancer Progression 
We next examined a large number of human colon cancer specimens to 
determine if the potential link between THAP11 expression and disease 
progression extends beyond colon cancer cell lines.  Immunohistochemical 
analysis of THAP11 expression in human colon cancer tissue microarrays 
revealed a close correlation between increased THAP11 immunoreactivity and 
disease progression (Figure 2.7).  The majority of samples from normal colonic 
epithelium (n=33) and benign adenomas (n=7) stained both weak and 
infrequently for THAP11 (Figure 2.7, panel N).  An increase in THAP11 staining 
frequency and intensity was progressively observed in low-grade (grade I, well-
differentiated) to high-grade (grade III, poorly differentiated) colon 
adenocarcinomas (n=133) (Figure 2.7 compare panels gI to gII and gIII).  
Frequent, high-intensity THAP11 staining was observed in both liver (n=3) and 
lymph node metastases (n=37) (Figure 2.7 panels LM and LNM) consistent with 
elevated THAP11 in metastatic colon cancer derived SW620 cells.  A quantitative 
assessment of THAP11 immunoreactivity in all tissue microarray samples using 
a dual-scoring system accounting for both staining frequency and intensity 
revealed a statistically significant increase in THAP11 expression in primary 
malignant adenocarcinomas and metastases compared with normal 
tissues/benign adenomas (Figure 2.7B).  Taken together, these data 
demonstrate that increased THAP11 expression correlates with colon cancer 
progression and suggests that SW620 cells may represent a tractable model to 
evaluate the function of THAP11 in colon cancer. 
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THAP10 and THAP11 Repress Transcription 
Previous work in our laboratory identified THAP7 as a novel transcriptional 
repressor (Macfarlan, Kutney et al. 2005).  THAP7 mediated repression was 
shown to be at least partially mediated through a THAP domain dependent 
association with HDAC3 (Macfarlan, Kutney et al. 2005). To ascertain whether 
THAP10 and THAP11 also possess transcriptional repressor function, we 
determined the effect of Gal4 DNA-binding domain THAP protein fusions on the 
activity of a luciferase reporter construct harboring four copies of a GAL4 DNA 
binding site in front of the minimal thymidine kinase promoter (p4xMH100-TK-
Luc) (Figure 2.8A).  Consistent with our previous THAP7 data, both THAP10 and 
THAP11 significantly repressed basal transcription as promoter targeted Gal4 
fusions (Figure 2.8B) while Gal4 DNA-binding domain alone weakly stimulated 
transcription (data not shown) as reported elsewhere (Hublitz, Kunowska et al. 
2005).  Importantly both Gal4-THAP10 and Gal4-THAP11 revealed a dose 
dependent transcriptional repression activity comparable to the well-
characterized nuclear hormone receptor co-repressors NCoR and SMRT 
suggesting that the extent of THAP10/11 transcriptional repressor function is 
likely to be biologically relevant.  To determine if THAP10 and THAP11 can also 
repress activator driven transcription, we performed transient transfection assays 
using a luciferase reporter containing both LexA and Gal4 binding sites (Figure 
2.8C).  LexA-VP16 mediated transcriptional activation was significantly 
abrogated by co-transfection with either Gal4-THAP10 or Gal4-THAP11 (Figure 
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2.8D) but not Gal4 DNA-binding domain alone (data not shown).  Finally, we 
wished to determine if additional THAP domain proteins also possess 
transcriptional repressor activity.  Gal4-DBD fusions of human THAP4, and 
THAP8 but not THAP6 repressed basal transcription from p4xMH100-TKLuc 
when transiently transfected in 293T/17 cells (Figure 2.9).  Taken together, these 
data indicate that THAP10 and THAP11, like THAP7, can potently repress both 
basal and activated transcription.  Furthermore, despite limited sequence 
homology, several THAP domain proteins display transcriptional repressor 
activity when artificially tethered to promoters as Gal4 DNA binding domain 
fusions.  These studies, together with previous results, strongly suggest that the 
human THAP family members may exert their physiologic effect by functioning as 
transcriptional repressors.   
THAP10 and THAP11 Associate with HDACs 
Since THAP10 and THAP11 repress transcription similarly to THAP7, we 
next addressed whether these THAP proteins can also associate with histone 
deacetylases, thereby providing a potential mechanism for THAP10/THAP11 
mediated transcriptional repression.  For this purpose, THAP11 and FLAG-
tagged HDACs were transiently transfected in 293T/17 cells and THAP11/HDAC 
in vivo association assessed by co-immunoprecipitation.  The class I histone 
deacetylases HDAC1 and HDAC3 were found to specifically co-precipitate 
THAP11 while class II HDACs, HDAC4 and 5 did not (Figure 2.10A).  
Additionally, HDAC1 and HDAC3 but not HDAC4 were found to directly associate 
with THAP11 in GST pull down assays using bacterially expressed GST-THAP11 
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and in vitro transcribed/translated 35S-labeled HDAC (Figure 2.10B).  Aside from 
the THAP domain, THAP11 also contains poly-glutamine and coiled-coil motifs 
(Figure 2.10C), either of which may be capable of interacting with histone 
deacetylases.  To determine the HDAC interacting region of THAP11 we 
repeated the GST pull down assay using either full-length (FL) GST-THAP11 or 
amino acid truncation mutants 1-90 and 91-314.  Relative to full-length protein, 
GST-THAP11 (1-90) showed slightly enhanced binding to HDAC3 while GST-
THAP11 (91-314) showed significantly diminished association (Figure 2.10D) 
indicating the THAP domain is likely the primary HDAC3 interacting motif of 
THAP11.  Similarly, THAP10 was also found to specifically co-precipitate with 
myc-tagged HDAC1 and HDAC3, but not HDAC4 in 293T/17 cells under identical 
transfection and immunoprecipitation conditions (Figure 2.11A).  Additionally, 
THAP10 was also found to associate directly with HDAC1 and HDAC3 by GST 
pulldown assay (Figure 2.11B).  These data indicate that THAP domains may 
function as HDAC interacting modules in addition to their role as sequence 
specific DNA binding domains. 
Discussion 
 Human THAP proteins have been suggested to function in DNA and 
chromatin dependent processes, including transcription.  However, the 
transcriptional regulatory properties of most human THAP proteins have not been 
reported.  In this chapter, we provide evidence to suggest that multiple human 
THAP proteins possess transcriptional repressor activity.  In addition, novel 
biological contexts within which to evaluate THAP protein transcriptional 
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repression were identified.  THAP10 was found to be DNA damage inducible 
while THAP11 expression was shown to correlate with colon cancer progression 
in human primary tumor specimens and cell lines. 
 Previous work from our laboratory has shown that THAP7 is 
transcriptionally repressive when artificially targeted to a promoter as a 
heterologous Gal4-DNA binding domain (Gal4-DBD) fusion protein (Macfarlan, 
Kutney et al. 2005).  The work described here extends this approach to 
demonstrate that Gal4-DBD fusions of THAP4, THAP8, THAP10, and THAP11 
repress basal transcription.  In addition, Gal4-THAP10 and Gal4-THAP11 also 
significantly blunted activator driven transcription resulting from simultaneous 
targeting of a LexA-DBD VP16 transactivation domain fusion protein.   In both 
instances, the extent of THAP10 and THAP11 mediated transcriptional 
repression was comparable to that observed with Gal4-DBD fusions of nuclear 
hormone receptor co-repressors NCoR and SMRT.  Since NCoR and SMRT 
have well characterized roles in transcriptional repression, similar findings with 
THAP proteins under identical assays conditions suggests that THAP protein 
mediated repression is likely to be biologically meaningful. 
 A caveat to this is the relevance of the Gal4-DBD system to assess the 
transcriptional regulatory properties of THAP proteins.  Gal4-DBD fusion proteins 
have been used extensively to successfully elucidate the transcriptional 
regulatory mechanisms of various DNA-binding or chromatin associated factors 
(Chen and Bieker 2001; Ishizuka and Lazar 2003; Hublitz, Kunowska et al. 2005; 
Sun, Yu et al. 2007; Pasini, Hansen et al. 2008).  Importantly, while the Gal4-
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THAP protein fusions described here repress transcription, a recent report from 
Mazars et al. demonstrates that Gal4-THAP3 activates transcription (Mazars, 
Gonzalez-de-Peredo et al. 2010).  This indicates that the Gal4-THAP mediated 
repression reported here is likely specific to these THAP proteins and not a 
general phenomenon associated with Gal4-THAP fusion proteins.  Nevertheless, 
definitive proof of THAP protein mediated transcriptional regulation undoubtedly 
requires additional experiments to identify directly regulated endogenous gene 
targets, as described for THAP11 in chapter 3 of this thesis. 
 Consistent with their role as transcriptional repressors, THAP10 and 
THAP11 were both found to physically associate with histone deacetylases 
HDAC1 and HDAC3.  THAP10 and THAP11 co-precipitated with HDAC1 and 
HDAC3 from transfected cells and GST-pulldown experiments suggested this 
interaction was direct.  It remains to be determined whether endogenous HDACs 
are also associated with THAP10 and THAP11.  Nonetheless, in vitro domain 
mapping studies identified the THAP domain of THAP11 as the primary 
determinant of interaction with HDAC3.  These results are strikingly similar to 
those reported previously for THAP7 and suggest that the THAP zinc-finger, like 
C2-H2 zinc-fingers, may function in protein-protein interactions in addition to 
sequence specific DNA binding (Brayer and Segal 2008).  THAP domains display 
low primary sequence identity but, as discussed previously, adopt similar folded 
structures which may account for the conservation of HDAC interaction amongst 
THAP7, THAP10, and THAP11.  Mutation of conserved zinc-coordinating or 
invariant residues has previously been shown to disrupt the THAP domain fold 
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and abolish sequence specific DNA binding (Clouaire, Roussigne et al. 2005).  
Use of recombinant THAP proteins harboring these mutations in future 
interaction studies may reveal a similar defect in HDAC binding. 
 We performed a meta-analysis of published gene expression datasets to 
identify conditions of differential THAP protein expression that may also suggest 
conditions of biological relevance.  This approach identified THAP10 as a DNA 
damage inducible transcript following treatment of HeLa cells with the 
topoisomerase poison camptothecin (Carson, Zhang et al. 2004).  We extended 
this finding to additional DNA damaging chemotherapeutics (etoposide, cis-
platin) and cell lines (HepG2).  Induction of THAP10 mRNA by DNA damage was 
compromised in p53-null Saos-2 cells and restoration of p53 by transient 
transfection was sufficient to markedly induce THAP10 mRNA.  Bioinformatic 
analysis of the THAP10 promoter failed to identify any high-probability p53 
binding sites (data not shown). However, a recent genome-wide screen for 
chromatin bound p53 in 5-fluorouracil treated HCT-116 cells identified p53 bound 
in the first intron of THAP10, approximately 2.8kb downstream of the 
transcription start site (Wei, Wu et al. 2006).  The relevance of this p53 bound 
region in regulating THAP10 DNA damage induction is currently unknown but 
suggests a potential for direct p53 mediated transcriptional activation.  Indirect or 
p53 independent mechanisms may also contribute to THAP10 mRNA induction 
following DNA damage.  For instance, ectopic expression of p53 in Saos-2 cells 
has previously been demonstrated to activate NF-κB as has camptothecin 
treatment of HeLa cells (Ryan, Ernst et al. 2000; Carson, Zhang et al. 2004).  
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Thus, multiple factors may contribute to THAP10 mRNA induction by DNA 
damaging agents and future experiments will be required to identify the 
necessary factor(s). 
 The status of endogenous THAP10 protein levels during DNA damage 
remains to be determined.  In our attempt to address this question, several 
polyclonal antibodies were raised against human THAP10.  Unfortunately, each 
custom antibody failed to detect endogenous or transiently transfected, 
overexpressed THAP10.  The insufficient quality of our custom antibodies and 
the current lack of commercial anti-THAP10 antibodies have significantly 
hampered our efforts to characterize endogenous THAP10.  Nevertheless, the 
existence of endogenous THAP10 has recently been reported in a proteomic 
screen searching for nuclear proteins differentially phosphorylated by EGF 
stimulation (Olsen, Blagoev et al. 2006).  Several phosphopeptides 
corresponding to the C-terminal portion of THAP10 were identified but not 
differentially phosphorylated by EGF treatment (Olsen, Blagoev et al. 2006). 
 If, as expected, endogenous THAP10 protein levels do increase during 
DNA damage then THAP10 dependent transcriptional repression may constitute 
a previously unrecognized component of the DNA damage response gene 
expression program.  Future studies should determine the gene targets of 
THAP10 under normal and DNA damage conditions, as well as the contribution 
of THAP10 mediated transcriptional repression to cell cycle arrest and apoptosis 
resulting from genotoxic insults.   
 49
The THAP10 gene is conserved in human and non-human primates, 
present in the marsupial Monodelphis domestica (grey short-tailed opossum) but 
absent in rodents.  Placental (eutherian) and marsupial (metatherian) mammals 
diverged 180 million years ago while rodents 40 million years ago, suggesting 
THAP10 was present in a shared ancestor but has since been lost in mouse and 
rat (Mikkelsen, Wakefield et al. 2007).  Consistent with this explanation is a 
deletion in mouse chromosome 9 between syntenic genes Lrrc49 and Larp6 
which, in the human genome, contains THAP10 (data not shown).  Accordingly, 
we speculate that THAP10 may either provide a functionally redundant role in 
humans or its loss compensated for in rodents. 
THAP11 was identified in a microarray dataset characterizing gene 
expression differences in the isogenic SW480/SW620 cell culture model of colon 
cancer progression.  THAP11 mRNA and protein levels were found be increased 
in metastatic SW620 cells versus primary tumor derived SW480 cells.  Elevated 
THAP11 protein levels were also found in the neuroendocrine colon carcinoma 
Colo320HSR and the metastasis derived LoVo cell line (data not shown) but 
other colon cancer cell lines exhibited markedly reduced, albeit detectable, 
THAP11 protein. 
THAP11 expression was also found to positively correlate with disease 
progression in human primary tumor specimens as determined by 
immunohistochemical analysis of tissue microarrays.  THAP11 immunoreactivity 
was largely absent in normal colonic epithelia but significantly increased in low- 
to high-grade carcinomas and metastases.  THAP11 immunoreactivity at 
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metastatic sites was only slightly greater than that observed at primary tumors 
suggesting the THAP11 gain-of-function event likely occurs within the primary 
tumor and persists following metastasis dissemination and metastatic site 
colonization.   
The contribution of THAP11 towards promoting primary tumor formation or 
distant metastasis remains an unanswered but pertinent question.  Gain of 
THAP11 expression in colon cancer may, via THAP11 mediated transcriptional 
repression, contribute to disease progression.  A similar scenario has been 
proposed for the E-box binding transcriptional repressors Snail and Zeb1.  
Increased expression of Snail and Zeb1 in colon cancer cells has previously 
been shown to affect tumorigenic and metastatic potential by repressing gene 
products associated with differentiated epithelial cells (Peinado, Olmeda et al. 
2007).  Alternatively, THAP11 may represent a “bystander gene” where 
increased expression in colon cancer results from, rather than drives, disease 
progression.  Discriminating between these possibilities will likely require multiple 
lines of further experimentation.  Cell based in vitro and nude mouse tumor 
xenograft assays using both THAP11 overexpression and RNA interference 
mediated knockdown in colon cancer cell lines should prove valuable in 
determining if THAP11 plays a functional role in colon cancer progression.  Initial 
results utilizing THAP11 knockdown in SW620 cells are described in chapter 3 of 
this thesis.   
While this work was in progress, two independent reports implicated 
THAP11 as a biologically relevant transcriptional repressor (Dejosez, 
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Krumenacker et al. 2008; Zhu, Li et al. 2009).  Zhu et al. reported that human 
THAP11 was ubiquitously expressed and largely downregulated in several 
human cancers including liver cancer (Zhu, Li et al. 2009).  This finding contrasts 
with our observations and may represent a tissue specific role for THAP11 in 
human liver versus colon cancers.  In addition, their assertion that THAP11 is 
ubiquitously expressed and repressed in human liver cancer was based solely on 
mRNA expression data and may not accurately reflect THAP11 protein status.  
Furthermore, close inspection of the THAP11 expression data from their multiple 
tissue northern blot array (Fig.1 in Zhu et al.) suggests elevated THAP11 mRNA 
in several tumor versus normal colon tissues, consistent with our 
immunohistochemistry results.  Additional conflicting data regarding the tissue 
distribution of THAP11 was also recently reported by Dejosez et al. who found 
detectable THAP11 (termed Ronin) mRNA in mouse ES cells but not adult 
tissues (Dejosez, Krumenacker et al. 2008).  Preliminary data generated by other 
members of our laboratory and not presented in this thesis demonstrates 
detectable THAP11 protein in nuclear extracts from human cancer cell lines of 
diverse origin including breast, prostate, ovary, uterus, and both T- and B-cell 
leukemia.  Whether this expression pattern represents the cancerous origin of 
these cells or reflects a species specific THAP11 expression pattern, as 
suggested by Zhu et al., remains to be determined.   
In agreement with our work, both recent THAP11 reports further 
substantiate our finding that THAP11 is a transcriptional repressor (Dejosez, 
Krumenacker et al. 2008; Zhu, Li et al. 2009).  Dejosez et al. used an in vitro 
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selection procedure to demonstrate that THAP11/Ronin could bind DNA directly 
and also found that overexpressed THAP11/Ronin repressed global transcription 
in mouse ES cells.  Zhu et al. reported that overexpressed THAP11 directly 
repressed c-myc transcription in the human HepG2 cells.  These findings, in 
conjunction with our results, provide substantial evidence to suggest that 
THAP11 likely functions as a transcriptional repressor. 
The data presented in this chapter provides important new evidence that 
further implicates THAP proteins in transcriptional regulation.  Several previously 
uncharacterized THAP proteins, including THAP10 and THAP11, were found to 
repress transcription.  THAP10 and THAP11 were shown to be differentially 
expressed during DNA damage and colon cancer progression, respectively, 
suggesting THAP protein relevance to human disease.  Future studies aimed at 
determining the function of THAP10 in DNA damage, THAP11 in colon cancer, 
and identification of their endogenous gene targets are currently underway in our 
laboratory and will be important new avenues of THAP protein research. 
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Figure 2.1:  Human THAP domain containing proteins.  (A) Schematic of human THAP proteins.  The N-terminally 
located THAP domains are indicated by the gray boxes.  Coiled-coil motifs present in THAP1-7 and THAP11 are indicated 
by black boxes.  The location of the poly-glutamine rich region of THAP11 and the extended region of P element 
transposase homology in THAP9 are indicated by red and blue boxes, respectively.  Adapted and re-drawn from (Mazars, 
Gonzalez-de-Peredo et al. 2010).(B)  Multiple sequence alignment of human THAP proteins.  Invariant residues are 
indicated by asterisks and the AVPTIF box is indicated with a bracket.    
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 Table 2.1:  THAP proteins in model organisms. 
  
Adapted from (Clouaire, Roussigne et al. 2005).
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Figure 2.2:  THAP10 mRNA is DNA damage inducible.  (A)  HeLa cells were treated with the indicated DNA damaging 
agent for 8 hours and THAP10 mRNA levels determined by quantitative RT-PCR.  Values represent the mean ± standard 
deviation of cells treated in quadruplicate.  (B)  HeLa cells were treated with increasing amounts of camptothecin as in (A) 
and apoptosis determined by immunoblotting for cleaved PARP. 
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Figure 2.3:  THAP10 mRNA induction by DNA damage in HepG2 and Saos-2 cells.  (A)  HepG2 and (B) Saos-2 cells 
were treated with the indicated DNA damaging agent for 8 hours and THAP10 mRNA levels determined by quantitative 
RT-PCR.  Values represent the mean ± standard deviation of cells treated in quadruplicate. 
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Figure 2.4:  Ecotopic p53 expression induces THAP10 mRNA.  (A) Saos-2 cells were transfected with either empty or 
p53 expression vector (2ug per well in a six-well plate) and analyzed for THAP10 and p21 mRNA levels by quantitative 
RT-PCR 24 hours later.  RNA levels are normalized to β-actin and expressed as fold change relative to empty vector 
transfected cells.  Values represent the mean ± standard deviation from three transfected wells from a representative 
experiment performed at least three times.  (B)  Immunoblot from cells transfected as in (A) indicating ectopic p53 
expression and resulting p21 upregulation.  
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Figure 2.5:  THAP11 expression in SW480 and SW620 colon cancer cell lines.  (A)  THAP11 mRNA levels in SW480 
and SW620 cells were determined by quantitative RT-PCR. THAP11 mRNA levels were normalized to β-actin and 
expressed relative to SW480.  Values represent the mean ± standard deviation of triplicate quantitative RT-PCR reactions 
from a representative experiment performed at least three times. (B)  THAP11 protein levels were determined by 
immunoblotting whole cell extracts from SW480 and SW620 cells using a custom polyclonal THAP11 antibody.  
Immunoblotting for β-actin served as a loading control.  (C) Immunofluoresence localization of endogenous THAP11 in 
SW620 cells.  THAP11 was detected in SW620 cells by indirect immunofluoresence using an affinity purified custom 
polyclonal THAP11 antibody as described in Experimental Procedures.  Nuclei were identified by counterstaining with 
DAPI and cells were visualized by differential interference contrast (DIC) microscopy.  Merge represents the overlay of 
THAP11, DAPI, and DIC images. 
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Figure 2.6:  THAP11 expression in colon cancer cell lines.  THAP11 protein levels were determined by 
immunoblotting nuclear extracts from the indicated colon cancer cell lines using a custom polyclonal THAP11 antibody.  
Immunoblotting for histone H3 served as a loading control. 
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Figure 2.7:  Immunohistochemical analysis of THAP11 expression in humor colon cancer specimens.  (A)  
Representative images of THAP11 immunohistochemical staining in normal colon epithelium (N), grade I (gI), grade II 
(gII), grade III (gIII) adenocarcinomas and metastases from liver (LM) and lymph node (LNM).  (B) Quantitative analysis of 
THAP11 expression in tissue microarray (TMA) samples.  THAP11 immunoreactivity was scored as described in 
Experimental Procedures and samples were placed into either high/strong (>3) or low/weak (≤3) THAP11 expression 
groups.  Asterisk (*) denotes statistical significance (p<0.05) relative to normal/adenoma as determined by T-test.   
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Figure 2.8:  THAP10 and THAP11 repress basal and activated transcription.  (A) Schematic of p4xMH100 luciferase 
reporter used to determine repression of basal transcription by Gal4DBD-fusion proteins. The luciferase reporter, minimal 
thymidine kinase promoter (TK) and four copies of the MH100 Gal4 upstream activating sequence (Gal4) are indicated.  
(B)  293T/17 cells in 48-well plates were co-transfected with 100ng of p4xMH100-TK-Luc, 5ng of pRL-SV40, and the 
indicated Gal4DBD-fusion expression vector as described in Experimental Procedures.  Cells were processed for dual 
luciferase assay 24 hours later and luciferase activity expressed relative to empty vector transfected cells. (C) Schematic 
of pL8G5 luciferase reporter used to determine repression of activated transcription by Gal4DBD-fusion proteins.  The 
luciferase reporter, TATA-box (TATA), five copies of Gal4 upstream activating sequence (Gal4), and eight copies of LexA 
binding sites (LexA) are indicated. 293T/17 cells in 48-well plates were co-transfected with 100ng of pL8G5-Luc, 5ng of 
pRL-SV40, 5ng of the indicated LexA expression vector and 1, 5, or 25ng of the indicated Gal4-THAP fusion protein as 
described in Experimental Procedures.  Cells were processed for dual luciferase assay 24 hours later and luciferase 
activity expressed relative to LexA-VP16 transfected cells. Values represent the mean ± standard deviation from 6 wells 
per condition of a representative experiment performed at least three times with similar results. 
 62
THAP6
0 1 5 25
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Transfected DNA (ng/6-wells)
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
A B 
C 
THAP8
0 1 5 25
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Transfected DNA (ng/6-wells)
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
THAP4
0 1 5 25
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Transfected DNA (ng/6-wells)
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 
Figure 2.9:  Transcriptional regulatory properties of THAP4, THAP6, and THAP8.  293T/17 cells in 48-well plates 
were co-transfected with 100ng of p4xMH100-TK-Luc, 5ng of pRL-SV40, and the indicated amounts of Gal4-THAP4 (A), 
Gal4-THAP6 (B) or Gal4-THAP8 (C) expression vectors as described in Experimental Procedures.   Cells were processed 
for dual luciferase assay 24 hours later and luciferase activity expressed relative to empty vector transfected cells.  Values 
represent the mean ± standard deviation from 6 wells per condition of a representative experiment performed at least 
three times with similar results. 
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Figure 2.10:  THAP11 associates with HDACs.  (A) THAP11 co-immunoprecipitates with HDAC1 and HDAC3.  293T/17 
cells were transfected with expression plasmids for THAP11 and the indicated FLAG-HDAC or empty vector (2μg each).  
Whole cell extracts were immunoprecipitated (IP) with anti-FLAG M2 monoclonal antibody and immunoblotted (IB) with 
anti-THAP11 antibody.  Whole cell extracts corresponding to 2% of input material (Input) were analyzed on a parallel blot.  
Blots were stripped and reprobed with anti-FLAG to reveal HDACs. IgG heavy-chain is indicated by the arrow. (B) 
THAP11 associates with HDAC1 and HDAC3 in vitro.  (Left panel) Coomassie Blue stained SDS-PAGE gel of 
recombinant GST and GST-THAP11 (GST-T11) used in GST-pulldown assay.  (Right panel) GST and GST-THAP11 
were incubated with in vitro transcribed and translated 35S-labeled HDAC1, HDAC3, and HDAC4.  Bound radiolabeled 
HDACs were resolved by SDS-PAGE and detected by autoradiography.  Input corresponds to 10% of starting material.  
(C)  Schematic of THAP11. THAP, poly-glutamine (Q), and coiled-coil motifs of THAP11.  Numbers below each motif 
correspond to the amino acid residues.  (D)  THAP domain is necessary and sufficient for HDAC interaction.  (Left panel) 
Coomassie Blue stained SDS-PAGE gel of GST and the indicated GST-THAP11 fusion protein:  full-length (FL), amino 
acids 1-90 (1-90) and amino acids (91-314).  (Right panel)  GST-pulldown assay using the indicated GST-THAP11 fusion 
protein was performed using 35S-labeled HDAC3 as described in (B). 
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Figure 2.11:  THAP10 associates with HDACs.  (A) THAP10 co-immunoprecipitates with HDAC1 and HDAC3.  293T/17 
cells were transfected with expression plasmids for THAP10-3xFLAG and the indicated myc-HDAC or empty vector (2μg 
each).  Whole cell extracts were immunoprecipitated (IP)  with anti-myc 9B11 monoclonal antibody and immunoblotted 
(IB) with anti-FLAG antibody to detect co-precipitated THAP10.  IgG heavy-chain is indicated by the arrow.  Whole cell 
extracts corresponding to 2% of input material (Input) were analyzed on a parallel blot.  Blots were stripped and reprobed 
with anti-myc to reveal HDACs.  (B) THAP10 associates with HDAC1 and HDAC3 in vitro.  (Left panel) Coomassie Blue 
stained SDS-PAGE gel of recombinant GST and GST-THAP10 (GST-T10) used in GST-pulldown assay.  (Right panel) 
GST and GST-THAP10 were incubated with in vitro transcribed and translated 35S-labeled HDAC1, and HDAC3.  Bound 
radiolabeled HDACs were resolved by SDS-PAGE and detected by autoradiography.  Input corresponds to 10% of 
starting material. 
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Chapter 3:  Identification of Endogenous THAP11 Gene 
Targets and a Potential Role for THAP11 in Colon Cancer 
Cell Proliferation  
Summary 
 THAP11 expression was previously shown to positively correlate with 
colon cancer progression in human tumor samples and cell lines.  This finding, in 
conjunction with the observation that promoter targeted THAP11 represses 
transcription, suggests THAP11 dependent transcriptional repression may 
contribute to primary tumor or metastasis formation through transcriptional 
regulation.  However, endogenous gene targets of THAP11 and its role in colon 
cancer cell biology are currently unknown.  In this chapter, we describe the use 
of retrovirus-delivered short-hairpin RNA to establish stable knockdown of 
THAP11 expression in metastatic colon cancer SW620 cells.  Microarray based 
gene expression profiling in THAP11 knockdown cells identified 80 differentially 
expressed genes, of which 70% were de-repressed upon THAP11 depletion.  
De-repressed genes were shown to contain chromatin bound THAP11 near their 
transcription start sites suggesting direct transcriptional repression by THAP11.  
THAP11 was subsequently shown to associate with and recruit HCF-1 to 
repressed promoters.  Knockdown of HCF-1 similarly de-repressed THAP11 
target genes suggesting HCF-1 is a critical effector of THAP11 mediated 
repression.  Knockdown of THAP11 in SW620 cells resulted in diminished cell 
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proliferation.  Taken together, these results implicate THAP11 transcriptional 
repression as a potential regulator of colon cancer cell growth in SW620 cells.          
Introduction 
  In the previous chapter, we demonstrated that several THAP proteins 
possess transcriptional repressor activity when tethered to promoters as 
heterologous Gal4-DNA binding domain fusion proteins.  THAP11 potently 
repressed basal and activated transcription and physically associated with 
histone deacetylases.  In agreement with these observations, two independent 
reports published while this work was in progress identified THAP11 dependent 
transcriptional repression in mouse embryonic stem cells and human liver cancer 
cell lines (Dejosez, Krumenacker et al. 2008; Zhu, Li et al. 2009).  These findings 
suggest that endogenous THAP11 likely functions as a biologically relevant 
transcriptional regulatory protein.  However, the identity of endogenous THAP11 
gene targets and mechanism of transcriptional regulation remain largely 
unknown.   
The work presented in chapter 2 also found THAP11 expression positively 
correlates with colon cancer progression.  Significantly increased THAP11 
protein levels were observed in primary and metastatic human tumor specimens.  
THAP11 mRNA and protein levels were also increased in metastatic SW620 
colon cancer cells relative to isogenic, primary tumor derived SW480 cells.  
Derived from a single patient at different stages of disease progression, SW480 
and SW620 cells retain several important phenotypic differences associated with 
primary and metastatic tumors, respectively.  SW620 xenografts in nude mice 
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show increased growth rates, are less well-differentiated, and invade surrounding 
normal tissues more readily than SW480 tumors (Hewitt, McMarlin et al. 2000).  
Also, intrasplenic injections of SW620 cells metastasize to liver whereas SW480 
cells do not (Hewitt, McMarlin et al. 2000).  Thus, SW620 cells represent a 
unique model to not only further characterize the transcriptional regulatory 
properties of endogenous THAP11 but also investigate the role of THAP11 in 
colon cancer progression.  To that end, work in this chapter describes the 
identification of directly repressed gene targets of endogenous THAP11 in 
SW620 cells.  In addition, we find that stable knockdown of THAP11 results in 
decreased SW620 cell proliferation suggesting THAP11 dependent 
transcriptional regulation may contribute to colon cancer progression.       
Experimental Procedures 
Plasmids and Cloning 
Retroviral expression vectors pBABE-puro and pBABE-hygro have been 
described elsewhere (Morgenstern and Land 1990).  Vector pBABE-EGFP was 
generated from pBABE-puro by replacing the puromycin resistance cassette 
(HindIII/ClaI excised) with the EGFP coding sequence which was PCR amplified 
from pEGFP-C2 (Clontech) using the forward primer 
AATTAAGCTTCACCATGGTGAGCAAGGGCGA and reverse primer 
AATTATCGATTTACTTGTACAGCTCGTCCATGC (restriction endonuclease 
sites are underlined).  
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Retroviral short-hairpin RNA expression vectors pSuper.Retro.Puro and 
pSuper.Retro.Neo+GFP, hereafter abbreviated pSRP and pSRNG, respectively, 
were purchased from Oligoengine as was the nonspecific shRNA pSRP MAMM-
X (designated shNS).  THAP11, Annexin A1 and HCF-1 shRNA targeting 
sequences were designed using Dharmacon’s siDesign Center website.  
Synthetic oligonucleotides corresponding to shRNA targeting sequences were 
cloned into BglII/HindIII linearized pSRP and pSRNG according to 
manufacturer’s instructions.  An additional control shRNA (designated shNS2) 
targeting GFP was also cloned into pSRP.  A summary of shRNA targets and the 
corresponding synthesized oligonucleotide sequences is provided in Table A.1 
and Table A.2, respectively. 
 An expression construct for non-silenceable THAP11 (p3xFLAG-THAP11-
Rescue) resistant to shRNAs T11A, T11C and T11E was generated by two 
successive rounds of site-directed mutagenesis using p3xFLAG-THAP11 and the 
QuikChange Site-Directed Mutagenesis Kit (Stratagene).  Each mutagenesis 
reaction introduced silent mutations into three consecutive codons within the 
shRNA targeting sequence using primers listed in Table A.3.  The p3xFLAG-
THAP11-Rescue construct was further subcloned by PCR amplifying the non-
silenceable THAP11 coding sequence including 3xFLAG tag with EcoRI/SalI 
adapted primers and inserting into the EcoRI/SalI sites of pBABE-puro and 
pBABE-EGFP.  The final retroviral expression constructs were named pBABE-
puro-THAP11-Rescue-3xFLAG and pBABE-EGFP-THAP11-Rescue-3xFLAG. 
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Sequence correctness of all constructs was verified by automated DNA 
sequencing.   
Immunoblotting 
 Extract preparation and immunoblotting procedures were previously 
described in Chapter 2.  Briefly, whole cell extracts were prepared using modified 
RIPA buffer (20mM Tris-HCl pH 7.6, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
IGEPAL CA-630, 1% sodium deoxycholate, 0.25% SDS) and protein 
concentration determined by BCA assay.  Proteins (30μg) were separated by 
SDS-PAGE on 8-16% precast polyacrylamide gels and transferred to 
nitrocellulose.  Blots were blocked in PBS, 0.05% Tween-20 (PBST) containing 
5% non-fat dry milk and incubated with primary antibody overnight at 4°C in 
PBST-5% non-fat dry milk.  Membranes were washed with PBST, probed with 
horseradish peroxidase-conjugated secondary antibodies in PBST-5% non-fat 
dry milk and developed using enhanced chemiluminescence.  Immunoblotting for 
THAP11 was performed using our custom generated THAP11 antibody.  Mouse 
monoclonal antibodies against β-actin (working diltution 1:10,000) and FLAG-M2 
(1:3000) were purchased from Sigma.  Monoclonal anti-annexin A1 (1:3000) was 
purchased from Becton-Dickinson.  HCF-1 antibody (1:5000) was purchased 
from Bethyl Laboratories.    
Cell Culture 
 293T/17 (CRL-11268) cells and human colon cancer cell lines SW620 
(CCL-227), HCT-116 (CCL-247), SW480 (CCL-228), Colo-320HSR (CCL-220.1) 
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and LoVo (CCL-229) were purchased from ATCC.  293T/17, SW480 and SW620 
were maintained in Dulbecco’s modified eagle medium (high glucose) containing 
10% fetal bovine serum.  Colo-320HSR, HCT-116 and LoVo were grown in 
RPMI-1640, McCoy’s 5A and F-12K, respectively, containing 10% fetal bovine 
serum.  All cells were grown without supplemental antibiotics in a humidified 
37°C incubator containing 5% CO2. 
Retrovirus Production 
 VSV-G pseudotyped retrovirus was produced in 293T/17 cells (~70% 
confluent in 10cm2 dishes) by co-transfection with pCMV-VSVG (4μg), pMLV-
GagPol (8μg), and retroviral construct (12μg) using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions.  Following overnight 
transfection, cells were given fresh media (DMEM, 10% FBS) and allowed to 
equilibrate for several hours in the 37°C cell culture incubator prior to being 
shifted to a 32°C, 5% CO2, humidified cell culture incubator for an additional 24-
30 hours.  Retroviral supernatants were harvested ~48 hours from the start of 
transfection, cleared of residual 293T/17 cells by centrifugation (2000 x g, 5 
minutes) and either used immediately or aliquoted and stored at -80°C for future 
use. 
Retroviral Transduction and Stable Cell Production 
 To generate pools of SW620 and Colo-320HSR cells stably expressing 
either control or THAP11 shRNA, cells in six-well plates (~20% confluent) were 
transduced with a 1:1 mixture of viral supernatant and fresh media, adjusted to 
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8μg/ml polybrene and spin-infected at 500 x g for two hours at 32°C.  Following 
spin-infection cells were returned to the 37°C incubator for 8-16 hours and then 
given fresh growth media.  Two days post-transduction, cells from individual 
wells of the six-well plate were split into 10cm2 dishes containing the appropriate 
selection medium (2μg/ml puromycin or 1mg/ml Geneticin).  Cells were grown 
under selection for an additional two (puromycin) to seven (Geneticin) days at 
which point mock transduced cells exhibited complete cell death.  For rescue 
experiments, SW620 cells were first transduced with pSRP shRNA virus and 24 
hours later transduced with the indicated pBABE-EGFP virus.  Doubly expressing 
cells were then selected with puromycin and sorted for GFP expression using 
fluorescence activated cell sorting (FACS).  Alternatively, rescue experiments 
were also performed using SW620 cells transduced with pSRNG shRNA virus, 
FACS sorted and then transduced with the indicated pBABE-puro rescue virus 
followed by puromycin selection.  To generate double-knockdown cells 
expressing THAP11 and Annexin A1 shRNAs, SW620 cells were first transduced 
with pSRP-THAP11 C retrovirus and 24 hours later transduced with pSRNG-
Annexin A1 D retrovirus.  Twenty-four hours after the second transduction, cells 
were split into 10cm2 dishes and selected with 2μg/ml puromycin and 1mg/ml 
Geneticin for seven days.         
RNA Isolation and Quantitative RT-PCR 
 Total RNA was isolated using Qiagen RNeasy Mini Kit according to 
manufacturer’s instructions.  Total RNA (1μg) was reverse transcribed using 
qScript cDNA synthesis mix (Quanta Biosciences) containing both random 
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hexamer and oligo dT primers.  Quantitative PCR was performed on diluted 
cDNA using an ABI PRISM 7900HT 384-well real time PCR machine (Applied 
Biosystems) in a final volume of 20μl using SYBR green PCR master mix 
(Applied Biosystems) and gene specific primers.  Fold change in mRNA levels 
was determined using the ΔΔCt method normalized to β-actin.   
Microarray Gene Expression Analysis 
 Gene expression analysis of SW620 cells stably expressing either control 
(pSRP-shNS, pSRP-shNS2) or THAP11 (pSRP-T11A, pSRP-T11C) shRNAs 
were determined using Nimblegen Homo sapiens 385K oligonucleotide 
microarrays.  Total RNA from two independent pools of SW620 cells per shRNA 
were isolated using Qiagen RNeasy Mini Kits as described above.  RNA quality 
was verified using an Agilent 2100 Bioanalyzer and provided to Nimblegen for 
subsequent cDNA synthesis, labeling and microarray hybridization.   
Nuclear Run-On Assay 
 Modified nuclear run-on assays using 5-bromouridine (BrU) labeled 
nascent RNA were performed as previously described with minor modifications 
(Core, Waterfall et al. 2008).  SW620 cells (~1 x 108) expressing either pSRP-
shNS, pSRP-shT11A, or pSRP-shT11C were rapidly cooled by rinsing in ice-cold 
PBS, scraped into ice-cold PBS and collected by centrifugation (500 x g, 5 
minutes, 4°C).  Cell pellets were resuspended in hypotonic lysis buffer (10mM 
Tris pH 7.6, 10mM NaCl, 3mM MgCl2) and immediately centrifuged as before.  
Cell pellets were loosened by gentle vortexing (setting 6), resuspended in 
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hypotonic lysis buffer containing 0.5% IGEPAL CA-630, and incubated on ice for 
5 minutes.  Cell lysis was routinely >90% as determined by trypan blue staining 
and hemacytometer counting.  Nuclei were recovered by centrifugation (1000 x 
g, 5 minutes, 4°C), washed once in hypotonic lysis buffer containing 0.5% 
IGEPAL CA-630 and centrifuged as before.  Recovered nuclei were resuspended 
in 1ml of freezing buffer (50mM Tris pH 8.0, 40% glycerol, 5mM MgCl2, 0.1mM 
EDTA, 40U RnasinPlus (Promega)) and aliquoted into 1.5ml tubes at 200μl (~107 
nuclei) per tube, snap frozen in liquid nitrogen and stored at -80°C.   
For run-on transcription, thawed nuclei were mixed with an equal volume 
(200μl) of 2x run-on buffer (10mM Tris pH 8, 5mM MgCl2, 300mM KCl, 1% 
Sarkosyl, 160U RNasinPlus, 5mM DTT, and 1mM each ATP, CTP, GTP, BrUTP) 
and incubated at 30°C for 30 minutes.  Following run-on transcription, samples 
were DNaseI and proteinase K digested.  Total RNA was extracted using acid 
phenol:chloroform:iso-amyl alcohol (25:24:1), ethanol precipitated and 
resuspended in nuclease-free water.  Total RNA was then further purified using 
Qiagen RNeasy mini spin columns according to the RNA cleanup procedure 
described by the manufacturer.  Anti-BrdU monoclonal antibody (Sigma, 5μl per 
IP, 15μl total) was pre-incubated with 90μl of Protein G Dynabeads in 1ml 
binding buffer (10mM Tris pH 7.6, 100mM NaCl, 1mM EDTA, 0.05% Tween-20, 
0.1% IGEPAL CA-630, 15μg yeast tRNA) for 1 hour at 4°C.  Dynabeads were 
washed three times in binding buffer without supplemental tRNA and 
resuspended in 90μl of binding buffer.  To immunoprecipitate BrU labeled 
nascent RNA, 25μg of nuclear run-on RNA, 2.5μg yeast tRNA and 40U 
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RNasinPlus were added to 500μl of binding buffer on ice.  Anti-BrdU bound 
Dynabeads (30μl per IP) were added and immunoprecipitation allowed to 
proceed for one hour at 4°C with end-over-end rotation.  Beads were 
subsequently washed three times in binding buffer and eluted by addition of 
300μl of Buffer RLT (Qiagen RNeasy Kit).  Immunoprecipitated RNAs were 
purified using Qiagen RNeasy Mini Kit and eluted in 30μl of water.  Isolated RNA 
was reverse transcribed and analyzed by quantitative RT-PCR as described 
above. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed essentially as described 
with minor modifications (Lee, Johnstone et al. 2006).  SW620 cells (~ 5 x 107) or 
those stably expressing the indicated retroviral constructs were cross-linked by 
addition of 1/10th volume of freshly prepared formaldehyde cross-linking buffer 
(11% formaldehyde, 10mM HEPES-KOH pH 7.6, 100mM NaCl, 1mM EDTA, 
0.5mM EGTA) to tissue culture dishes and incubated for 10 minutes at room 
temperature.  Cross-linking was terminated by addition of 1/20th volume 2.5M 
glycine.  Cross-linked cells were washed three times with ice-cold PBS, scraped 
into PBS and recovered by centriguation (1500 x g, 10 minutes, 4°C).  Cell 
pellets were resuspended in 10mls of lysis buffer 1 (50mM HEPES-KOH pH 7.6, 
140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% IGEPAL-CA630, 0.25% Triton X-
100, 1x protease inhibitors) and incubated for 10 minutes at 4°C with gentle 
rocking.  Nuclei were recovered by centrifugation, resuspended in 10mls of lysis 
buffer 2 (10mM Tris-HCl pH 8.0, 200mM NaCl, 1mM EDTA, 0.5mM EGTA, 1x 
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protease inhibitors ) and extracted for 10min at room temperature with gentle 
inversion.  Nuclei were again recovered by centrifugation, resuspended in 3.5mls 
of lysis buffer 3 (10mM Tris-HCl pH 8.0, 100mM NaCl, 1mM EDTA, 0.5mM 
EGTA, 0.1% Na-Deoxycholate, 0.5% Sarkosyl, 1x protease inhibitors) and 
sonicated in an ice-water bath using a Misonix micro-tip equipped sonicator at 
setting 6 (~6W RMS ouput power) for 12 cycles of 15 seconds sonication 
followed by a 1 minute cooling interval.  The sonicated chromatin was adjusted to 
1% Triton X-100 from a 10% stock solution and debris removed by centrifugation 
at 20,000 x g at 4°C for 20 minutes.  The protein concentration of solubilized 
chromatin was determined by BCA assay and approximately 1mg of chromatin 
was immunoprecipitated overnight at 4°C with the indicated antibodies.  Protein 
G Dynabeads (30μl) blocked overnight in PBS containing 0.5% BSA and 0.1% 
Triton X-100 were added and immunoprecipitation allowed to proceed for an 
additional two hours.  Beads were collected using a Dynal MPC magnetic stand 
(Invitrogen) and washed four times with 1ml of ChIP-RIPA wash buffer (50mM 
HEPES-KOH pH 7.6, 500mM LiCl, 1mM EDTA, 1.0% IGEPAL-CA630, 0.7% Na-
Deoxycholate) and once with TE containing 50mM NaCl.   
Following the final wash DNA was recovered as described by Nelson et al.  
(Nelson, Denisenko et al. 2006).  Briefly, Dynabeads as well as precipitated input 
chromatin were resuspended in 100μl of 10% Chelex resin (BioRad) and 
incubated for 10 minutes at 100°C.  Samples were cooled to room temperature 
and then digested with proteinase K (0.2mg/ml) for one hour at 55°C.  Samples 
were again boiled for 10 minutes to inactivate proteinase K and centrifuged at 
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14,000 x g for 3 minutes to pellet the Chelex/Dynabeads mixture.  Supernatants 
(80μl) containing the immunoprecipitated DNA were transferred to clean 1.5ml 
tubes and the Chelex/Dynabead resins were resuspended in an additional 120μl 
of water, vortexed, and centrifuged as before.  Supernatants were combined 
yielding 200μl of immunoprecipitated DNA.   
Determination of relative enrichment was performed by qPCR using an 
ABI PRISM 7900HT 384-well real time PCR machine with SYBR green PCR 
master mix (Applied Biosystems) and primers designed as described below.  
Threshold cycle (Ct) values of ChIP-enriched DNA were exponentiated and 
expressed as percent recovery relative to input DNA analyzed in parallel. 
Primer pairs for qPCR were designed using Primer3Plus against human 
genome sequence (NCBI36/hg18) retrieved using the UCSC Genome Browser 
(Kent, Sugnet et al. 2002).  The primer sequences and relative position of the 
ChIP amplicons is provided in Table A.4. 
Co-immunoprecipitation and Immunoblot Analysis 
 Cells in 15cm2 tissue culture dishes were rinsed three times with ice-cold 
PBS, scraped into PBS and collected by centrifugation at 500 x g for five minutes 
at 4°C.  Cells were then resuspended in 5 pellet cell volumes (PCV) of Buffer A 
(10mM HEPES-KOH pH 7.6, 10mM KCl, 1.5mM MgCl2) containing Complete 
protease inhibitors (Roche) and allowed to swell for 10 minutes on ice.  
Cytoplasmic membranes were lysed by drop-wise addition of IGEPAL CA-630 
from a 10% stock solution to a final concentration of 0.5% while gently mixing the 
cells by vortexing at half-maximum setting.  Cells were incubated on ice for 5 
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minutes and plasma membrane lysis was verified by trypan blue staining.  Nuclei 
were isolated by centrifugation at 2000 x g for 5 minutes at 4°C, washed once 
with Buffer A, collected by centrifugation and resuspended in 1 PCV of Buffer C 
(20mM HEPES-KOH pH 7.6, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% 
glycerol) supplemented with Complete protease inhibitors (Roche).  Nuclei were 
extracted for 45 minutes at 4°C with gentle inversion.  Nuclear extracts were 
clarified by centrifugation (20,000 x g for 15 minutes at 4°C), diluted with one 
volume of Buffer C without glycerol or NaCl, and adjusted to 0.5% IGEPAL CA-
630.  Nuclear extracts were re-clarified by centrifugation to remove precipitates 
formed by dilution and protein concentration determined by BCA assay.  
Immunoprecipitations were performed with 0.5-1mg of nuclear extract and 1-2μg 
of either affinity purified rabbit polyclonal anti-HCF-1 (Bethyl Laboratories) or 
normal rabbit IgG (Sigma) overnight at 4°C with inversion.  Protein G Dynabeads 
(20μl) were added and immunoprecipitations allowed to proceed for an additional 
two hours.  Beads were then washed four times with binding buffer (20mM 
HEPES-KOH pH 7.6, 150mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5% IGEPAL 
CA-630) and bound proteins eluted by boiling in 2x Laemmli buffer.  Proteins 
were resolved by SDS-PAGE, transferred to nitrocellulose membrane and 
immunoblotted with HCF-1 and THAP11 antibodies.  Blots were developed by 
enhanced chemiluminescence using an anti-rabbit light chain specific HRP-
conjugated secondary antibody (Jackson Immunoresearch) to minimize 
obscuring THAP11 signal by co-migrating IgG heavy chains. 
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Alamar Blue Cell Proliferation Assay 
Proliferation of SW620 knockdown cells was determined using the Alamar 
Blue cell viability reagent according to manufacturer’s instructions (Invitrogen).  
Puromycin or puromycin/geneticin selected (as indicated) SW620 knockdown 
cells were seeded at 5000 cells per well (n = 8 wells per condition) in black-
walled 96-well tissue culture plates in 100μl of DMEM, 1% FBS.  Five identical 
96-well plates were seeded for determination of cell viability on five consecutive 
days.  Twenty-four hours after seeding, 10μl of Alamar Blue reagent was added 
per well to one 96-well plate and this plate was incubated for two hours at 37°C 
in the cell culture incubator.  Fluorescence measurements were then performed 
with a BioTek Synergy HT multi-detection microplate reader equipped with 
540nm excitation and 590nm emission filters.  Average background fluorescence 
was calculated from wells (n = 16) containing media alone and subtracted from 
wells containing cells.  This process was repeated every 24 hours for 5 
consecutive days using one replicate 96-well plate per day.  
Results 
Gene Expression Profiling in SW620-THAP11 Knockdown cells 
 To further characterize the transcriptional regulatory properties of THAP11 
in a physiologically relevant system, we performed microarray based gene 
expression profiling using SW620 cells depleted of THAP11 via retrovirally 
expressed short-hairpin RNAs (shRNA).  Central to this approach was the 
creation of multiple THAP11 specific shRNA constructs.  As shown in Figure 3.1, 
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shRNA constructs shT11A, shT11C, shT11D, and shT11E significantly 
diminished THAP11 mRNA (Figure 3.1A) and protein (Figure 3.1B) as 
determined by quantitative RT-PCR and immunoblotting, respectively.  Of these 
four shRNA constructs, shT11D appeared slightly less effective and was not 
used in subsequent studies.  Additionally, constructs shT11C and shT11E were 
found to have partially overlapping targeting sequences (Figure 3.1C); therefore 
we selected shRNAs shT11A, and shT11C for use in creating loss-of-function 
stable cell lines.  Two independent pools of SW620 cells were transduced with 
either control (shNS, shNS2) or THAP11 (shT11A, shT11C) shRNA expressing 
retrovirus and analyzed for global gene expression changes using Nimblegen 
oligonucleotide microarrays.  Genes displaying a 1.5 fold change and a p-value < 
0.01 (t-Test) between control (shNS, shNS2) and THAP11 (shT11A, shT11C) 
shRNA expressing cells were defined as differentially expressed.  This gene set 
was further processed to remove predicted genes which have been subsequently 
“discontinued” by the NCBI and additionally lack supporting mRNA or EST 
sequences.  This analysis identified 80 transcripts (excluding THAP11) as 
differentially expressed between THAP11 and control knockdown groups (Figure 
3.2A).  Of these differentially expressed RNAs, 70% (56/80) showed increased 
expression with THAP11 knockdown, consistent with our previous observation 
suggesting THAP11 possesses transcriptional repressor activity.  Quantitative 
RT-PCR using the same RNA also analyzed by microarray allowed for 
independent verification of microarray determined gene expression changes.  As 
shown in Figure 3.2B, most of the microarray results were recapitulated by qRT-
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PCR suggesting the dataset as a whole likely represents a biologically relevant, 
THAP11 dependent gene expression program.   
Gene expression measurements determined by oligonucleotide 
microarray and quantitative RT-PCR reflect steady-state mRNA levels and by 
themselves are incapable of assessing whether regulation occurs at the 
transcriptional or post-transcriptional level.  To determine if the gene expression 
changes observed in THAP11 knockdown cells were at least partially attributable 
to increased transcription, we performed a modified nuclear run-on assay in 
SW620 cells expressing either control or THAP11 shRNAs (Core, Waterfall et al. 
2008).  As illustrated in Figure 3.3A, run-on transcription from isolated nuclei was 
performed using BrUTP, in place of 32P-UTP, to label nascent RNA transcripts in 
the presence of 0.5% sarkosyl.  Inclusion of sarkosyl in run-on reactions prevents 
re-initiation of transcription thus allowing only the completion of transcripts 
actively engaged by RNA Polymerase II at cell lysis (Core, Waterfall et al. 2008).  
BrU labeled nascent transcripts were then specifically immunoprecipitated from 
total nuclear RNA using a monoclonal anti-BrdU antibody, which recognizes BrU 
as well as BrdU, and transcript levels determined by quantitative RT-PCR.  In 
THAP11 knockdown cells we found nascent transcript levels for Lsmd1, 
ncRNA00095, AA862256 and Annexin A1 up-regulated in a manner qualitatively 
similar to their steady-state mRNAs (Figure 3.3B and data not shown).  
Importantly, THAP11 steady-state but not nascent transcript levels were depleted 
in SW620 cells expressing THAP11 shRNAs (Figure 3.3B).  This expected 
discrepancy is in agreement with the proposed mechanism of RNA interference 
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as a post-transcriptional gene silencing event and provides an important 
verification of the specificity of the nuclear run-on assay to detect nascent rather 
than mature transcripts (Meister and Tuschl 2004).  Taken together, we conclude 
that the increased RNA levels observed in THAP11 knockdown cells for Lsmd1, 
ncRNA00095, AA862256, Annexin A1 and, perhaps the microarray dataset as a 
whole, likely reflects increased transcription.  However, we cannot exclude the 
possibility that post-transcriptional regulatory mechanisms may also contribute to 
the gene expression profile of THAP11 knockdown cells. 
Transcripts induced by THAP11 knockdown may represent direct gene 
targets of THAP11 mediated repression.  Alternatively, these gene expression 
changes may arise from secondary events subsequent to THAP11 knockdown or 
possibly from nonspecific shRNA events despite our use of multiple control and 
THAP11 targeted shRNAs.  To discriminate between these possibilities, we 
performed rescue experiments using a THAP11 expression construct rendered 
non-silenceable by mutation of three consecutive codons in each of the shRNA 
targeting sequences (Figure 3.4A).  SW620 cells were first transduced with either 
control or THAP11 shRNA, and then with either control or THAP11-Rescue-
3xFLAG retroviruses. Cells expressing both constructs were selected by 
puromycin resistance (shRNA) and fluorescence activated cell sorting (THAP11 
rescue).  Immunoblotting with THAP11 antibody revealed a robust re-expression 
of THAP11 in cells expressing THAP11-Rescue-3xFLAG but not control virus 
(Figure 3.4B, upper panel).  The 3xFLAG-tagged THAP11 rescue protein 
migrates at a slightly higher molecular weight allowing comparison of expression 
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levels between rescue and endogenous THAP11 (compare bands in lane 4) and 
verification that endogenous THAP11 remains depleted in THAP11-Rescue-
3xFLAG expressing cells (lanes 5 and 6).  The identity of the THAP11 bands in 
rescue expressing cells was further validated by immunoblotting with monoclonal 
anti-FLAG antibody (Figure 3.4B, lower panel).   
If the gene expression profile observed in THAP11 knockdown cells is 
attributable to specific depletion of THAP11, than restoration of THAP11 status in 
THAP11-Rescue-3xFLAG cells should reverse this effect.  Indeed, quantitative 
RT-PCR of several putative THAP11 gene targets including Lsmd1, 
ncRNA00095, AA862256, Praf2 and Alg14 revealed that expression of non-
silenceable THAP11 prevented the differential gene expression previously 
observed in THAP11 knockdown cells (Figure 3.4C and Table 3.1).  Importantly, 
this rescue effect was functional irrespective of the magnitude of putative target 
gene induction.  Modestly induced genes (1.2-1.6 fold) such as Smarca1 and 
Atg4a and robustly induced genes (3-8 fold) including Lsmd1 and AA862256 
were equally rescued by non-silenceable THAP11.  The expression of THAP11-
Rescue-3xFLAG re-repressed putative THAP11 gene targets below the level 
observed in cells expressing endogenous amounts of THAP11 (shNS and 
Empty), likely due to rescue construct over-expression.  To determine if THAP11 
knockdown de-represses these genes in additional colon cancer cell lines, we 
expressed THAP11 shRNAs in Colo320HSR cells which also have elevated 
THAP11 expression (Figure 2.6).  As shown in Figure 3.5, knockdown of 
THAP11 in Colo320HSR cells de-represses putative THAP11 gene targets 
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Alg14, Lsmd1, and AA862256 similar to knockdown in SW620 cells.  Similar de-
repression following THAP11 knockdown in Colo320HSR was also observed for 
ncRNA00095 and AK021933 (data not shown).  Taken together, these results 
indicate that the majority of gene expression changes observed in THAP11 
knockdown cells likely reflects an authentic cellular response to diminished 
THAP11 protein levels and represents the first characterization of a THAP11 
dependent gene expression network in human cells. 
Identification of Direct THAP11 Gene Targets in SW620 cells 
 Direct THAP11 gene targets should be readily determined by identifying 
THAP11 at relevant genomic control regions, such as proximal promoters, by 
chromatin immunoprecipitation.  However, the paucity of known endogenous 
THAP11 gene targets and the suitability of our custom THAP11 antibody for 
chromatin immunoprecipitation make this a difficult task.  To circumvent these 
issues, we utilized our SW620 THAP11-Rescue-3xFLAG cells which have stably 
depleted endogenous THAP11 and over-expressed 3xFLAG tagged, non-
silenceable THAP11.  Since the non-silenceable THAP11 in these cells 
functionally rescues endogenous THAP11 knockdown, as assessed by re-
repression of THAP11 shRNA induced gene expression, we reasoned that direct 
THAP11 gene targets should be identified by ChIP assay directed against the 
3xFLAG epitope.  THAP11-Rescue-3xFLAG cells were processed for ChIP 
assay using anti-FLAG monoclonal antibody and enrichment of 
immunoprecipitated chromatin was monitored by quantitative PCR using 
amplicons spaced approximately 500bp apart and spanning at least 2kb on either 
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side of the transcriptional start sites of Lsmd1 and ncRNA00095 (Figure 3.6A).  
As shown in Figure 3.6B, this approach identified a peak of THAP11-Rescue-
3xFLAG binding in both putative THAP11 gene targets.  At Lsmd1, THAP11-
Rescue-3xFLAG binding peaks at an amplicon centered at +392 relative to the 
annotated transcriptional start site while at ncRNA00095 two amplicons centered 
at -212 and +335 show apparently equivalent enrichment.  No enrichment was 
observed when ChIP was performed using a species and isotype matched 
control IgG in SW620 rescue cells or with FLAG antibody in SW620 control cells 
(data not shown) confirming the specificity of the ChIP assay.  We subsequently 
extended this approach to additional putative THAP11 gene targets including 
Praf2, AA862256, C1orf83, and ZSCAN20 (Figures 3.7 and 3.8).  Interestingly, 
each examined target gene displayed a peak of THAP11-3xFLAG binding within 
500 base pairs of the annotated transcriptional start site.  Because each of the 
aforementioned genes were effectively re-repressed by and contain chromatin 
bound THAP11-Rescue-3xFLAG near their transcriptional start sites, we 
conclude that these genes are likely direct targets of THAP11 mediated 
transcriptional repression. 
 Having identified direct THAP11 gene targets using chromatin 
immunoprecipitation in conjunction with THAP11-Rescue-3xFLAG, we next 
confirmed that these regions were indeed bound by endogenous THAP11.  
Normal SW620 cells were analyzed by chromatin immunoprecipitation using anti-
THAP11 antibody at the previously identified THAP11 bound or distal genomic 
regions of Lsmd1, ncRNA00095, and AA862256.  Chromatin bound, endogenous 
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THAP11 was identified at the same regions previously found to contain THAP11-
3xFLAG-Rescue.  Amplicons centered at Lsmd1 +392, ncRNA00095 -212, and 
AA862256 +101 (Figure 3.9A) were enriched relative to normal rabbit IgG while 
amplicons located at least 1kb upstream were not.  To further confirm the 
specificity of the anti-THAP11 ChIP assay, we repeated the experiment in 
THAP11 knockdown SW620 cells.  As expected, cells expressing THAP11 
shRNA exhibited reduced, albeit detectable levels of chromatin bound THAP11 
at Lsmd1 +392 (Figure 3.9B).  Taken together, these data indicate that an 
experimental approach consisting of knockdown of endogenous chromatin bound 
proteins in conjunction with epitope-tagged, non-silenceable rescue expression is 
a viable strategy for interrogating the chromatin occupancy profile of proteins 
intractable to conventional chromatin immunoprecipitation.  More importantly, 
these findings provide the necessary orthogonal data to conclude that Lsmd1, 
ncRNA00095, AA862256, C1orf83, Praf2, and ZSCAN20 are direct targets of 
THAP11 mediated transcriptional repression. 
RNAPII and Acetylated-Histone Occupancy at THAP11 Repressed Genes 
 To begin determining the mechanism associated with THAP11 mediated 
transcriptional repression, we examined RNAPII occupancy at THAP11 target 
genes Lsmd1 and ncRNA00095.  Chromatin immunoprecipitation using an 
antibody that recognizes the hypophosphorylated C-terminal domain (CTD) of 
RNAPII revealed increased RNAPII binding at the TSS of both genes 
concomitant with THAP11 knockdown (Figure 3.10).  The elevated RNAPII 
occupancy observed at Lsmd1 in THAP11 knockdown cells was reversed in 
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SW620 rescue cells that simultaneously express non-silenceable THAP11 thus 
confirming that increased RNAPII occupancy reflects diminished THAP11 levels 
(Figure 3.11).  Taken together, these results suggest that THAP11 may repress 
transcription by limiting or destablilizing RNAPII at THAP11 target genes.   
 Data presented in chapter 2 of this thesis demonstrate that THAP11 
physically associates with histone deacetylases (HDACs).  To determine if 
recruitment of HDACs by THAP11 may account for THAP11 dependent 
transcriptional repression, we examined the histone acetylation status of Lsmd1 
and ncRNA00095 by ChIP assay in THAP11 knockdown cells.  Increased acetyl-
K9/K18-H3 (AcH3) was observed in the promoter of Lsmd1 but not ncRNA00095 
in THAP11 knockdown SW620 cells (Figure 3.12), suggesting histone 
deacetylation is not a universal mechanism of THAP11 mediated transcriptional 
repression.  However, it is also possible that THAP11 may recruit HDACs and 
regulate transcription by deacetylation of non-histone proteins.  However, several 
attempts to chromatin immunoprecipitate HDACs at THAP11 bound chromatin 
were unsuccessful (data not shown), which may reflect either a technical 
limitation of the ChIP assay or a limited role for HDACs in repression by THAP11.      
THAP11 associates with HCF-1 
 In mouse embryonic stem cells, THAP11 has recently been shown to 
repress transcription and associate in a large, multimeric complex containing the 
transcriptional co-regulator host cell factor 1 (HCF-1) (Dejosez, Krumenacker et 
al. 2008).  While the role of HCF-1 in THAP11 mediated transcriptional 
repression was not directly demonstrated, a recent report by Mazars et al. 
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showed that HCF-1 is an essential effector of THAP1 mediated transcriptional 
activation of RRM1 in human vascular endothelial cells (Mazars, Gonzalez-de-
Peredo et al. 2010).  Multiple THAP proteins, including THAP11, were also found 
to interact with HCF-1 by yeast two-hybrid assay (Mazars, Gonzalez-de-Peredo 
et al. 2010).  HCF-1 associating THAP proteins contain the HCF-1 binding motif 
(HBM), a conserved tetrapeptide sequence (D/EHxY) known to mediate the 
interaction of various cellular and viral proteins with the N-terminal kelch domain 
of HCF-1 (Freiman and Herr 1997; Lu, Yang et al. 1997).  These observations 
inspired us to ask whether THAP11 associates with HCF-1 in SW620 cells and if 
so, if the interaction contributes to THAP11 mediated repression.  To address 
this question, we immunoprecipitated HCF-1 from SW620 nuclear extract and 
probed the immunoprecipitate for endogenous THAP11 using our custom 
THAP11 antibody.  As shown in Figure 3.13A, endogenous THAP11 was found 
to specifically co-precipitate with endogenous HCF-1.  This observation was also 
extended to additional colon cancer cell lines where THAP11 was found to co-
precipitate with HCF-1 from nuclear extracts prepared from Colo320HSR, 
SW480, and HCT-116 cells (Figure 3.13B). To determine if the THAP11/HCF-1 
interaction was dependent on DNA present in the nuclear extract preparation, we 
repeated the co-immunoprecipitation experiment in the presence of ethidium 
bromide, a technique frequently used to assess the DNA dependence of nuclear 
protein interactions (Lai and Herr 1992).  As shown in Figure 3.13C, HCF-1 
immunoprecipitation from SW620 nuclear extract in the presence of ethidium 
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bromide did not diminish the amount of co-precipitated THAP11, suggesting that 
THAP11 and HCF-1 can stably associate in the absence of DNA binding.       
THAP11 recruits HCF-1 to promoters of THAP11 repressed genes 
 Because endogenous THAP11 and HCF-1 physically associate in living 
cells, we next wished to determine if HCF-1 is also recruited to promoter regions 
of THAP11 target genes in SW620 cells.  Chromatin immunoprecipitation was 
performed for endogenous HCF-1 and THAP11 in SW620 cells and the 
occupancy profile of each was determined at the THAP11 target gene Lsmd1.  
As shown in Figure 3.14A-C, both HCF-1 and THAP11 displayed a strikingly 
similar distribution at Lsmd1.  ChIP assay also detected HCF-1 at THAP11 target 
genes C1orf83, ncRNA00095, AA862256 and ZSCAN20 in SW620 cells (Figure 
3.14D) suggesting HCF-1 is recruited to THAP11 bound and repressed 
promoters.  HCF-1 is not known to possess intrinsic DNA binding activity and its 
association with chromatin is thought to require interaction with sequence 
specific DNA binding factors (Wysocka, Reilly et al. 2001).  Accordingly, 
sequence specific binding by THAP11 at a targeted genomic region may result in 
HCF-1 recruitment by virtue of their physical interaction.  To test this directly, we 
repeated the ChIP assay for HCF-1 in SW620 cells depleted of endogenous 
THAP11 by shRNA.  As shown in Figure 3.15, SW620 THAP11 knockdown cells 
show a marked reduction in HCF-1 occupancy at Lsmd1 (Figure 3.15A) and 
ncRNA00095 (Figure 3.15B) suggesting THAP11 is the chromatin bound factor 
that recruits HCF-1 to these target promoters.  Importantly, HCF-1 protein levels 
were unaltered in THAP11 knockdown cells (Figure 3.15C) indicating that the 
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differential recruitment of HCF-1 observed at THAP11 target promoters does not 
result from a reduction in total HCF-1 protein.   
HCF-1 is required for THAP11 mediated repression 
 Having established that THAP11 physically associates with and recruits 
HCF-1 to THAP11 repressed promoters, we next asked whether HCF-1 plays a 
functional role in THAP11 mediated repression.  Knockdown of endogenous 
HCF-1 using retrovirally delivered shRNAs produced a marked depletion of HCF-
1 protein while THAP11 protein levels were unchanged (Figure 3.16A).  
Quantitative RT-PCR analysis of THAP11 target genes Lsmd1 and ncRNA00095 
in HCF-1 knockdown cells revealed increased steady-state mRNA levels 
comparable to that observed by THAP11 knockdown (Figure 3.16B).  The extent 
of Lsmd1 and ncRNA00095 transcript induction was found to be proportional to 
level of HCF-1 knockdown.  As expected, ChIP analysis of HCF-1 in shHCF-1 
expressing cells showed a strong reduction in HCF-1 occupancy at Lsmd1 
(Figure 3.17) and ncRNA00095 (data not shown) promoters.  Importantly, 
examination of RNAPII by chromatin immunoprecipitation showed increased 
occupancy at Lsmd1 (Figure 3.17) and ncRNA00095 (data not shown) promoters 
in HCF-1 knockdown cells suggesting HCF-1 is a critical effector of THAP11 
mediated repression.   
Affinity purification of THAP11/HCF-1 protein complex  
   HCF-1 is believed to function as a molecular scaffold, affecting 
transcription by linking sequence specific DNA binding factors to chromatin 
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modifying activities, and has been identified in multiprotein complexes of 
opposing transcriptional activities (Wysocka, Myers et al. 2003; Liang, Vogel et 
al. 2009; Chikanishi, Fujiki et al. 2010).  As a transcriptional co-activator, HCF-1 
has been found associated with Set1/MLL histone H3 lysine 4 methyltransferase 
while transcriptional co-repressor function has revealed HCF-1 associated with 
SIN3/HDAC activity (Wysocka, Myers et al. 2003; Tyagi, Chabes et al. 2007).  In 
addition, HCF-1 is also frequently found associated with O-linked N-
acetylglucosamine (O-GlcNAc) transferase (OGT) which has been alternately 
linked to transcriptional activation or repression (Wysocka, Myers et al. 2003; 
Fujiki, Chikanishi et al. 2009; Ozcan, Andrali et al. 2010).  To identify the 
constituents of the THAP11/HCF-1 repression complex we performed a two-step 
affinity purification as outlined in Figure 3.18A using SW620 cells stably 
expressing THAP11-3xFLAG.  Since HCF-1 itself is O-GlcNAcylated, HCF-1 and 
associated proteins can be partially purified from nuclear extracts by lectin affinity 
chromatography using wheat germ agglutinin (WGA) conjugated agarose 
(Wysocka, Myers et al. 2003).  WGA-agarose bound HCF-1 complexes were 
eluted with GlcNAc and subsequently immunoprecipitated with anti-FLAG.  As 
shown in Figure 3.18B, the majority of endogenous and 3xFLAG-tagged THAP11 
were bound by WGA-agarose (compare Input and WGA-FT lanes).  WGA-
eluates immunoprecipitated with FLAG-agarose recovered HCF-1 only from 
THAP11-3xFLAG and not empty vector expressing cells (Figure 3.18B).  The 
relatively small proportion of total cellular HCF-1 recovered (compare FLAG-
agarose and Input lanes, Figure 3.18B) is consistent with the idea that HCF-1 
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functions in many discrete complexes (Wysocka, Reilly et al. 2001).  WGA and 
FLAG immunoprecipitates were then analyzed by immunoblot for the presence of 
known HCF-1 (OGT, HDAC1, HDAC2, mSIN3A, Lsd1) or THAP11 (HDAC1, 
HDAC3) interacting proteins consistent with transcriptional repression.  The 
results of the two-step affinity purification revealed HCF-1, OGT, and HDAC1 
associated with THAP11-3xFLAG following WGA purification (Figure 3.18C) 
Lsd1 was not detected in the WGA enriched material suggesting the association 
of Lsd1 with HCF-1 in SW620 cells does not occur to an appreciable degree or 
does not survive the purification (data not shown).  Next, the co-localization of 
OGT with THAP11 and HCF-1 on chromatin was detemined by ChIP assay.  
OGT was found at a subset of genomic regions similarly as THAP11 and HCF-1 
including C1orf83, Lsmd1, and ncRNA00095 but not AA862256 and ZSCAN20 
(Figure 3.19).  Taken together, these data suggest that THAP11 recruits a 
multimeric complex composed of HCF-1/OGT/HDAC1 to mediate transcriptional 
repression.         
Annexin A1 is de-repressed by THAP11 knockdown                    
Many of the THAP11 dependent differentially expressed transcripts we 
have examined either lack protein coding capacity (ncRNA00095, AA862256, 
AK021933) or encode uncharacterized proteins without commercially available 
antibodies (Lsmd1, Alg14).  In contrast, Annexin A1 is a well-characterized 
member of the annexin superfamily of phospholipid binding proteins with 
documented roles in inflammation, cell proliferation and apoptosis (Lim and 
Pervaiz 2007; Tabe, Jin et al. 2007; Blume, Soeroes et al. 2009; Perretti and 
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D'Acquisto 2009; Zhang, Huang et al. 2010).  Immunoblotting for Annexin A1 in 
SW620 THAP11 knockdown cells revealed increased Annexin A1 protein (Figure 
3.20A) consistent with elevated Annexin A1 mRNA levels detected in those same 
cells (Figure 3.20B).  Interestingly, we observe that knockdown of THAP11 in 
SW620 cells restores both Annexin A1 mRNA and protein to levels expressed in 
SW480 cells (Figure 3.20).  Consistent with transcriptional de-repression of 
Annexin A1 upon THAP11 knockdown, we observed increased RNAPII and 
acetyl-histone H3 occupancy at the Annexin A1 proximal promoter by ChIP 
assay (data not shown).  This data suggests that a gain in THAP11 function in 
SW620 cells may be at least partially responsible for the loss of Annexin A1 in 
these cells.  Congruent with this hypothesis, we find that Annexin A1 protein 
levels inversely correlate with THAP11 protein levels in a panel of colon cancer 
cell lines as shown in Figure 3.21.  However, we failed to detect direct binding of 
THAP11/HCF-1/OGT/HDAC1 on the Annexin A1 proximal promoter in SW620 
cells suggesting THAP11 may indirectly regulate Annexin A1 gene expression 
(data not shown). 
Cell growth suppression in THAP11 knockdown SW620 cells 
 During routine subculturing of THAP11 knockdown cells we noticed that 
cells expressing THAP11 shRNAs grew more slowly than those expressing 
control shRNA.  To explore the possibility that THAP11 knockdown may affect 
cellular growth, we performed the Alamar Blue cell enumeration assay which 
detects the metabolic conversion of non-fluorescent resazurin to fluorescent 
resorufin in viable cells.  SW620 cells were transduced with control (shNS) or 
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THAP11 shRNA (shT11A or shT11C) retrovirus and two days post-transduction 
selected with puromycin for an additional two days and then seeded into 96-well 
plates for the Alamar Blue assay.  As shown in Figure 3.22, THAP11 knockdown 
resulted in a decrease in the number of viable cells over time with shRNA T11C 
slightly more effective than shRNA T11A.  Decreased cell proliferation, colony 
formation and enhanced apoptosis have been reported in prostate cancer cell 
lines following restoration of Annexin A1 expression (Hsiang, Tunoda et al. 
2006).  Therefore, we next addressed if elevated Annexin A1 expression 
resulting from THAP11 knockdown may similarly contribute to the cell growth 
defect observed in those cells.  To test this possibility, double-knockdown SW620 
cells expressing control, THAP11, or Annexin A1 shRNAs were established.  
Cells were first transduced with control or THAP11 knockdown virus (pSRP) and 
24 hours later transduced with control or Annexin A1 virus (pSRNG).  Double-
knockdown cells were selected by puromycin and Geneticin resistance and 
subjected to the Alamar Blue assay as described above.  As shown in Figure 
3.23A, knockdown of Annexin A1 in cells also depleted of THAP11 restores 
Annexin A1 expression to levels observed in control knockdown cells.  However, 
Annexin A1/THAP11 double knockdown cells did not exhibit growth kinetics 
different from THAP11 knockdown alone (Figure 3.23B), suggesting that 
increased Annexin A1 is dispensable for the growth defect conferred by THAP11 
knockdown in SW620 cells. 
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Discussion 
Evidence of the transcriptional regulatory properties of THAP proteins has 
been previously demonstrated using luciferase reporter constructs regulated by 
Gal4 DNA-binding domain THAP protein fusions.  However, very little is known 
regarding the identity of THAP protein gene targets, the mechanisms by which 
THAP proteins regulate transcription, or the cellular consequence of THAP 
protein function.  The work presented within this chapter provides substantial 
evidence to suggest that endogenous THAP11 functions as a transcriptional 
repressor in living cells.  An RNA interference based loss-of-function cell culture 
model was used to investigate the transcriptional regulatory properties of 
THAP11 in SW620 metastatic colon cancer cells.  Using this model, a THAP11 
dependent gene expression program was identified and found to contain both 
protein coding and non-coding genes.  De-repressed genes were shown to have 
chromatin bound THAP11 near their transcription start sites suggesting direct 
transcriptional repression.  THAP11 was found to recruit Host cell factor 1 (HCF-
1) to repressed genes and depletion of chromatin bound THAP11 and/or HCF-1 
resulted in increased transcription concomitant with elevated RNAPII occupancy.  
In addition, knockdown of endogenous THAP11 resulted in decreased cell 
proliferation suggesting THAP11 mediated transcriptional repression may 
contribute to cell growth regulation during colon cancer progression.  
  Loss-of-function cell culture models using RNA interference provide 
accessible biological systems to evaluate the function of novel transcription 
factors.  We employed this strategy to identify a THAP11 dependent gene 
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expression program in SW620 metastatic colon cancer cells which exhibit robust 
expression of THAP11.  Multiple THAP11 targeting and control short-hairpin 
RNAs were used to identify a core set of THAP11 responsive genes, the majority 
of which were de-repressed upon THAP11 knockdown.  Additional validation was 
provided by expression of a non-silenceable THAP11 construct which rescued 
the gene expression profile induced by both THAP11 knockdown constructs.  
The functional redundancy of this approach was necessary for several reasons.  
First, gene expression profiling using RNA interference frequently results in off-
target effects.  Multiple shRNAs and non-silenceable rescue expression increase 
the likelihood of finding authentic THAP11 gene targets.  Second, at the time of 
this undertaking no endogenous THAP11 regulated genes had been reported.  
While this work was in progress, an independent report identified c-myc as a 
directly repressed gene target of THAP11 in human HepG2 liver cancer cells 
(Zhu, Li et al. 2009).  Similarly, characterization of THAP11 in mouse embryonic 
stem cells identified GATA4 and GATA6 as direct gene targets of THAP11 
repression (Dejosez, Krumenacker et al. 2008).  We find that knockdown of 
THAP11 in SW620 did not de-repress c-myc, GATA4 or GATA6 and suggest cell 
type specific mechanisms may be responsible.  Importantly, several of the 
THAP11 gene targets identified here (Lsmd1, ncRNA00095, AA862256) were 
found to be induced by THAP11 knockdown in multiple human colon cancer cell 
lines and these genes may provide more tractable models to investigate the 
mechanism of THAP11 mediated repression. 
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 Knockdown of THAP11 resulted in a moderate but reproducible decrease 
in cell proliferation.  We speculated that increased Annexin A1 expression may 
explain the cell proliferation defect observed in THAP11 knockdown cells.  The 
role of Annexin A1 in cancer cell function is complex but several reports have 
suggested Annexin A1 can function in an anti-proliferative capacity.  Restoration 
of Annexin A1 in prostate cancer cell lines diminishes cell proliferation and 
sensitizes cells to apoptosis inducing agents (Hsiang, Tunoda et al. 2006).  
Similarly, HDAC inhibitor mediated apoptosis in Kasumi-1 leukemia cells is 
dependent on upregulation of endogenous Annexin A1 (Tabe, Jin et al. 2007).  
Of particular interest is the finding that Annexin A1 induction correlates with the 
differentiation status of colon cancer cell lines following butyrate treatment 
(Guzman-Aranguez, Olmo et al. 2005; Lecona, Barrasa et al. 2008).  However, 
simultaneous knockdown of Annexin A1 in THAP11 knockdown SW620 cells 
failed to rescue the THAP11 knockdown induced cell proliferation defect.  
Furthermore, constitutive overexpression of Annexin A1 in normal SW620 also 
failed to phenocopy the reduced cell proliferation associated with THAP11 
knockdown (data not shown).  Since increased Annexin A1 expression in SW620 
cells is neither necessary nor sufficient to perturb cell proliferation, an additional 
Annexin A1 independent mechanism must be at work.  Additional experiments 
will be required to determine if altered cell cycle kinetics or cell attrition due to 
apoptosis explain the THAP11 dependent cell proliferation defect.  It should be 
noted that while this data likely precludes Annexin A1 from a role in THAP11 
dependent colon cancer cell proliferation, additional biological outcomes resulting 
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from THAP11 directed repression of Annexin A1 may be identified.  For instance, 
cell surface externalized Annexin A1 functions as an “eat me” signal to promote 
phagocytosis of apoptotic cells while in necrotic cells Annexin A1 has been 
shown to be an important mechanism to prevent proinflammatory cytokine 
production following phagocytosis by macrophages (Tabe, Jin et al. 2007; Blume, 
Soeroes et al. 2009).  An interesting but currently unexplored corollary suggests 
that Annexin A1 deficient apoptotic/necrotic tumor cells may trigger 
proinflammatory cytokine production following phagocytosis by tumor associated 
macrophages thereby promoting a microenvironment favorable for tumor 
formation and metastasis dissemination.  This may be especially relevant in 
colon cancer metastasis to the liver where Kupffer cells (liver macrophages) line 
the hepatic sinusoids and provide the first barrier to intravasation and 
colonization by circulating tumor cells (Bayon, Izquierdo et al. 1996; Timmers, 
Vekemans et al. 2004).          
Amongst the protein coding genes identified as directly repressed by 
THAP11 is Lsmd1.  Lsmd1 (also referred to as hMak31p and hNAA38p) is a 
recently identified subunit of the Nα-terminal acetyltransferase complex C (NatC) 
(Starheim, Gromyko et al. 2009).  Three Nα-terminal acetyltransferase 
complexes, NatA, NatB and NatC have been identified and partially 
characterized in human cells.  Each NAT complex displays specificity for 
particular N-terminal peptide sequences but collectively account for the vast 
majority of protein Nα-terminal acetylation in eukaryotic cells (Starheim, Gromyko 
et al. 2009).  More than 80% of human proteins contain Nα-terminal acetylation 
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and several studies have linked this modification with cell proliferation, survival, 
differentiation, and cancer (Starheim, Gromyko et al. 2009). 
Repression of Lsmd1 resulting from increased THAP11 expression during 
colon cancer progression may decrease NatC function and Nα-terminal 
acetylation of NatC substrates.  Only two NatC substrates have been identified to 
date; in human cells the Arf-like GTPase hArl8b and in zebrafish the target of 
rapamycin (TOR) (Wenzlau, Garl et al. 2006; Starheim, Gromyko et al. 2009).  
Experimental models of loss of NatC function have demonstrated mislocalization 
of hArl8b in HeLa cells and loss of TOR expression and signaling in zebrafish, 
thereby underscoring the relevance of Nα-terminal acetylation in proper 
biological function of NatC substrates (Wenzlau, Garl et al. 2006; Starheim, 
Gromyko et al. 2009).  In addition, RNA interference mediated depletion of 
Lsmd1 or additional NatC subunits resulted in cell growth arrest and apoptosis in 
a p53 dependent manner.  Knockdown of NatC subunits in HeLa or HCT-116 
cells decreased Mdm2 protein levels resulting in stabilized p53 and increased 
transcription of pro-apoptotic p53 target genes (Starheim, Gromyko et al. 2009).  
Importantly, HCT-116 p53-/- cells were unaffected by NatC complex knockdown 
confirming the role of functional p53 in the apoptotic response to loss of NatC 
function (Starheim, Gromyko et al. 2009).  This apparent p53 requirement may 
explain the paradoxical finding that gain of THAP11 expression can repress 
Lsmd1 expression without triggering an apoptotic response.  Human colon 
cancer cell lines expressing the highest THAP11 protein amounts (SW620, 
Colo320HSR) also contain gain-of-function p53 mutations which effectively 
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divorce p53 from the apoptotic transcriptional program (Brosh and Rotter 2009).  
Rather, gain-of-function mutant p53R273H/P309S, basally expressed at high levels in 
SW480 and SW620 cells, has been shown to confer increased tumorigenic 
properties to SW480 cells (Yan and Chen 2009).  Thus, gain-of-function mutation 
in p53 may provide a favorable genetic environment for increased THAP11 
expression and concomitant reduction in Lsmd1.        
In addition to protein coding genes, several annotated or putative long 
non-coding RNAs were also identified as direct targets of THAP11 mediated 
transcriptional repression including ncRNA00095 and AA862256.  The fortuitous 
discovery of these ncRNAs as THAP11 regulated transcripts by microarray 
based gene expression profiling likely reflects their previous but erroneous 
annotation as protein coding genes with subsequent inclusion in the microarray 
design.  Many long ncRNAs have been discovered to be regulated by the same 
transcriptional control mechanisms also utilized by protein coding mRNAs 
including recruitment of RNAPII, regulation by positive and negative trans-acting 
factors, and deposition of histone modifications associated with active promoters 
and RNA splicing (Guttman, Amit et al. 2009).  Accordingly, we speculate that 
additional long ncRNAs are likely regulated by THAP11.  Recent advances in 
massively parallel sequencing technology should greatly facilitate the complete 
annotation of both coding and non-coding THAP11 regulated RNAs. 
Long ncRNAs are now well established to contribute to a diverse array of 
biological functions including transcriptional regulation, cell growth and apoptosis 
(Taft, Pang et al. 2010).  However the vast majority of long ncRNAs are 
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uncharacterized.  It is tempting to speculate that THAP11 mediated regulation of 
non-coding RNAs, including ncRNA00095 and AA862256, plays a critical role in 
cancer cell growth.  Future studies will be necessary to identify the biological 
function of THAP11 repressed non-coding RNAs ncRNA00095 and AA862256.  
Knockdown of these ncRNAs in conjunction with THAP11 knockdown should 
reveal if their increased expression is necessary for the cell proliferation defect 
observed in THAP11 knockdown cells.  
 THAP11 was found to physically associate with HCF-1 in various colon 
cancer cell lines and recruit HCF-1 to repressed gene promoters.  Since HCF-1 
lacks intrinsic DNA binding capacity, THAP11 likely functions as the sequence 
specific determinant responsible for HCF-1 recruitment to chromatin.  In support 
of this assertion, we find that the chromatin occupancy profile of HCF-1 closely 
parallels that observed for THAP11 and knockdown of THAP11 releases HCF-1 
from chromatin.  Loss of HCF-1 from THAP11 repressed promoters either by 
diminished recruitment resulting from THAP11 knockdown or reduction in total 
cellular HCF-1 arising from HCF-1 knockdown resulted in increased RNAPII 
occupancy coincident with increased transcription.  This indicates an essential 
role for HCF-1 in THAP11 mediated repression.  In agreement with these results, 
a previous biochemical purification of THAP11 from mouse embryonic stem cells 
also identified THAP11 in complex with HCF-1 but the contribution of HCF-1 
towards THAP11 dependent transcriptional repression was not established 
(Dejosez, Krumenacker et al. 2008). 
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While the association with HCF-1 may be a general feature of THAP11 
mediated repression, additional cell type specific mechanisms may also occur.  
For instance, loss of THAP11 from GATA4 and GATA6 promoters during ES cell 
differentiation correlated with a decrease in dimethylation of H3K9 at those 
promoters coincident with transcriptional activation (Dejosez, Krumenacker et al. 
2008).  In contrast, we find no detectable H3K9 dimethylation at THAP11 targets 
in SW620 cells (data not shown).   
This specificity may be determined by THAP11 or alternatively may be 
dictated by HCF-1.  HCF-1 is synthesized as a 230-kDa precursor which 
undergoes autocatalytic proteolysis at a series of 20-amino acid repeats present 
in the central domain of the protein (Vogel and Kristie 2000).  The resulting 
proteolytic fragments remain tightly associated forming mature HCF-1; a 
heterodimeric complex of non-covalently associated amino- and carboxy-terminal 
subunits (Vogel and Kristie 2000).  These site-specific processing events have 
been previously shown to influence both the protein interaction and 
transcriptional regulatory properties of HCF-1 and may account for the 
mechanistic differences observed in THAP11 mediated repression between 
mouse ES and human colon cancer cell lines (Vogel and Kristie 2006).   
 In the context of transcriptional repression, HCF-1 is known to associate 
with the SIN3/HDAC histone deacetylase complex and results presented in 
chapter 2 of this thesis demonstrate THAP11 can also associate with HDACs.  
Consistent with that data, a small but detectable amount of HDAC1 was found 
present in the THAP11/HCF-1 complex.  However, de-repression associated with 
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release of THAP11 results in increased histone acetylation only at Lsmd1 and 
not at ncRNA00095.  This suggests that either THAP11 or HCF-1 tethers an 
additional, HDAC independent transcriptional repressor to THAP11 bound 
chromatin.  An intriguing candidate to mediate the HDAC independent 
component of THAP11/HCF-1 repression is O-linked glycosyltransferase (OGT) 
which catalyzes the reversible addition of a single N-acetylglucosamine in O-
glycosidic linkage (O-GlcNAc) to serine or threonine residues.  OGT has 
previously been demonstrated to account for the HDAC independent component 
of SIN3 mediated transcriptional repression and has recently been shown to be 
necessary for Polycomb repression of Hox genes during development in 
Drosophila (Yang, Zhang et al. 2002; Gambetta, Oktaba et al. 2009; Sinclair, 
Syrzycka et al. 2009).  We find OGT stably associated with the THAP11/HCF-1 
complex and bound to THAP11 repressed promoters.  Interestingly, SIN3 was 
not found associated with the THAP11/HCF-1 complex but because OGT is 
known to co-purify with HCF-1 this may obviate the requirement for SIN3.     
Numerous transcription factors including Sp1 and RNAPII have been 
found to be O-GlcNAcylated with corresponding alterations in their transcriptional 
regulatory properties (Comer and Hart 2001; Ozcan, Andrali et al. 2010).  
Modification of Sp1 activation domains with O-GlcNAc inhibits Sp1 mediated 
transcriptional activation by disrupting the hydrophobic interactions between Sp1 
and members of the transcriptional activation complex including the TFIID 
subunit TAF4 (Yang, Su et al. 2001).  Similarly, O-GlcNAcylation of RNAPII at 
serine residues in its C-terminal domain (CTD) is thought to negatively regulate 
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transcriptional elongation by preventing CTD phosphorylation which is essential 
for the transition from transcription initiation to elongation (Comer and Hart 2001; 
Yang, Zhang et al. 2002).  Each of the direct THAP11 gene targets examined 
here (Lsmd1, ncRNA00095, AA862256, Praf2, C1orf83, ZSCAN20) resides 
within a CpG island and accordingly contain several putative Sp1 binding GC-
boxes.  Chromatin immunoprecipitation experiments find RNAPII and Sp1 (data 
not shown) enriched at THAP11 bound regions.  Thus, an intriguing possibility is 
that chromatin bound THAP11 may recruit an HCF-1/OGT complex resulting in 
O-GlcNAcylation of Sp1 and/or RNAPII CTD.  The resulting transcriptional 
repression may arise from either decreased transcription initiation, elongation or 
a combination of the two.  Consistent with this hypothesis we find that 
knockdown of THAP11 increases the occupancy of RNAPII at THAP11 
repressed genes.  Ongoing studies are actively engaged in determining the role 
of OGT and O-GlcNAc modification in THAP11 mediated transcriptional 
repression. 
HCF-1 was initially identified as a transcriptional co-activator necessary for 
the expression of immediate early genes following α-herpesvirus infection and 
has also been shown to associate with several DNA binding proteins including 
both activating and repressing E2F family members (Tyagi, Chabes et al. 2007).  
With respect to E2F proteins, HCF-1 plays a directive role, tethering the 
appropriate transcriptional regulatory complex with the corresponding activating 
(E2F1) or repressing (E2F4) E2F protein (Tyagi, Chabes et al. 2007).  When 
bound to E2F1, HCF-1 functions as a transcriptional co-activator by recruiting 
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histone H3 lysine 4 methyltransferase activities (Tyagi, Chabes et al. 2007).  In 
association with E2F4 however, HCF-1 mediates transcriptional repression by 
recruiting the SIN3/HDAC complex (Tyagi, Chabes et al. 2007).   
The role of HCF-1 in THAP protein regulated transcription appears to 
parallel the transcriptional dichotomy observed with E2F proteins.  As described 
above, HCF-1 is an integral component of THAP11 mediated repression.  In 
contrast, HCF-1 has recently been shown to be necessary for THAP1 and 
THAP3 mediated transcriptional activation (Mazars, Gonzalez-de-Peredo et al. 
2010).  Loss of HCF-1 diminished THAP1 activation of the RRM1 gene in human 
primary vascular endothelial cells (Mazars, Gonzalez-de-Peredo et al. 2010).  
Similarly, THAP3 tethered to the minimal promoter of an integrated luciferase 
reporter construct as a Gal4-DNA binding domain fusion protein was shown to 
positively regulate transcription in an HCF-1 dependent manner (Mazars, 
Gonzalez-de-Peredo et al. 2010).  Thus, like E2F proteins, THAP domain 
proteins appear to utilize HCF-1 to direct opposing transcriptional outcomes.   
The majority of human THAP proteins (THAP1-7, THAP9, and THAP11) 
have been shown to possess HCF-1 binding motifs and interact with HCF-1 by 
yeast two-hybrid assay (Mazars, Gonzalez-de-Peredo et al. 2010). Previously 
published results from our laboratory and presented within chapter 2 of this 
thesis has demonstrated that several of these putative HCF-1 binding THAP 
proteins including THAP7 and THAP4 repress basal transcription as Gal4-DNA 
binding domain fusion proteins.  Future studies should determine if HCF-1 plays 
a similar role in regulating the transcriptional repressor functions of those THAP 
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proteins.  In addition, subsequent work should also be performed to determine 
the mechanistic basis for THAP protein/HCF-1 complex mediated transcriptional 
activation versus repression.  
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Figure 3.1:  THAP11 knockdown by retrovirally delivered shRNA in SW620 cells.  (A)  SW620 cells were transduced 
with retrovirus expressing the indicated shRNA and selected with puromycin as described in Experimental Procedures.  
Whole cell extracts were prepared four days post-transduction and immunoblotted for THAP11 and β-actin.  (B)  
Quantitative RT-PCR analysis of THAP11 mRNA in cells expressing the indicated shRNA as in (A).  RNA levels are 
normalized to β-actin and expressed as percentage of THAP11 mRNA relative to non-specific shRNA (shNS).  Values 
represent the mean ± standard deviation of triplicate quantitative RT-PCR reactions from a representative experiment. 
Experiments in (A) and (B) were performed three times with similar results.  (C) Schematic depicting the position of the 
indicated shRNA targeting sequences (black rectangles) on the intronless THAP11 gene.  THAP11 coding sequence is 
represented by the thick blue rectangle while untranslated sequence is represented by thin blue rectangles. 
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Figure 3.2:  Gene expression analysis in THAP11 knockdown SW620 cells.  (A)  Heat map depicting microarray-
based gene expression profiling in SW620 cells expressing either control (shNS and shNS2) or THAP11 (shT11A and 
shT11C) shRNAs.  (B)  Validation of microarray determined gene expression changes by qRT-PCR.  Values represent 
mean ± standard deviation of triplicate quantitative RT-PCR reactions of a representative experiment performed at least 
three times.
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Figure 3.3:  Nuclear run-on assay in THAP11 knockdown SW620 cells.  (A) Schematic of modified nuclear run-on 
assay.  Adapted from (Core, Waterfall et al. 2008).  (B)  Steady-state and nascent mRNA levels of putative THAP11 gene 
targets in THAP11 knockdown SW620 cells.  Steady-state mRNA determinations of the indicated genes was performed 
by qRT-PCR from total RNA prepared from cells expressing either control (shNS) or THAP11 (shT11C) shRNA.  Nascent 
mRNA levels were analyzed from identical cell populations as steady-state determinations using a modified nuclear run-
on assay as described in Experimental Procedures.  Steady-state and nascent mRNA levels were normalized to β-actin 
and expressed as fold change relative to SW620 expressing control (shNS) shRNA.  Values represent mean ± standard 
deviation of triplicate quantitative RT-PCR reactions of a representative experiment performed at least twice.   
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Figure 3.4:  Expression of non-silenceable THAP11 reverses gene expression induced by THAP11 knockdown.  
(A) Schematic of the site-directed mutagenesis stratagey used to create a non-silenceable THAP11 rescue construct.  
Silent mutations (in red) were introduced into three consecutive codons of a THAP11-3xFLAG expression construct at 
targeting sequences corresponding to shRNAs shT11A and shT11C.  The encoded amino acids are indicated below their 
respective codons.  (B)  Immunoblot analysis of SW620 cells expressing either control (Empty) or THAP11-Rescue-
3xFLAG (Rescue) and the indicated shRNA.  Whole cell extracts were first immunoblotted with anti-THAP11 antibody to 
detect endogenous (red arrow) or rescue (black arrow) THAP11.  Blots were stripped and reprobed with anti-FLAG and 
anti-β-actin.  (C)  Quantitative RT-PCR analysis of THAP11 and Lsmd1 expression in SW620 cells expressing either 
control (Empty) or THAP11-Rescue-3xFLAG (Rescue) and the indicated shRNA.  RNA levels are normalized to β-actin 
and expressed as fold change relative to SW620 expressing control shRNA (shNS) and rescue (Empty) constructs.  
Values represent mean ± standard deviation of triplicate quantitative RT-PCR reactions.  (B) and (C) are representative 
experiments of at least three separate experiments with similar results. 
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Table 3.1:  Summary of genes re-repressed by THAP11 rescue. 
 
Quantitative RT-PCR analysis of THAP11 target genes in SW620 cells expressing either control (Empty) or THAP11-
Rescue-3xFLAG (Rescue) and the indicated shRNA as in Figure 3.4.  RNA levels are normalized to β-actin and 
expressed as fold change relative to SW620 expressing control shRNA (shNS) and rescue (Empty) constructs.  Values 
represent mean ± standard deviation of triplicate quantitative RT-PCR reactions from a representative experiment. 
 111
 
Figure 3.5:  THAP11 knockdown de-represses putative THAP11 gene targets in Colo320HSR cells.  SW620 and 
Colo320HSR were transduced with retrovirus encoding control (shNS) or THAP11 (shT11A or shT11C) shRNA.  Cells 
were harvested four days post-transduction and gene expression determined by quantitative RT-PCR.  Values were 
normalized to β-actin and expressed as fold change relative to control (shNS) shRNA.   Values represent mean ± 
standard deviation of triplicate quantitative RT-PCR reactions from a representative experiment performed at least three 
times with similar results.
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Figure 3.6:  Chromatin immunoprecipitation (ChIP) analysis of THAP11-Rescue-3xFLAG binding at Lsmd1 and 
ncRNA00095.  (A)  Schematic depicting the location of the regions (ChIP Amplicons) analyzed for THAP11-Rescue-
3xFLAG binding at Lsmd1 and ncRNA00095.  Numbers correspond to amplicon midpoint relative to transcription start site 
(TSS).  Amplicons exhibiting peak THAP11 binding are colored red.  (B)  SW620 cells depleted of endogenous THAP11 
by shT11A and expressing THAP11-Rescue-3xFLAG as in Figure 3.4 were analyzed by ChIP using anti-FLAG M2 
monoclonal antibody or control IgG as described in Experimental Procedures.  ChIP enriched DNA was analyzed by 
quantitative PCR at the regions depicted in (A) and expressed as percent recovery relative to input.  Values represent the 
mean ± standard deviation of duplicate quantitative PCR reactions from a representative experiment performed twice. 
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Figure 3.7:  Chromatin immunoprecipitation (ChIP) analysis of THAP11-Rescue-3xFLAG binding at AA862256 and 
Praf2.  (A)  Schematic depicting the location of the regions (ChIP Amplicons) analyzed for THAP11-Rescue-3xFLAG 
binding at AA862256 and Praf2.  Numbers correspond to amplicon midpoint relative to transcription start site (TSS).  
Amplicons exhibiting peak THAP11 binding are colored red. (B)  SW620 cells depleted of endogenous THAP11 by 
shT11A and expressing THAP11-Rescue-3xFLAG and were analyzed by ChIP using anti-FLAG M2 monoclonal antibody 
or control IgG as described in Figure 3.6.  ChIP enriched DNA was analyzed by quantitative PCR at the regions depicted 
in (A) and expressed as percent recovery relative to input.  Values represent the mean ± standard deviation of duplicate 
quantitative PCR reactions from a representative experiment performed twice. 
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Figure 3.8:  Chromatin immunoprecipitation (ChIP) analysis of THAP11-Rescue-3xFLAG binding at C1orf83 and 
ZSCAN20.  (A)  Schematic depicting the location of the regions (ChIP Amplicons) analyzed for THAP11-Rescue-3xFLAG 
binding at C1orf83 and ZSCAN20.  Numbers correspond to amplicon midpoint relative to transcription start site (TSS).  
Amplicons exhibiting peak THAP11 binding are colored red. (B)  SW620 cells depleted of endogenous THAP11 by 
shT11A and expressing THAP11-Rescue-3xFLAG and were analyzed by ChIP using anti-FLAG M2 monoclonal antibody 
or control IgG as described in Figure 3.6.  ChIP enriched DNA was analyzed by quantitative PCR at the regions depicted 
in (A) and expressed as percent recovery relative to input.  Values represent the mean ± standard deviation of duplicate 
quantitative PCR reactions from a representative experiment performed twice. 
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Figure 3.9:  Chromatin immunoprecipitation (ChIP) analysis of endogenous THAP11. (A) THAP11 occupancy at the 
indicated regions in SW620 cells as determined by ChIP assay using anti-THAP11 or control IgG.  (B) Control (shNS) or 
THAP11 (shT11C) knockdown SW620 cells were analyzed by ChIP as in (A).  ChIP enriched DNA was analyzed by 
quantitative PCR at the indicated regions and expressed as percent recovery relative to input.  Values represent the mean 
± standard deviation of duplicate quantitative PCR reactions from a representative experiment performed three times with 
similar results. 
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Figure 3.10:  Chromatin immunoprecipitation (ChIP) analysis of RNAPII at Lsmd1 and ncRNA00095 in THAP11 
knockdown SW620 cells. RNAPII occupancy at (A) Lsmd1 and (B) ncRNA00095 in control (shNS) or THAP11 (shT11C) 
knockdown SW620 cells were determined by ChIP assay.  ChIP enriched DNA was analyzed by quantitative PCR at the 
indicated regions and expressed as percent recovery relative to input.  Values represent the mean ± standard deviation of 
duplicate quantitative PCR reactions from a representative experiment performed three times. 
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Figure 3.11:  Chromatin immunoprecipitation (ChIP) analysis of RNAPII at Lsmd1 and β-actin in THAP11 
knockdown and THAP11 rescue SW620 cells.  (A) ChIP analysis of RNAPII occupancy at Lsmd1 in SW620 cells 
expressing either control (shNS) or THAP11 (shT11A) shRNA and either control (Empty) or THAP11-Rescue-3xFLAG 
(Rescue).  (B) ChIP analysis of RNAPII occupancy at the β-actin promoter from the indicated SW620 cells as in (A) ChIP 
enriched DNA was analyzed by quantitative PCR at the indicated regions and expressed as percent recovery relative to 
input.  Values represent the mean ± standard deviation of duplicate quantitative PCR reactions from a representative 
experiment performed three times. 
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Figure 3.12:  Chromatin immunoprecipitation (ChIP) analysis of Acetyl-K9/K18 histone H3 at Lsmd1 and 
ncRNA00095 in THAP11 knockdown SW620 cells. Acetyl-K9/K18 histone H3 (AcH3) occupancy at (A) Lsmd1 and (B) 
ncRNA00095 in control (shNS) or THAP11 (shT11C) knockdown SW620 cells were analyzed by ChIP assay.  ChIP 
enriched DNA was analyzed by quantitative PCR at the indicated regions and expressed as percent recovery relative to 
input.  Values represent the mean ± standard deviation of duplicate quantitative PCR reactions from a representative 
experiment performed three times. 
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Figure 3.13:  THAP11 interacts with HCF-1 in colon cancer cells.  (A)  Endogenous THAP11 co-precipitates with HCF-
1 in SW620 cells. SW620 nuclear extract was immunoprecipitated with either control IgG or HCF-1 antibody and the 
immunoprecipitates were immunoblotted with either HCF-1 or THAP11 antibodies.  Input corresponds to 2% (40μg) of 
starting material.  (B)  THAP11 associates with HCF-1 in various colon cancer cell lines.  Nuclear extracts from 
Colo320HSR, SW480, or HCT-116 were immunoprecipitated and immunoblotted as in (A).  Input corresponds to 10% 
(40μg) of starting material.  (C) HCF-1 and THAP11 can stably associate in the absence of DNA binding.  SW620 nuclear 
extracts were immunoprecipitated as in (A) (-EtBR panel) or preincubated with 100μg/ml ethidium bromide for 30 minutes 
prior to antibody addition (+EtBr panel) as described in Experimental Procedures.  Blots are representative of experiments 
performed at least twice.  HCF-1 precursor and proteolytic polypeptides are denoted by the arrow and bracket, 
respectively.  THAP11 is denoted by the arrow migrating beneath the IgG heavy chain which is indicated with an asterisk.    
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Figure 3.14:  THAP11 and HCF-1 co-occupancy on chromatin.  Chromatin immunoprecipitation of THAP11 (A) or 
HCF-1 (B) at Lsmd1 in SW620 cells.  ChIP enriched DNA was analyzed by quantitative PCR and expressed as percent 
recovery relative to input.  Values represent the mean ± standard deviation of duplicate quantitative PCR reactions from a 
representative experiment performed twice. (C) The chromatin occupancy profiles in (A) and (B) re-plotted as percent of 
maximum ChIP signal.  (D)  Chromatin immunoprecipitation of HCF-1 at THAP11 bound chromatin.  
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Figure 3.15:  Knockdown of THAP11 decreases HCF-1 occupancy on THAP11 target genes Lsmd1 and 
ncRNA00095.  SW620 cells expressing either control (shNS) or THAP11 (shT11C) shRNA were analyzed for HCF-1 
occupancy at Lsmd1 (A) or ncRNA00095 (B) by ChIP assay using either HCF-1 antibody or control IgG.  ChIP enriched 
DNA was detected by quantitative PCR and expressed as percent recovery relative to input.  Values represent the mean 
± standard deviation of duplicate quantitative PCR reactions from a representative experiment performed twice.  (C) 
Immunoblot of HCF-1 in whole cell extracts of SW620 cells expressing either control (shNS) or THAP11 knockdown 
(shT11C).  HCF-1 precursor and proteolytic polypeptides are indicated with the arrow and bracket, repsectively. 
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Figure 3.16:  Knockdown of HCF-1 de-represses THAP11 target genes. SW620 cells were retrovirally transduced with 
the indicated pSRNG shRNA and transduction was verified by GFP fluorescence (data not shown).  Four days post-
transduction cells were harvested for whole cell extract and total RNA isolation.  (A)  Whole cell extracts were 
immunoblotted with HCF-1, THAP11, and β-actin antibodies. HCF-1 precursor and proteolytic polypeptides are denoted 
by the arrow and bracket, respectively.  THAP11 is indicated with an arrow and a non-specific band detected by anti-
THAP11 antibody is denoted with an asterisk.  (B)  RNA levels for Lsmd1 and ncRNA00095 were determined by 
quantitative RT-PCR, normalized to β-actin and expressed as fold change relative to control (shNS) shRNA.  Values 
represent the mean ± standard deviation of duplicate RT-PCR reactions.   (A) and (B) represent a single experiment 
repeated twice with similar results. 
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Figure 3.17:  Knockdown of HCF-1 increases RNA Polymerase II occupancy at Lsmd1.  HCF-1 and RNAPII 
occupancy at Lsmd1 in SW620 cells expressing either control (shNS) or HCF-1 (shHCF-1B) shRNA was determined by 
ChIP assay using antibodies to HCF-1 (top left), RNAPII (top right), or control IgG (bottom left). ChIP enriched DNA was 
detected by quantitative PCR and expressed as percent recovery relative to input.  Values represent the mean ± standard 
deviation of duplicate quantitative PCR reactions from a representative experiment performed twice.    
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Figure 3.18:  Affinity purification of THAP11/HCF-1/OGT/HDAC-1 complex from SW620 cells.  (A)  Schematic of two-
step affinity purification procedure using wheat germ agglutinin (WGA) and anti-FLAG agarose resins as described in 
Experimental Procedures.  (B)  Two-step purification of THAP11/HCF-1 complexes from SW620 cells expressing empty 
vector (E) or THAP11-3xFLAG (T11).  Recovery of HCF-1 and THAP11 was monitored by immunoblotting 5% of each 
fraction:  Nuclear extract (Input), WGA-FT (WGA-agarose flow through), WGA-Eluate (WGA-agarose bound and GlcNac 
eluted), FLAG-Eluate (FLAG-agarose bound and eluted by boiling).  Red arrow indicates endogenous THAP11; black 
arrow indicates THAP11-3xFLAG. (C) THAP11/HCF-1 complex contains OGT and HDAC1.  Two-step purified (FLAG 
Eluate) and WGA-purified (WGA Eluate) fractions from control (E) and THAP11-3xFLAG (T11) expressing SW620 cells 
were immunoblotted using antibodies for SIN3A, OGT, and HDAC1.  Arrows indicate the protein of interest.  IgG heavy 
chain is indicated with an asterisk.    
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Figure 3.19:  OGT occupancy at THAP11 repressed gene promoters.  ChIP assay was performed in SW620 using 
anti-OGT or normal rabbit IgG.  ChIP enriched DNA was detected by quantitative PCR and expressed as percent 
recovery relative to input.  Values represent the mean ± standard deviation of duplicate quantitative PCR reactions from a 
representative experiment performed twice.    
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Figure 3.20:  Knockdown of THAP11 restores Annexin A1 expression in SW620 cells.  (A) Annexin A1 (Anxa1) 
mRNA levels were determined in SW480, SW620 and SW620 cells expressing the indicated shRNA by quantitative RT-
PCR.  Values represent the mean ± standard deviation of triplicate quantitative PCR reactions from a representative 
experiment performed twice with similar results.  (B) Immunoblot analysis of whole cell extracts from cells in (A). 
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Figure 3.21:  Annexin A1 and THAP11 expression inversely correlate in colon cancer cell lines.  Whole cell extracts 
prepared from the indicated colon cancer cell lines were immunoblotted for THAP11 and Annexin A1 (Anxa1). 
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Figure 3.22:  Knockdown of THAP11 decreases cell proliferation.  SW620 cells were transduced with retrovirus 
expressing the indicated shRNA.  Four days post-transduction cells were plated in 96-well plates (5000 cells/well) and 
viable cells detected using Alamar Blue every 24 hours for 5 days as described in Experimental Procedures.  Values 
represent the mean ± standard deviation (n=8 wells) from a representative experiment performed four times with similar 
results. 
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Figure 3.23:  Annexin A1 de-repression is dispensable for decreased cell proliferation in THAP11 knockdown 
cells.  SW620 cells were transduced with pSRP retrovirus expressing control (shNS) or THAP11 (shT11) shRNA.  
Twenty-four hours later cells were transduced with pSRNG retrovirus expressing either control (shNS) or Annexin A1 
(shAnxa1) retrovirus.  Double-knockdown cells were selected with 2μg/ml puromycin and 1mg/ml Geneticin for 7 days.  
(A) Immunoblot analysis of Annexin A1 (Anxa1) expression in double-knockdown SW620 cells.  (B) Alamar Blue cell 
proliferation assay in double-knockdown SW620 cells. Values represent the mean ± standard deviation (n=8 wells) from a 
representative experiment performed twice with similar results. 
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Chapter 4:  General Conclusions and Future Directions 
THAP domain containing proteins are a recently identified and relatively 
uncharacterized family of proteins with putative function in DNA and chromatin 
dependent processes, including transcription.  The data presented within this 
thesis demonstrates that THAP4, THAP8, THAP10 and THAP11 possess 
transcriptional repressor activity when tethered to promoters as heterologous 
Gal4-DNA binding domain fusion proteins.  This finding is consistent with 
previous reports implicating THAP1 and THAP7 in transcriptional regulation and 
suggests that the majority of THAP proteins may function in this capacity.  
Further characterization of endogenous THAP11 revealed a THAP11 dependent 
gene expression program characterized by direct, THAP11 mediated 
transcriptional repression.  Directly repressed gene targets were found to contain 
chromatin bound THAP11 near their transcription start sites.  In addition, 
THAP11 was found to physically associate with and recruit the multi-functional 
transcriptional regulator HCF-1 to repressed promoters.  HCF-1 in turn was 
shown to be a critical effector of THAP11 mediated repression; knockdown of 
HCF-1 mirrored the transcriptional de-repression observed by THAP11 
knockdown.  THAP11 was also shown to be differentially expressed during 
human colon cancer progression.  Significantly higher THAP11 protein levels 
were observed in primary and metastatic tumor specimens as determined by 
immunohistochemical analysis of tissue microarrays.  Similar differential THAP11 
expression was also observed in human colon cancer cell lines including the 
SW480/SW620 isogenic cell culture model of colon cancer progression.  The 
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increase in THAP11 expression in colon cancer tumors and cell lines suggests 
that THAP11 dependent transcriptional repression may contribute to disease 
progression.  Consistent with this hypothesis we find that knockdown of THAP11 
in metastatic SW620 colon cancer cells results in a modest but significant 
decrease in cell proliferation.  Collectively, this data provides the first 
characterization of a directly regulated, THAP11 dependent gene expression 
program in human cells and suggests THAP11 may be an important 
transcriptional regulator in human colon cancer. 
Because the cognate DNA binding sequences of most THAP proteins are 
currently unknown, the data presented herein relied initially on the use of Gal4-
DNA binding domain fusion proteins to investigate the transcriptional regulatory 
properties of THAP proteins.  Endogenous THAP11 was subsequently shown to 
directly repress transcription, suggesting Gal4-THAP fusion proteins faithfully 
recapitulate the biological function of endogenous THAP proteins.  Nevertheless, 
definitive evidence of THAP protein mediated repression requires identification of 
directly regulated target genes.  The strategy employed here, knockdown of 
endogenous THAP protein with short hairpin RNAs in conjunction with epitope 
tagged non-silenceable rescue expression, should prove useful in identifying 
additional THAP protein gene targets using genome wide expression and 
chromatin occupancy profiling.  This approach should be immediately applicable 
to determining THAP10 gene targets under DNA damage conditions despite the 
current lack of THAP10 specific antibodies.  Furthermore, DNA binding site 
determination using genome wide chromatin immunoprecipitation techniques 
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avoids the inherent limitations associated with determining binding sites using in 
vitro iterative selection procedures like SELEX, including binding site over-
selection. 
The mechanism governing THAP11 chromatin occupancy near 
transcription start sites of directly repressed gene targets has not yet been 
determined.  The THAP domain of THAP11 may function as a sequence specific 
DNA binding zinc finger as reported for THAP1 and the Drosophila P element 
transposase.  Consistent with this possibility, Dejosez et al. reported a SELEX 
derived THAP11 binding sequence during their characterization of THAP11 as a 
mouse embryonic stem cell pluripotency factor.  However, a bioinformatic 
analysis has not identified this sequence in the THAP11 bound promoters 
described here.  This may reflect flexibility in the nucleotide sequences 
recognized by THAP11 or may indicate over-selection in the SELEX derived 
sequence.  Because the chromatin immunoprecipitation experiments described 
here have localized THAP11 to an approximately 500bp region, future 
experiments using DNAse I footprinting and electrophoretic mobility shift assays 
should allow us to determine if THAP11 directly binds DNA.  If THAP11 does 
indeed bind directly to DNA, then we anticipate several new lines of 
experimentation which should further our understanding of THAP11.  First, since 
we have currently identified six directly repressed target gene promoters, DNase 
I footprinting and EMSA with each bound promoter region should allow us to 
derive a biologically relevant THAP11 binding DNA motif.  Next, using this newly 
derived motif we should be able to identify the nucleotide determinants of 
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THAP11 binding using systematic nucleotide substitution and quantitative in vitro 
binding assays such as fluorescence polarization or EMSA.  Finally, alanine 
scanning mutagenesis of THAP domain amino acids should be useful in 
identifying the residues responsible for THAP11 sequence specific binding.  It 
remains possible that THAP11 does not bind to DNA directly.  In this scenario, 
THAP11 may bind specifically to histones or non-histone chromatin associated 
proteins.  THAP7 was previously shown to bind histones through its C-terminal 
histone interaction domain.  However, the C-termini of THAP proteins are poorly 
conserved suggesting THAP11 likely does not contain this domain. 
THAP11 mediated repression was shown to be dependent on HCF-1 but 
the precise molecular mechanism underpinning this repression remains to be 
determined (Figure 4.1).  The THAP11/HCF-1 complex was shown to contain 
HDAC1 and OGT.  Chromatin bound OGT was found at THAP11 repressed 
promoters but several attempts to ChIP HDAC1 were inconclusive.  Furthermore, 
histone acetylation was increased only at Lsmd1 and not at other de-repressed 
gene promoters following THAP11 knockdown.  This suggests that HCF-1 
tethers an HDAC independent transcriptional repressor activity to chromatin 
bound THAP11.  We speculate that this factor may be OGT but other factors may 
also be involved.  For instance, the HCF-1 carboxy-terminal subunit has 
previously been shown to associate with protein phosphatase 1.  Protein 
phosphatase 1 (PP1) is known to be capable of de-phosphorylating RNAPII CTD 
and, similarly to OGT, may repress transcription by inhibiting the conversion of 
RNAPII to the hyperphosphorylated elongating form.  An intriguing possibility 
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involves the combined effect of THAP11 recruited PP1 and OGT to 
dephosphorylate and O-GlcNAcylate RNAPII CTD, locking RNAPII in the 
hypophosphorylated state rendering it stalled at transcriptional start sites.  A 
similar mechanism involving dephosphorylation and O-GlcNAcylation of Sp1 may 
also account for THAP11 mediated repression.  These possibilities may explain 
the prevalence of chromatin bound THAP11 near transcriptional start sites of 
CpG island promoters.  Future experiments including co-immunoprecipitation, 
ChIP, and RNA interference should determine if either OGT or PP1 function in 
THAP11 mediated repression.  An unbiased purification of the THAP11/HCF-1 
protein complex is also warranted.  We anticipate that using an affinity 
purification scheme similar to the one outlined in chapter 3 in conjunction with 
mass spectrometry based proteomics should identify relevant candidate co-
effectors of THAP11 mediated transcriptional repression. 
THAP10 and THAP11 were found to be differentially expressed during 
DNA damage and colon cancer progression, respectively.  The contribution of 
these particular THAP proteins to the physiological processes associated with 
these distinct events remains to be determined.  With respect to THAP10, DNA 
damage frequently results in either cell cycle arrest or apoptosis depending on 
the cell type and extent of damage incurred.  Thus, future experiments with 
THAP10 will likely focus on its potential role in modulating these cellular 
responses to genotoxic insults.  These experiments would encompass both 
overexpression and knockdown of THAP10 in a variety of human cancer cell 
lines followed by DNA damage induction and subsequent determination of cell 
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cycle arrest and apoptotic response.  Future experiments aimed at determining 
the role of THAP11 in colon cancer progression will initially utilize the 
SW480/SW620 cell culture model.  As shown in chapter 3, knockdown of 
THAP11 in metastatic SW620 cells resulted in decreased cell proliferation.  This 
diminished proliferation may result from a cell cycle defect or cell attrition 
resulting from increased apoptosis.  Cell cycle analysis and apoptosis assays in 
THAP11 knockdown SW620 cells should be helpful in discriminating between 
these possibilities.  SW620 are more tumorigenic and metastatic than SW480 
cells in nude mouse xenograft assays and the role of THAP11 in promoting this 
phenotype will also be explored using SW620 knockdown cells.  To that end, we 
have recently created SW620 cells harboring both GFP and luciferase reporter 
constructs that should facilitate the detection of metastatic SW620 cells in live 
mice and dissected organs (Figure 4.2).  Similar experiments using 
overexpression of THAP11 in low-expressing colon cancer cell lines such as 
HCT-116 and HT-29 may also be informative. 
The experiments as described above will be critical in determining if 
THAP10 and THAP11 are “driver” or “bystander” genes in human DNA damage 
response and colon cancer progression, respectively.  These results 
notwithstanding, elucidation of the transcriptional regulatory properties of these 
and other THAP proteins remains a worthwhile endeavor.  Future lines of 
research may ascribe previously unforeseen roles for THAP proteins in normal or 
disease processes.  Having previously established molecular mechanisms for 
these THAP proteins may expedite the functional characterization of these 
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proteins in novel biological contexts.  Such a scenario appears to be playing out 
with respect to THAP1 where prior knowledge regarding its DNA binding and 
transcriptional regulatory properties has allowed dystonia researchers to 
hypothesize that mutations in THAP1 may account for DYT6 dystonia through 
disrupted THAP1 dependent gene expression. 
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Figure 4.1:  Proposed model of THAP11 mediated transcriptional repression.  THAP11 bound at promoters recruits 
HCF-1 to mediate transcriptional repression.  Repression by THAP11/HCF-1 may require additional effectors including 
HDAC1, OGT, and unknown (?) proteins.   
 
 138
 
Figure 4.2:  Creation of GFP and luciferase expressing SW620 THAP11 knockdown cells.  A) Procedure for creating 
SW620 cells stably expressing luciferase, GFP and shRNA.  SW620 cells were transduced with retrovirus expressing 
luciferase-IRES-GFP.  GFP positive cells were selected by fluorescence activated cell sorting (FACS).  SW620Luc-GFP cells 
were then transduced with retrovirus expressing THAP11 (shT11A, shT11C, shT11D) or control (shNS) and selected with 
puromycin.  (B, Left Panel)  Phase contrast and fluorescence microcospy images of SW620Luc-GFP cells.  (B, Right Panel)  
Whole cell extracts from parental SW620Luc-GFP cells and cells expressing the indicated shRNA were immunobloted 
THAP11, β-actin, luciferase and GFP.   
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Appendix 
Table A.1:  shRNA sequences 
Target shRNA Targeted mRNA Sequence 
THAP11 T11A GCGAAGAACUGCGUGAGAA 
THAP11 T11C UGAUGGAAGUGAAGAUGAA 
THAP11 T11D GAGAAGACGUGAAGCCCAU 
THAP11 T11E GAAGUGAAGAUGAAAGAGA 
THAP11 T11F CUGAAUGAGCAGCGGGACA 
THAP11 T11I CCGCAAGACCUACACGGUA 
Annexin A1 Anxa1A CAAAGGAGAUUAUGAGAAA 
Annexin A1 Anxa1B GGAUGAAACACUUAAGAAA 
Annexin A1 Anxa1C GAGAGGAACUGAAGAGAGA 
Annexin A1 Anxa1D GAAAGGUGACAUUGAGAAA 
HCF-1 HCF-1A GGAGCUCAUCGUGGUGUUU 
HCF-1 HCF-1B GGAAGAGACUCAAAGCAAA 
HCF-1 HCF-1C AGUCCAAGCUGGUGAUCUA 
HCF-1 HCF-1D GAGAAGGAGUGGAAGUGUA 
 
Table A.2:  shRNA cloning oligonucleotides 
Oligo Name Sequence 
T11A Top GATCCCCGCGAAGAACTGCGTGAGAATTCAAGAGATTCTCACGCAGTTCTTCGCTTTTTA 
T11A Bottom AGCTTAAAAAGCGAAGAACTGCGTGAGAATCTCTTGAATTCTCACGCAGTTCTTCGCGGG 
T11C Top GATCCCCTGATGGAAGTGAAGATGAATTCAAGAGATTCATCTTCACTTCCATCATTTTTA 
T11C Bottom AGCTTAAAAATGATGGAAGTGAAGATGAATCTCTTGAATTCATCTTCACTTCCATCAGGG 
T11D Top GATCCCCGAGAAGACGTGAAGCCCATTTCAAGAGAATGGGCTTCACGTCTTCTCTTTTTA 
T11D Bottom AGCTTAAAAAGAGAAGACGTGAAGCCCATTCTCTTGAAATGGGCTTCACGTCTTCTCGGG 
T11E Top GATCCCCGAAGTGAAGATGAAAGAGATTCAAGAGATCTCTTTCATCTTCACTTCTTTTTA 
T11E Bottom AGCTTAAAAAGAAGTGAAGATGAAAGAGATCTCTTGAATCTCTTTCATCTTCACTTCGGG 
T11F Top GATCCCCCTGAATGAGCAGCGGGACATTCAAGAGATGTCCCGCTGCTCATTCAGTTTTTA 
T11F Bottom AGCTTAAAAACTGAATGAGCAGCGGGACATCTCTTGAATGTCCCGCTGCTCATTCAGGGG 
T11I Top GATCCCCCCGCAAGACCTACACGGTATTCAAGAGATACCGTGTAGGTCTTGCGGTTTTTA 
T11I Bottom AGCTTAAAAACCGCAAGACCTACACGGTATCTCTTGAATACCGTGTAGGTCTTGCGGGGG 
Anxa1A Top GATCCCCCAAAGGAGATTATGAGAAATTCAAGAGATTTCTCATAATCTCCTTTGTTTTTA 
Anxa1A Bottom AGCTTAAAAACAAAGGAGATTATGAGAAATCTCTTGAATTTCTCATAATCTCCTTTGGGG 
Anxa1B Top GATCCCCGGATGAAACACTTAAGAAATTCAAGAGATTTCTTAAGTGTTTCATCCTTTTTA 
Anxa1B Bottom AGCTTAAAAAGGATGAAACACTTAAGAAATCTCTTGAATTTCTTAAGTGTTTCATCCGGG 
Anxa1C Top GATCCCCGAGAGGAACTGAAGAGAGATTCAAGAGATCTCTCTTCAGTTCCTCTCTTTTTA 
Anxa1C Bottom AGCTTAAAAAGAGAGGAACTGAAGAGAGATCTCTTGAATCTCTCTTCAGTTCCTCTCGGG 
Anxa1D Top GATCCCCGAAAGGTGACATTGAGAAATTCAAGAGATTTCTCAATGTCACCTTTCTTTTTA 
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Anxa1D Bottom AGCTTAAAAAGAAAGGTGACATTGAGAAATCTCTTGAATTTCTCAATGTCACCTTTCGGG 
HCF-1A Top GATCCCCGGAGCTCATCGTGGTGTTTTTCAAGAGAAAACACCACGATGAGCTCCTTTTTA 
HCF-1A Bottom AGCTTAAAAAGGAGCTCATCGTGGTGTTTTCTCTTGAAAAACACCACGATGAGCTCCGGG 
HCF-1B Top GATCCCCGGAAGAGACTCAAAGCAAATTCAAGAGATTTGCTTTGAGTCTCTTCCTTTTTA 
HCF-1B Bottom AGCTTAAAAAGGAAGAGACTCAAAGCAAATCTCTTGAATTTGCTTTGAGTCTCTTCCGGG 
HCF-1C Top GATCCCCAGTCCAAGCTGGTGATCTATTCAAGAGATAGATCACCAGCTTGGACTTTTTTA 
HCF-1C Bottom AGCTTAAAAAAGTCCAAGCTGGTGATCTATCTCTTGAATAGATCACCAGCTTGGACTGGG 
HCF-1D Top GATCCCCGAGAAGGAGTGGAAGTGTATTCAAGAGATACACTTCCACTCCTTCTCTTTTTA 
HCF-1D Bottom AGCTTAAAAAGAGAAGGAGTGGAAGTGTATCTCTTGAATACACTTCCACTCCTTCTCGGG 
T11A Top GATCCCCGCGAAGAACTGCGTGAGAATTCAAGAGATTCTCACGCAGTTCTTCGCTTTTTA 
 
Table A.3:  Non-silenceable THAP11 site-directed mutagenesis primers 
Primer Sequence 
T11A Rescue F GCTGCGCGAAGAGCTCCGCGAGAAGGATCGGC 
T11A Rescue R GCCGATCCTTCTCGCGGAGCTCTTCGCGCAGC 
T11CE Rescue F GACATCCTGGCTCTGATGGAGGTCAAAATGAAAGAGATGAAAGGC 
T11CE Rescue R GCCTTTCATCTCTTTCATTTTGACCTCCATCAGAGCCAGGATGTC 
 
 
Table A.4:  ChIP primer sequences 
Amplicon 
(Gene, Center Position 
Relative to TSS) 
Forward Primer  
Sequence 
Reverse Primer 
 Sequence 
AA862256, -1778 CAATTACGGCCAGCTGTCTT TTATGTCCCACCCTTTGGAG 
AA862256, -1340 CTAAGCCCTTCCCAGATTCC CACAGTCCCCTTTTCTCAGC 
AA862256, -909 CATCTAGCGCCATCACAAAA TGGTTATGCGCAAGAAAACA 
AA862256, -566 CCTCGCCTTAGAGGCTTTCT GCACCAGTTGGTGGAAACTT 
AA862256, 101 GGCGACTCTACAAGCCTCAC GAGGGAAGGGTAAGGTGTCC 
AA862256, 619 TTGATGAAGCACGCAACTTC AACCCTACAAGGCGGGTACT 
AA862256, 1254 GCACGAAGGTAACCACCACT GTAGCCCAACAAGCAAGGTC 
AA862256, 1827 TGAATCCCAGGAGCACTTTC CAGGTAGGGATGCAGGTTGT 
AA862256, 2454 CCTTTCAATTGCATGGTGGT CCTCCCAAACCAGTTTTGAT 
AA862256, 2993 TCTGTGGGATCCAGAGTGGT CATCCTAGCATTGCTTGAAAA 
AA862256, 3656 AGGGGCCATGTAACAGTGAG TTCCGTCTCCTCACAAAGAAA 
AA862256, 4430 GCCTGACAATGTGATTGGTG ATGGGGTGAAAGCCTGATTA 
AA862256, 5141 TTGAAGCCCAACCCTTAGTG TAAAGCCACCAATCCAATCC 
AA862256, 5757 GAAACTGAGCAGGCCTTTTG TAAGGGGTAGGCCTGGAACT 
AA862256, 5981 ACCTGAGGCACCAGACACAT TTTGGGTTGACTGGATGGAT 
AA862256, 6426 CTGAAACAGGCTAGGCATGG CATGAAGGAAGAAGGGAGCA 
Alg14, -1869 ACGCATTTGTAAGCCCAGAG AAGGGTGGAGAAAGTTCATAGTTG 
Alg14, -1247 GAATGGACACGCTGGTTACA CAGACTCCCAGGGTCCATTA 
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Alg14, -767 CATCATTTTGGCTGAGGACA TGCAAAGCTCAGTGGCTCTA 
Alg14, -80 ATTGTGACTGGGACCTCAGC GTCTTGGTGGGCTGGTCTT 
Alg14, 659 AAAACAATGATCTACGGGCTGT TGACAGGTCAGTGTGTTGCTC 
Alg14, 1195 TGCTATGGCAGTCTTCAGGA GGCTGTCCCTCATCTGACTA 
Alg14, 1800 CCACAGGCCTCTAGGTTGTC ACAGAAGGTTCAGCGAGGTT 
Lsmd1, 1105 GGACACCACATCGTTTCCAT TCTGAAAGGTAAGCGCCATC 
Lsmd1, 816 CATGACAGATGGACGGACAC TAAGGTTCCGCCACATTACC 
Lsmd1, 392 CCCAACCTGAAAGGTGCTTA CGACTGCAACAGCCATTCT 
Lsmd1, 129 AAAACAAGGGAGGAGGCAGT TCGCGAGACCTTTACCTCTG 
Lsmd1, -506 ACTTCCACGATGGGTTTCAG TACAAGGGTAAGGGCCACAC 
Lsmd1, -944 GGGATTCCCCATTCCTTCTA GTGGCAGGGGTCGTATTATG 
Lsmd1, -1502 AGGGGAGATAGCGGTGTAGG GAAGCTGCTATCTGCCAAGG 
Lsmd1, -1688 TTGCCTACAACTCCGTGAGA GGGAAGAACCTGAACATGGA 
Lsmd1, -2139 AAGCCAGCTTTGTATGGTCAA TGGCAATGATGGAAATGAGA 
Lsmd1, -2473 ACTTGAGGCCAGGAGGTTG TGCCTTGAGTAGCTGGGACT 
Lsmd1, -2846 CTGCAAACTCCCTTCCAGAG GTCCTAGGATCCCTGCACAA 
Lsmd1, -3176 TTGGTCACCAGGAGAGTTTTCT GACGGTGACTCCAAAAGAGG 
Lsmd1, -3434 AAGCCAACAGCAATGTTTCC GTGGCCCCTGTGAGATACTG 
Lsmd1, -4080 GTGAGGGTCTGAGGCAAGAC AATCAGGCTCATCTCGCAAC 
Lsmd1, -4538 TTTGGATATTGGGGAAGCAA AGGATGTCTGGTTCCTGTGC 
Lsmd1, -4912 TGGGGAAATGACAGATGGAT GGCAACAAGAACGAAACTCC 
ncRNA00095, -1739 CAAGATCTCAGCCCCTCTTG CCCAAGGAATTTGGGAGATT 
ncRNA00095, -1218 CTGAGGATGAATGGGAGTGG GTGTGAGGTGGGTTCATGC 
ncRNA00095, -830 AGGGTGCTCAGCTTCTGC GGGAAGGGGCCAGTTAAAG 
ncRNA00095, -212 CCCCTCTTTACTCCCTCCTT GTTCGTCCTGGAAAGTGGAG 
ncRNA00095, 335 CTTAAGAATGGCGGAACCAG AGACCGGGAGAGGCTAGGTA 
ncRNA00095, 955 TAAAGAATGTCCGCCTCTCC GACTGATTCCTGCTGCCTTC 
ncRNA00095, 1368 GCGGTGGTAGATCCCTTTCT TGCGGGTCAGTTTTCTTCTC 
ncRNA00095, 1771 TTGCTCTGTCACTTGGGTTG GTGCCTGAAGTCCCAGGTAT 
ncRNA00095, 2268 CCGCTCAGGCTTTATCAGTC CAAGCAGAGGGAACAGGGTA 
ncRNA00095, 2903 GTGAGGCCCCATCTTTACAA TCTCAGCCTCAAGCAATCCT 
ncRNA00095, 3400 GGCGACAGCGAGACTCTATC GCGGTACCACTCATCCATTC 
ncRNA00095, 3883 AGGATCCTGAGGCATGAGA GAGTGTAGTGGCATTGTCTTGG 
Praf2, -1769 TAGGTTGGTGGACTGGCTTC TGATCGTGAATGGAGCAGAC 
Praf2, -1164 TTCACTGTGCCTGCTGAGTC CTGTTCCCACTCACCAATGA 
Praf2, -829 TCCTGATGGAAACTGCAACA CCCCAGGGTCCTTAAAAGTC 
Praf2, -287 TCCTTGTGACAGTCCCTCCT CCCTTAAAACTGCCATCCAC 
Praf2, 112 CCCTGGACGACTTTGTTCTG ATGCCGAAGCAGAGAAGGTA 
Praf2, 805 GTTGGAAAGCCTGAGACCAG TCAGCCCCACTCTGAACTTT 
Praf2, 1158 GGACCTGAGGAAGACAGGAC CTCCCGACTCACCCTTGTAG 
Praf2, 1905 ACGTTGCCAAGCCAATTACT GGGGTGGTCAGTGGAATAGA 
Praf2, 2298 GCCCAAACAAAACAGGACAT AGGCTGGGGAAGACTCTTGT 
Praf2, 2839 AGGGAATGGGGCGTATATGT AGGCCACTTCTGTCCTTTGA 
ZSCAN20, 1602 TCTAGGCAGCCACTTCCAGT CTTAAGCCAGGGAGAGCAAA 
ZSCAN20, 1051 CTTGCCCTTCACCTTCTTTG TTGGGGGTGACTTAATTTGC 
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ZSCAN20, 457 CCCTGGCAAGAAGTGAAGAG CCACTGGGTTCCAGAGGTAA 
ZSCAN20, -87 GGCTGAAGACGTCTGAAAGG CACAATTCCCAGAAGGAACC 
ZSCAN20, -530 GGCCCTGAGCTAATCGTTTT TGGCATCCATGTCACAGAGT 
ZSCAN20, -1307 TTCCCTAAGCCGCATAACC GAGACGGAAGGATCGCTTTA 
ZSCAN20, -1850 GTCCTTACCTGACCCTGCAA AGCCGGAAACATTTGAGAGA 
C1orf83, 1313 GTGGGCTTTGATGCTGTTCT GCCTCTTTCCCAGTCTCAGC 
C1orf83, 810 CTGCCCTCTTTCTTGACCAG TTCTGGATTCTAGGCGTTCG 
C1orf83, 360 GACCCTCTGCTGAGTTCTGG ACCACAGCCATAATCCCAAG 
C1orf83, -56 CTGTCGGGAAAGTTGGTCTC CAGAATGCACTGCGAAGAAA 
C1orf83, -303 TTTTCTCGGAAGGGTTTCCT TCGTAGTCCCAGAGGTGAGG 
C1orf83, -1012 TGTCTGACTCCCCGAAGACT TAGAAAGGGAGGCGCAGATA 
C1orf83, -1557 TCTCCGTAGCCACTCCAGTT TGTTGATGTTGCTGGTGGTT 
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